

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Facilitators and barriers to healthcare providers' adoption of the harm reduction approach to cannabis use: a scoping review protocol

| | |
|-------------------------------|--|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2023-078427 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 01-Aug-2023 |
| Complete List of Authors: | Haddad, Roula; University of Montreal, Psychology Dagenais, Christian; University of Montreal, Psychology Huynh, Christophe ; University of Montreal, Psychiatry and addictology Fallu, Jean-Sébastien; University of Montreal, Psychoeducation |
| Keywords: | PUBLIC HEALTH, MENTAL HEALTH, Substance misuse < PSYCHIATRY |
| | |

SCHOLARONE™
Manuscripts

1
2
3 **Facilitators and barriers to healthcare providers' adoption of the harm reduction approach**
4 **to cannabis use: a scoping review protocol**
5
6
7

8 Roula Haddad¹, Christian Dagenais¹, Christophe Huynh², Jean-Sébastien Fallu³
9
10

11 ¹ Department of Psychology, University of Montreal
12

13 ² Department of Psychiatry and Addictology, University of Montreal
14

15 ³ School of Psychoeducation, University of Montreal
16
17

18 Correspondence to Roula Haddad; roula.haddad@umontreal.ca
19
20
21

22 **ABSTRACT**
23

24 **Introduction.** The high prevalence of cannabis use and the potential for negative effects indicate
25 the need for effective prevention strategies and treatment of people who use cannabis. Studies
26 show that the harm reduction (HR) approach to cannabis use is effective in minimizing the harmful
27 consequences of the substance. However, health professionals often misunderstand it and resist its
28 adoption due to various obstacles and barriers. To our knowledge, to date there has been no review
29 of the scientific literature on the factors that facilitate or hinder practitioners' adoption of HR in
30 cannabis use. To fill this gap, we aim to identify, through a scoping review, facilitators and barriers
31 to healthcare providers' adoption of HR in cannabis use in Organisation for Economic Co-
32 operation and Development countries.
33
34
35
36
37
38
39
40

41 **Methods and analysis.** Our methodology will be guided by the six-step model initially proposed
42 by Arksey and O'Malley (2005). Our search strategy will be executed on different databases and
43 the grey literature will also be searched. Key journals related to the field of study and reference
44 lists of selected articles will be searched manually to identify any publications missed by the
45 electronic searches. Relevant systematic reviews will be scanned to identify the studies included.
46 Finally, the search strategy will be supplemented by contacting authors, existing networks, and
47 organizations. All study designs will be included, and the selected studies will be those presenting
48 factors that facilitate or hinder healthcare providers' adoption of HR in cannabis use.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Ethics and dissemination.** Ethics approval is not required. The results will be disseminated
4 through various activities and will be used to develop and implement a knowledge translation
5 process among healthcare practitioners working in addiction rehabilitation services in Quebec with
6 adolescents and young adults. This process will mainly aim to change practitioners' practices and
7 improve their adoption of HR in cannabis use.
8
9
10
11
12

13 **Strengths and limitations of this study**

- 14 - To our knowledge, this scoping review will be the first to identify factors that facilitate or
15 hinder healthcare providers' adoption of HR in cannabis use. Other reviews have studied
16 other HR interventions among practitioners with the adult population.
17
- 18 - The search strategy was co-developed by two information management specialists in the
19 addiction and knowledge translation fields.
20
- 21 - Two reviewers will independently select the studies to be included in the scoping review.
22
- 23 - Even though not mandatory, the methods employed in the selected studies will be subject
24 to a quality assessment using the Mixed Methods Appraisal Tool grid.
25
- 26 - The included studies will be limited to those published in French or English.
27
28
29
30
31

32 **Key words:** *harm reduction; cannabis; knowledge translation; healthcare*
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Cannabis use

Psychoactive substances (e.g., cannabis, alcohol, nicotine) are defined as substances whose use affects mental processes (e.g., perception, cognition, emotions, and mood) and behaviors without necessarily leading to addiction (1). After tobacco and alcohol, cannabis represents the third most consumed psychoactive substance globally among adults and youth (2-4). Since the 2000s, rates of cannabis use in Canada and Quebec have been declining (5). Despite this change, Canada is still among the developed countries with the highest rates of cannabis use among adolescents and young adults, with high prevalence in Quebec and multiple patterns of use (e.g., smoking, eating, vaporizing, vaping) (2, 5-7). In 2022, 27% of those 16 years of age and older reported using cannabis in the 12 months prior to the study (8). Among young people with psychosocial adjustment difficulties admitted to Quebec's foster youth centers, 78% have used cannabis at some time, and nearly half presented a problematic use (5, 9). Cannabis use does not necessarily lead to dependence due to its limited addictive power, infrequent use by most people who use it, and minimal consequences at low rates of use (10, 11). However, harm may sometimes occur at the personal (e.g., decreased academic performance), health (e.g., overuse of drugs and deterioration of mental health), behavioral (e.g., delinquency and risky behaviors), psychosocial, and legal levels (3, 4, 11-13). These consequences, along with the high prevalence of cannabis use, make it essential to implement intervention programs among young people who use cannabis (5).

Abstinence approach

To address this reality, prevention and treatment programs have been developed based on the abstinence approach, which entails total elimination of substance use (10, 14). The emergence of these programs has been also influenced by policies such as the "War on Drugs" (15). The abstinence approach forms the basis of most programs developed to prevent or treat problematic substance use among adolescents and young adults and has been applied with at-risk or marginalized populations (e.g., youth in the foster care system) (13). Despite its potential to decrease the frequency or amount of substance use, the abstinence approach with youth has been criticized for various reasons (13). First, it does not provide them with the necessary skills to identify and mitigate the harms associated with their use (13, 16). Second, the abstinence approach focuses on the negative consequences of use through strategies that evoke fear in people who use

1
2
3 psychoactive substances and bypasses key factors contributing to substance use, such as peer
4 pressure and social context (12, 13). Third, the risks of relapse and dropout among adolescents and
5 youth in these programs are also found to be high: only one-third of this population manages to
6 eliminate any kind of substance use during treatment, leaving a significant number for whom this
7 goal remains unattainable (12, 17). Given these limitations of abstinence-oriented programs, other
8 alternative and more flexible treatments that are acceptable to youth, such as harm reduction (HR),
9 are essential (17, 18, 19).

16 17 **Harm reduction (HR)**

18 19 Description

20 HR in cannabis use aims to minimize the harmful consequences of the substance at the individual,
21 psychological, legal, and social levels among users (12, 17, 18). It offers a public health framework
22 based on values of pragmatism and humanism, as it does not view substance use through a moral
23 lens, but as an inevitable societal fact of long standing (3, 10, 20, 21). Whether among adults or
24 adolescents, elimination of substance use is unrealistic at the population level and should be the
25 individual's choice without being imposed, as it represents an unwanted and impractical goal for
26 some (e.g., recreational/occasional users, or in cases of dual diagnosis combining psychiatric and
27 substance use disorders) (16-18, 22, 23). HR also seeks to equip people who use substances to
28 make responsible and rational decisions and learn ways to reduce the negative consequences
29 associated with use (10-12, 16, 18, 21). To this end, it clarifies the notion of safe substance use
30 that is determined by the interaction of three components: the individual (height, weight, gender,
31 physical and mental health status, state of mind, etc.); the drug (quantity, frequency of use,
32 tolerance to the product, combination with other products, quality, etc.); and the setting (location,
33 time of day, interpersonal relationships, conflicts, laws, etc.) (3, 12, 16). Unlike adults, adolescents
34 and young adults are often referred for treatment by their parents, school, or the juvenile justice
35 system, which may limit their internal motivation to change their substance use behaviors (12, 18).
36 In such cases, HR takes into account their personal characteristics (impulsivity, sensation-seeking,
37 etc.) and addresses their ambivalence about stopping substance use, feelings of failure upon
38 relapse, decision-making, goal-setting, engagement in treatment, social skills, emotional
39 regulation, etc. (12).

HR efficacy

Interventions based on HR for non-injected drugs have been most widely studied among adults (for example, in housing programs among people diagnosed with substance use disorders and psychiatric disabilities) and have shown promising results in decreasing the negative consequences associated with substance use (12, 13, 17). However, among adolescents and young adults, the focus is more on school-based programs that combine preventive strategies, early interventions, and HR practices to reduce substance use (4, 6). Additionally, most studies have focused on alcohol, and few have focused on cannabis or the implementation and effectiveness of intensive treatment based on HR in this population (4, 6, 12). Indeed, current school-based HR programs (e.g., SHAHRP in the United Kingdom and SCIDUA in Canada) are effective in developing safer attitudes toward substance use and reducing negative consequences related to use (13, 24, 25). A study by the Academic Institute on Addictions (*Institut universitaire sur les dépendances*) in Quebec as part of the IP-Youth project confirms that “effective early interventions targeting college and university students with at-risk cannabis use” are those that reduce the harms associated with cannabis use (e.g., Computerized Brief Intervention for Cannabis, eCHECKUP TO GO - Marijuana) (26-29). As a result, researchers have suggested integrating HR into interventions targeting adolescents and young adults (28).

Acceptability of harm reduction

Despite its proven effectiveness, the acceptability of HR among healthcare providers remains controversial, and various factors facilitate or hinder its adoption (30, 31). MacCoun (32) showed that, among practitioners who did not adopt an HR approach to substance use (i.e., not limited to cannabis), some had based their decision on moral grounds, regardless of its effectiveness. Various barriers limit its use by practitioners. First, ambiguities in its conceptualization play an influential role; for example, some practitioners perceive HR as sending the wrong message, i.e., one of tolerating or even encouraging substance use (16, 17, 20, 33). Some do not perceive total cessation of substance use as a legitimate goal that could be achieved through HR (34). As well, there is often confusion between reducing use (frequency, quantity, etc.) and reducing harm (modifying consumption practices, such as contexts and mixtures, to reduce consequences) (20). These misconceptions point to the need for awareness-raising, training, and supervision of practitioners interested in this approach (17). Second, the adoption of HR can be hindered by ethical dilemmas,

1
2
3 as well as by issues related to the personal and collective values of healthcare workers and the
4 therapeutic model of abstinence (20). Indeed, it runs counter to traditional treatments by tolerating
5 risky behaviors and accepting that HR in drug use is a legitimate outcome (20, 33). Practitioners
6 may also fear the emergence of legal, social, and health problems among their clients (17). Third,
7 its adoption may also be limited by contextual barriers, such as lack of funding, stigma that
8 undermines demand for care, resistance from local jurisdictions, and lack of services and trained
9 personnel, particularly in the mental health sector (30).

10
11
12
13
14
15 However, several factors seen as HR benefits have been found to facilitate implementation
16 by healthcare providers, such as: broadening the spectrum of acceptable goals, improving clients'
17 decision-making skills, creating positive and quality relationships, and managing relapses (17). A
18 study by Sharp et al. (2020) showed that clarifying the positive impacts of HR at the community
19 level (e.g., safety) and ensuring the availability of resources could increase the likelihood of its
20 adoption.
21
22
23
24
25

26 27 **Purpose**

28
29 Despite its proven effectiveness, HR remains under-implemented, especially among youth, due to
30 health professionals' resistance (20, 30). However, to date there has been no review of the scientific
31 literature that identifies facilitators and barriers to the adoption of HR in cannabis use. To fill this
32 gap, we aim to identify, through a scoping review, facilitators and barriers to healthcare providers'
33 adoption of HR in cannabis use.
34
35
36
37
38
39

40 **METHODS AND ANALYSIS**

41
42 This study will follow the methodological steps of scoping reviews (35). This type of review has
43 become more prevalent in recent years and is a type of knowledge synthesis review (35, 36). There
44 is no universal definition for scoping reviews; however, a variety of factors distinguish them from
45 other types of knowledge synthesis (37). First, scoping reviews address broad research questions
46 and include studies with different designs and multiple sources of evidence to provide an overview
47 of the available knowledge around a concept (38). A systematic review following Cochrane
48 standards, on the other hand, explores more specific research questions based on detailed inclusion
49 and exclusion criteria (39-41). Second, while assessment of the methodological quality of included
50 studies is recommended for scoping reviews, it is not mandatory, whereas assessment of the risk
51
52
53
54
55
56
57
58
59
60

of bias of included studies is required for Cochrane-type systematic reviews (39, 41). Researchers undertake scoping reviews for a variety of reasons: 1) to review research activity in a given area; 2) to determine the feasibility and appropriateness of conducting a systematic review based on Cochrane standards; 3) to summarize and disseminate the results of existing research on a topic; and/or 4) to identify a gap in the literature and draw conclusions regarding a topic (38). Our methodological choice is underpinned by three of these reasons: once the research activity around the topic has been consulted, the findings will be summarized and used to support a second study aimed at disseminating knowledge to practitioners through a knowledge translation process. This will also allow us to identify gaps in the literature and draw conclusions related to the topic.

Arksey and O'Malley (2005) were the first to propose a six-step model for conducting scoping reviews. Our methodology will be guided by this model, which was later refined by Levac et al. (2010) and revised by members of the Johanna Briggs Institute (39). The six stages we will follow are:

- Stage 1: Determining the research question and the objective
- Stage 2: Identifying relevant studies
- Stage 3: Selecting studies
- Stage 4: Charting the data
- Stage 5: Collating, summarizing, and reporting the results
- Stage 6: Conducting a consultation exercise

The research protocol will be reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) grid (36). This grid is an extension of the PRISMA grid originally developed for Cochrane-type systematic reviews and helps to ensure the transparency and reproducibility of the study (36, 39).

Stage 1: Determining the research question and the objective

Arksey and O'Malley's (2005) model suggests that scoping reviews should begin not only with identifying research questions, but also clarifying the resulting objectives (37, 39). Our scoping review is exploratory in nature and aims to identify facilitators and barriers to healthcare providers' adoption of HR in cannabis use in OECD countries. Based on the Population-Concept-Context (PCC) model, which allows the broad scope of the study to be respected without specifying restrictive inclusion criteria (39), we formulated the research question: What factors influence

1
2
3 providers (population) in the healthcare field (context) to adopt HR in cannabis use (concept)?
4
5 Specific research questions associated with the components of the PCC model were also identified.

- 6 - Question 1, related to the concept component: What is the definition of HR in cannabis
7 use?
8
- 9 - Question 2, related to the concept and context components: What are the facilitators and
10 barriers to healthcare providers' adoption of HR in cannabis use?
11
- 12 - Question 3, related to the population component: Who are the clientele of the providers
13 identified in the studies (e.g., adolescents and young adults, pregnant women, individuals
14 with psychotic disorders, etc.)?
15
- 16 - Question 4, related to the concept component: What are the gaps in the literature and the
17 future research needs?
18
19
20
21
22
23

24 **Stage 2: Identifying relevant studies**

25 Search strategy

26
27 The search strategy was developed through an iterative process. A senior librarian at the Quebec
28 Addiction Library (*Bibliothèque québécoise sur les dépendances*) first developed three search
29 strategies with different concepts and ran them on the Medline database. We consulted the first 50
30 results of each strategy and chose the one that grouped key terms related to the following concepts:
31 harm reduction, clinicians, and cannabis (see Supplemental Appendix 1). The search strategy was
32 then reviewed by a second information professional working in the RENARD Team for
33 Knowledge Translation who, in turn, adapted it to the selected databases. The final search strategy
34 executed on all the databases was then validated by the RENARD Team information specialist.
35
36 The Peer Review of Electronic Search Strategies (PRESS) tool served as a guide for the librarians
37 in this process (42). The search strategy executed on Medline and adapted for the other selected
38 databases is presented in Supplemental Appendix 1.
39
40
41
42
43
44
45
46
47

48 Information sources

49 To identify relevant published and unpublished studies for inclusion in the study, various sources
50 of information will be reviewed (35, 38, 39). With the guidance of the two librarians, the search
51 strategy will be executed on the leading health and intervention databases: Medline, PsycINFO,
52 CINAHL, Web of Science, Embase, and Sociological Abstracts. To explore the grey literature
53
54
55
56
57
58
59
60

1
2
3 (e.g., theses, research reports, etc.), the search strategy will be adapted to the Google Web and
4 Google Scholar search engines, as well as the Érudit (French database) and BASE databases. All
5 documents identified will be entered into Zotero software for the research team members to access.
6
7 Key journals related to the field of study (e.g., *Harm Reduction Journal*; *International Journal of*
8 *Drug Policy*) and reference lists of selected articles will be manually searched to identify any
9 publications missed by the electronic searches. Systematic reviews will be scanned to identify
10 studies included. Finally, the search strategy will be supplemented by contacting authors, existing
11 networks, and organizations.
12
13
14
15
16
17
18

19 **Stage 3: Study selection**

20 After running the search strategy on the selected databases and completing the second stage, all
21 identified duplicates will be removed. The remaining documents will then be entered into
22 Covidence software. Two reviewers will independently select relevant documents for inclusion by
23 reading the titles and abstracts of the identified studies. Their decisions will be based on the
24 specified inclusion and exclusion criteria. They will meet regularly to resolve selection conflicts
25 and refine the eligibility criteria as needed. After this first step, the inter-rater agreement between
26 the reviewers will be calculated. The documents selected and deemed potentially relevant will then
27 be the subject of the second step, the full-text reading. Again, the two reviewers will independently
28 record their choices on Covidence and resolve any new conflicts, and the inter-rater agreement for
29 this step will then be calculated. A third reviewer will be called upon as needed for any conflict
30 resolution. This will complete the document selection stage, whose steps will be presented in a
31 PRISMA diagram (43).
32
33
34
35
36
37
38
39
40
41
42

43 **Inclusion and exclusion criteria**

44 Inclusion and exclusion criteria have been specified and will be fine-tuned as needed to select
45 relevant studies (Table 1). Using this process, we will select empirical studies of quantitative,
46 qualitative, or mixed designs, including from the grey literature, and will focus on projects based
47 on identifying factors that facilitate or hinder healthcare providers' adoption of HR in cannabis
48 use. To facilitate comparison and generalization of the results to the Quebec context, the review
49 will be limited to studies conducted in any of the 38 Organisation for Economic Co-operation and
50 Development (OECD) countries. Articles published from 1990 onwards will be included, as it was
51
52
53
54
55
56
57
58
59
60

early in that decade that HR gained international prominence and its scope of application began to expand. Papers not meeting these inclusion criteria will be excluded. While systematic reviews will be excluded to avoid duplication and ensure equal representation of the selected papers, their reference lists will nevertheless be examined to identify additional relevant studies.

Table 1. Inclusion and exclusion criteria

| Criteria | Inclusion criteria | Exclusion criteria |
|---|--|---|
| Type of study | <ul style="list-style-type: none"> - Empirical study: quantitative, qualitative, or mixed | <ul style="list-style-type: none"> - Study that does not present empirical results (e.g., theoretical study, conceptual framework, etc.) or knowledge review (e.g., systematic or literature review) - Interviews |
| Type of documents | <ul style="list-style-type: none"> - Peer-reviewed scientific articles, research reports, dissertations, theses | <ul style="list-style-type: none"> - Books and practice guides |
| Conceptual framework | <ul style="list-style-type: none"> - Harm reduction (HR) in cannabis use - Cannabis risk reduction - Non-abstinence in cannabis use | <ul style="list-style-type: none"> - Another conceptual framework |
| Objective | <ul style="list-style-type: none"> - Identification of factors¹ facilitating or hindering practitioners' adoption of the HR approach² in cannabis use | <ul style="list-style-type: none"> - Evaluation of the effectiveness of interventions based on HR OR - Stakeholder perceptions of the use of cannabis as an HR strategy to circumvent the effects of other drugs OR - Attitudes toward decriminalization of cannabis |
| Psychoactive substance being studied | <ul style="list-style-type: none"> - Marijuana, hashish, or cannabis for non-medical purposes - "Drug" if cannabis is part of its conceptualization in the study | <ul style="list-style-type: none"> - Any substance other than marijuana, hashish, or non-medical cannabis (e.g., tobacco, alcohol, medical cannabis, MDMA, Ecstasy) - Study that focuses on "performance and image enhancing drugs" or "crack" or "new psychoactive substances" |
| Target population | <ul style="list-style-type: none"> - Practitioners³ working in the health field - Pre-practitioners (in training to become practitioners) | <ul style="list-style-type: none"> - People who use cannabis⁴ |

| | | |
|-------------------------|-------------------------|--|
| Country of study | - OECD countries | - Other countries |
| Publication date | - From 1990 onwards | - Before 1990 |
| Language | - French and/or English | - Languages other than French or English or text not available |

¹ “Factors” include perceptions, beliefs, facilitators, obstacles, oppositions, attitudes, opinions, barriers, biases, motivations, preferences, determinants, incentives, influences, and perspectives on the adoption of HR in cannabis use, as well as its acceptability and receptivity.

² “Approach” refers to strategies, interventions, practices, services, methods, techniques, treatments, programs, or guides for the HR approach in cannabis use.

³ “Practitioners” includes healthcare personnel, professionals, or practitioners, allied healthcare personnel, professionals, or practitioners, social workers, counsellors, psychoeducators, educators, nurses, criminologists, psychologists, clinicians, caregivers, therapists, psychotherapists, and physicians.

⁴ Studies addressing the views of people who use cannabis regarding HR or its adoption by practitioners will be excluded.

Stage 4: Charting the data

To analyze the selected studies on a common basis, specific variables of interest will be identified based on the research questions (38). These will form the components of summary sheets that will be developed in Microsoft Excel and used to extract results (Table 2). This method is an analytical descriptive recording of the data (38, 39, 44). The first author (RH) will extract the data from the included studies and create the summary sheets. The research supervisor (CD) will validate the summary sheets throughout the process and ensure their alignment with the research questions (39). At this stage, the quality of the methods employed in the selected studies will be assessed using the Mixed Methods Appraisal Tool grid (45).

Table 2. Summary sheets

| General variables | Specific variables |
|---|-------------------------|
| General characteristics of the study | Study title |
| | Author(s) |
| | Language of publication |
| | Date of publication |
| | Period of publication |
| | Journal |
| | Type of article |
| Full reference | |

| | |
|---------------------|--|
| | Country of study |
| | Psychoactive substance under study |
| | Legal status of cannabis in country of study |
| Introduction | Main concepts |
| | Definition of the main concept: HR in cannabis use |
| | Research question(s) |
| | Objective(s) |
| | Hypothesis |
| Methodology | Study design |
| | Target population |
| | Place of work of the target population |
| | Inclusion criteria of participants |
| | Recruitment method |
| | Sample size |
| | Country of origin of participants |
| | Clientele of the population recruited |
| | Data collection method |
| | Analysis steps |
| Results | Sample presentation |
| | Key findings: 1) facilitators and 2) barriers to practitioners' adoption of HR in cannabis use |
| | Secondary outcomes or other results |
| Conclusion | Study strengths |
| | Study limitations |
| | Gaps in the literature and future research needs |

Stage 5: Collating, summarizing, and reporting the results

Based on the eligibility criteria, studies deemed relevant will be collected, summarized, and reported. They will be subjected to: 1) a numerical analysis, and 2) a narrative organization encompassing a descriptive qualitative analysis (36, 38, 39). A numerical analysis of the scope, nature, and distribution of the included studies will be performed in relation to various characteristics: date of publication, country of origin of the studies, and type of document. Subsequently, a narrative organization of the results will be produced to identify the relationships between the data and the research questions. The summary sheets will be combined, tabulated, and synthesized, and will then be subjected to a descriptive qualitative analysis (Table 3).

Table 3. Narrative organization of the included studies

| Data | Study 1 | Study 2 | Study ... |
|---|---------|---------|-----------|
| Type of publication | | | |
| Date of publication | | | |
| Country of study | | | |
| Legal status of cannabis in the country of the study | | | |
| Definition of HR to cannabis use | | | |
| Design of the study | | | |
| Target population | | | |
| Place of work of the target population | | | |
| Clientele of the target population | | | |
| Data collection method | | | |
| Key findings: <ul style="list-style-type: none"> <li data-bbox="250 848 699 884">- Facilitators or enabling conditions <li data-bbox="250 898 651 934">- Barriers or adverse conditions | | | |
| Secondary outcomes | | | |

Stage 6: Consultation exercise

Expert consultation is an optional step that promotes methodological rigor in scoping reviews (38). In this study, the project's supervisor and co-researchers will be solicited as consultants. Members of the RENARD team and researchers involved in the field of substance use and harm reduction will be consulted to help clarify findings and validate the resulting recommendations (38). Consultations will be conducted: 1) after preliminary results have been obtained, and 2) after analyses of the results have been completed.

ETHICS AND DISSEMINATION

To our knowledge, this is the first scoping review on factors that facilitate or hinder healthcare providers' adoption of HR in cannabis use. This study will provide a clear picture of the factors at play when adopting HR, and the results could potentially be generalizable to OECD countries. The present study is exempt from ethics approval because it involves no patient or personal data collection. The results are expected to be ready by March 2024. After completing the scoping review, we will be able to refine the knowledge translation plan that we aim to implement among practitioners working in addiction rehabilitation services in Quebec with adolescents (12–17 years)

1
2
3 and young adults (18–21 years) presenting psychosocial adjustment difficulties. The goal of our
4 knowledge translation process will be mainly to change practitioners' practices and expand the
5 adoption of HR in cannabis use.
6
7

8
9
10 **Acknowledgments.** We wish to thank Karine Bélanger, senior librarian at the *Bibliothèque*
11 *québécoise sur les dépendances* in Quebec for developing the initial search strategy used in this
12 scoping review. We also wish to thank Julie Desnoyers, the information specialist affiliated with
13 the RENARD Team for Knowledge Translation at Université de Montréal, for validating the
14 search strategy and adapting it to the selected databases. Finally, we want to thank Donna Riley
15 for editing the manuscript.
16
17
18
19

20
21
22 **Authors' contributions.** RH, CD, CH, and JSF conceptualized the study. RH drafted the protocol.
23 CD, CH, and JSF critically revised the manuscript. RH wrote the final draft manuscript, and all
24 the authors approved it.
25
26
27

28
29 **Funding statement.** This work was supported by the *Ministère de la Santé et des Services sociaux*
30 (MSSS), *Fonds de recherche du Québec – Santé* (FRQS), and *Fonds de recherche du Québec –*
31 *Société et culture* (FRQSC) (Grant number: 2023-0PTR-322652).
32
33
34
35

36 **Competing interests statement.** None declared.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FULL REFERENCES

1. World Health Organization. Drugs (psychoactive) [online]; 2022. https://www.who.int/health-topics/drugs-psychoactive#tab=tab_1 (accessed 13 Jul 2023).
2. Adinoff B, Cooper ZD. Cannabis legalization: progress in harm reduction approaches for substance use and misuse. *Am J Drug Alcohol Abuse* 2019;45(6):707–12. doi: 10.1080/00952990.2019.1680683
3. Melamed R. Harm reduction-the cannabis paradox. *Harm Reduct J* 2005;2(1):17. doi: 10.1186/1477-7517-2-17
4. Jiloha RC. Prevention, early intervention, and harm reduction of substance use in adolescents. *Indian J Psychiatry* 2017;59(1):111–8. doi: 10.4103%2F0019-5545.204444
5. Gouvernement du Québec. Plan d'action interministériel en dépendances 2018-2028 – Prévenir, réduire et traiter les conséquences associées à la consommation de substances psychoactives, à la pratique de jeux de hasard et d'argent et à l'utilisation d'Internet [online]. 2018. <https://publications.msss.gouv.qc.ca/msss/document-002078/> (accessed 13 Jul 2023).
6. Poulin C, Elliott D. Alcohol, tobacco and cannabis use among Nova Scotia adolescents: implications for prevention and harm reduction. *CMAJ* 1997;156(10):1387–93. PMID: **9164396**
7. Zuckermann AM, Gohari MR, Romano I, et al. Changes in cannabis use modes among Canadian youth across recreational cannabis legalization: data from the COMPASS prospective cohort study. *Addict Behav* 2021;122:107025. doi: 10.1016/j.addbeh.2021.107025
8. Government of Canada. Canadian Cannabis Survey 2022: Summary [online]. 2022. <https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/canadian-cannabis-survey-2022-summary.html> (accessed 13 Jul 2023).
9. Laventure M, Déry M, Pauzé R. Profils de consommation d'adolescents, garçons et filles, desservis par des centres jeunesse [Consumption profiles of adolescents (boys and girls) who receive services from youth centres]. *Drogues Sante Soc* 2008;7(2):9–45. doi: 10.7202/037564ar
10. Hathaway AD, Erickson PG. Drug reform principles and policy debates: harm reduction prospects for cannabis in Canada. *J Drug Issues* 2003;33(2):465–95. doi: [10.1177/002204260303300209](https://doi.org/10.1177/002204260303300209)
11. Swift W, Copeland J, Lenton S. Cannabis and harm reduction. *Drug Alcohol Rev* 2000;19(1):101–12. doi: 10.1080/09595230096200
12. Bagot KS, Kaminer Y. Harm reduction for youth in treatment for substance use disorders: one size does not fit all. *Curr Addict Rep* 2018;5(3):379–85. doi: 10.1007/s40429-018-0217-8
13. Jenkins EK, Slemon A, Haines-Saah RJ. Developing harm reduction in the context of youth substance use: insights from a multi-site qualitative analysis of young people's harm minimization strategies. *Harm Reduct J* 2017;14(1):53. doi: 10.1186/s12954-017-0180-z

14. Stockings E, Hall WD, Lynskey M, et al. Prevention, early intervention, harm reduction, and treatment of substance use in young people. *Lancet Psychiatry* 2016;3(3):280–96. doi: 10.1016/S2215-0366(16)00002-X
15. Buchanan J, Young L. The war on drugs – a war on drug users? *Drugs (Abingdon Engl)* 2000;7(4):409–22. doi: 10.1080/dep.7.4.409.422
16. Fallu J-S. Réduction des méfaits: histoire, concepts, pratiques, développements et enjeux [online]. Journée de la toxicomanie. Oral presentation, Journée de la toxicomanie, 23 Nov 2017; St-Liguori, Québec, Canada. https://www.reseautoxicomanie.com/wp-content/uploads/2017/12/Conférence-JS-Fallu_PNMVH-23-septembre-2017.pdf (accessed 13 Jul 2023).
17. Mancini MA, Linhorst DM, Broderick F, et al. Challenges to implementing the harm reduction approach. *J Soc Work Pract Addict* 2008;8(3):380–408. doi: 10.1080/15332560802224576
18. Karoll BR. Applying social work approaches, harm reduction, and practice wisdom to better serve those with alcohol and drug use disorders. *J Soc Work* 2010;10(3):263–81. doi: 10.1177/1468017310363635
19. Jenkins EK, Slemon A, Haines-Saah RJ. Developing harm reduction in the context of youth substance use: insights from a multi-site qualitative analysis of young people’s harm minimization strategies. *Harm Red J* 2017;14(1):53. doi: 10.1186/s12954-017-0180-z
20. Fallu J-S, Brisson P. La réduction des méfaits liés à l’usage des drogues: historique, état des lieux, enjeux. In: Massé R, Mondou I, eds. *Réduction des méfaits et tolérance en santé publique: enjeux éthiques et politique*. Presses de l’Université Laval 2013:105–27.
21. Ritter A, Cameron J. A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs. *Drug Alcohol Rev* 2006;25(6):611–24. doi: 10.1080/09595230600944529
22. Lau N, Sales P, Averill S, Murphy F, et al. A safer alternative: cannabis substitution as harm reduction. *Drug Alcohol Rev* 2015;34(6):654–9. doi: 10.1111/dar.12275
23. Tsemberis S, Gulcur L, Nakae M. Housing first, consumer choice, and harm reduction for homeless individuals with a dual diagnosis. *Am J Public Health* 2004;94(4):651–6. doi: 10.2105/AJPH.94.4.651
24. Poulin C, Nicholson J. Should harm minimization as an approach to adolescent substance use be embraced by junior and senior high schools?: empirical evidence from an integrated school- and community-based demonstration intervention addressing drug use among adolescents. *Int J Drug Policy* 2005;16(6):403–14. doi: 10.1016/j.drugpo.2005.11.001
25. McBride N, Farrington F, Midford R, et al. Harm minimization in school drug education: Final results of the School Health and Alcohol Harm Reduction Project (SHAHRP). *Addiction* 2004;99(3):278–91. doi: 10.1111/j.1360-0443.2003.00620.x
26. Fischer B, Jones W, Shuper P, et al. 12-month follow-up of an exploratory ‘brief intervention’ for high-frequency cannabis users among Canadian university students. *Subst Abuse Treat Prev Policy* 2012;7(1):15. doi: 10.1186/1747-597X-7-15

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
27. Grossbard JR, Mastroleo NR, Kilmer JR, et al. Substance use patterns among first-year college students: secondary effects of a combined alcohol intervention. *J Subst Abuse Treat* 2010;39(4):384–90. doi: 10.1016/j.jsat.2010.07.001
28. Bertrand K, Blanchette-Martin N, Dufour M, et al. Projet IP-Jeunes : recenser et promouvoir les critères d'efficacité reconnus en intervention précoce auprès des jeunes présentant des comportements à risque quant à la consommation d'alcool et d'autres drogues, à la pratique des jeux de hasard et d'argent et à l'utilisation d'internet. Synthèse des résultats préliminaires, 2019-2020 [online]. IUD: Institut universitaire sur les dépendances; 2020. <https://chairejeunesse.ca/documentation/projet-ip-jeunes-recenser-et-promouvoir-les-criteres-defficacite-reconnus-en-intervention-precoce-aupres-des-jeunes-presentant-des-comportements-a-risque-quant-a-la-consommation-da/> (accessed 13 Jul 2023).
29. Palfai TP, Saitz R, Winter M, et al. Web-based screening and brief intervention for student marijuana use in a university health center: pilot study to examine the implementation of eCHECKUP TO GO in different contexts. *Addict Behav* 2014;39(9):1346–52. doi: 10.1016/j.addbeh.2014.04.025
30. Sharp A, Barnett JT, Vroom EB. Community perceptions of harm reduction and its implications for syringe exchange policy. *J Drug Issues* 2020;50(4):507–23. doi: 10.1177/0022042620932289
31. Fallu J-S, Gilbert-Lambert MH, D'Arcy Dubois L, et al. Prévention de la consommation à risque ou problématique de substances psychoactives chez les jeunes hébergés en institution au Québec [online]. Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l'Île-de-Montréal (Québec). Direction de l'enseignement universitaire et de la recherche. Institut universitaire sur les dépendances. 2022. <https://iud.quebec/fr/etudes-et-recherche/programme-sur-lusage-et-les-dependances-aux-substances-puds/publications> (accessed 13 Jul 2023).
32. MacCoun RJ. Toward a psychology of harm reduction. *Am Psychol* 1998;53(11):1199–1208. doi: 10.1037/0003-066X.53.11.1199
33. Mancini MA, Wyrick-Waugh W. Consumer and practitioner perceptions of the harm reduction approach in a community mental health setting. *Community Ment Health J* 2013;49(1):14–24. doi: 10.1007/s10597-011-9451-4
34. Koutroulis G. “That original tension”. Negotiating abstinence in clinicians' accounts of harm reduction in nonresidential treatment of heroin withdrawal. *J Subst Abuse Treat* 2000;19(1):89–98. doi: 10.1016/S0740-5472(99)00087-2
35. Peters MDJ, Godfrey CM, Khalil H, et al. Guidance for conducting systematic scoping reviews. *Int J Evid Based Healthc* 2015;13(3):141–6. doi: 10.1097/XEB.0000000000000050
36. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med* 2018;169(7):467–73. doi: 10.7326/M18-0850
37. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implement Sci* 2010;5(1):69. doi: 10.1186/1748-5908-5-69
38. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol* 2005;8(1):19–32. doi: 10.1080/1364557032000119616

- 1
- 2
- 3
- 4 39. Peters MDJ, Godfrey C, McInerney P, et al. Chapter 11: Scoping reviews. In: Aromataris E,
- 5 Munn Z, eds. *JBIM Manual for Evidence Synthesis*. JBI, 2020. doi: 10.46658/JBIMES-20-12
- 6
- 7 40. Peterson J, Pearce PF, Ferguson LA, et al. Understanding scoping reviews: definition,
- 8 purpose, and process. *J Am Assoc Nurse Pract* 2017;29(1):12–6. doi: 10.1002/2327-
- 9 6924.12380
- 10
- 11 41. Pollock D, Tricco AC, Peters MD, et al. Methodological quality, guidance, and tools in
- 12 scoping reviews: a scoping review protocol. *JBIM Evid Synth* 2022;20(4):1098–105. doi:
- 13 10.11124/JBIES-20-00570
- 14
- 15 42. McGowan J, Sampson M, Salzwedel DM, et al. PRESS peer review of electronic search
- 16 strategies: 2015 guideline statement. *J Clin Epidemiol* 2016;75:40–6. doi:
- 17 10.1016/j.jclinepi.2016.01.021
- 18
- 19 43. Gedda M. Traduction française des lignes directrices PRISMA pour l'écriture et la lecture
- 20 des revues systématiques et des méta-analyses [French translation of the PRISMA Reporting
- 21 Guidelines for writing and reading systematic reviews and meta-analyses]. *Kinesither Rev*
- 22 2015;15(157):39–44. doi: 10.1016/j.kine.2014.11.004
- 23
- 24 44. Colquhoun HL, Levac D, O'Brien KK, et al. Scoping reviews: time for clarity in definition,
- 25 methods, and reporting. *J Clin Epidemiol* 2014;67(12):1291–4. doi:
- 26 10.1016/j.jclinepi.2014.03.013
- 27
- 28 45. Hong QN, Pluye P, Fàbregues S, et al. Mixed methods appraisal tool (MMAT) version 2018
- 29 user guide. Registration of copyright (#1148552) [online]. Canadian Intellectual Property
- 30 Office, Industry Canada; 2018. <https://www.nccmt.ca/knowledge-repositories/search/232>
- 31 (accessed 13 Jul 2023).
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Appendix 1: Medline Search Strategy

Searched online: 10/10/2022

Search results: 251

| # | Concept | Equations | Results | |
|----|--|--|------------------|-------|
| 1 | Harm reduction | Harm Reduction/ | 3898 | |
| 2 | | Risk Reduction Behavior/ | 14132 | |
| 3 | | (protective adj2 strateg*).ab,kf,ti. | 2818 | |
| 4 | | ((reduc* or minimi*) adj5 (harm? or harmful or risk?)).ab,kf,ti. | 239459 | |
| 5 | | 1 or 2 or 3 or 4 | 251821 | |
| 6 | Clinicians | exp Health Personnel/ | 588634 | |
| 7 | | Social Workers/ | 971 | |
| 8 | | Counselors/ | 541 | |
| 9 | | exp Health Occupations/ | 1819039 | |
| 10 | | exp Allied Health Occupations/ | 52626 | |
| 11 | | exp Allied Health Personnel/ | 53169 | |
| 12 | | (worker? or psychoeducator? or psycho-educator? or educator? or nurse? or criminologist? or psychologist? or clinician? or practitioner? or physician? or professional? or provider? or co?nselor or co?nselors or caregiver? or giver? or therapist? or psychotherapist? or staff? or personnel? or employee? or doctor?).ab,kf,ti. | 2002544 | |
| 13 | | 6 or 7 or 8 or 9 or 10 or 11 or 12 | 3625104 | |
| 14 | | Cannabis | Cannabis/ | 12307 |
| 15 | | | "Marijuana Use"/ | 1689 |
| 16 | | | Marijuana Abuse/ | 6905 |
| 17 | Marijuana Smoking/ | | 5425 | |
| 18 | (mari?uana or cannabis or hashish or Pot or weed or tetrahydrocannabinol or THC or CDB or cannabidiol or cannabinoid?).ab,kf,ti. | | 100005 | |
| 19 | 14 or 15 or 16 or 17 or 18 | | 102988 | |
| 20 | Strategies | ("strateg*" or "approach*" or intervention? or prevent* or practice? or service? or "method*" or technique? or tactic? or co?nseling or treatment? or program? or "guide*").ab,kf,ti. | 15074452 | |
| 21 | Combination of 3 concepts | 5 and 13 and 19 | 272 | |
| 22 | Limit date | limit 21 to yr="1990 -Current" | 272 | |
| 23 | Limit language | limit 22 to (english or french) | 263 | |
| 24 | Filter OECD | | | |
| 25 | TOTAL | 23 not 24 | 249 | |
| 22 | Combination of 4 concepts | 5 and 13 and 19 and 20 | 251 | |

Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist

| SECTION | ITEM | PRISMA-ScR CHECKLIST ITEM | REPORTED ON PAGE # |
|---|------|--|--------------------|
| TITLE | | | |
| Title | 1 | Identify the report as a scoping review. | |
| ABSTRACT | | | |
| Structured summary | 2 | Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results, and conclusions that relate to the review questions and objectives. | |
| INTRODUCTION | | | |
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach. | |
| Objectives | 4 | Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts, and context) or other relevant key elements used to conceptualize the review questions and/or objectives. | |
| METHODS | | | |
| Protocol and registration | 5 | Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number. | |
| Eligibility criteria | 6 | Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language, and publication status), and provide a rationale. | |
| Information sources* | 7 | Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed. | |
| Search | 8 | Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated. | |
| Selection of sources of evidence† | 9 | State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review. | |
| Data charting process‡ | 10 | Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was done independently or in duplicate) and any processes for obtaining and confirming data from investigators. | |
| Data items | 11 | List and define all variables for which data were sought and any assumptions and simplifications made. | |
| Critical appraisal of individual sources of evidence§ | 12 | If done, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate). | |
| Synthesis of results | 13 | Describe the methods of handling and summarizing the data that were charted. | |



| SECTION | ITEM | PRISMA-ScR CHECKLIST ITEM | REPORTED ON PAGE # |
|---|------|---|--------------------|
| RESULTS | | | |
| Selection of sources of evidence | 14 | Give numbers of sources of evidence screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram. | |
| Characteristics of sources of evidence | 15 | For each source of evidence, present characteristics for which data were charted and provide the citations. | |
| Critical appraisal within sources of evidence | 16 | If done, present data on critical appraisal of included sources of evidence (see item 12). | |
| Results of individual sources of evidence | 17 | For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives. | |
| Synthesis of results | 18 | Summarize and/or present the charting results as they relate to the review questions and objectives. | |
| DISCUSSION | | | |
| Summary of evidence | 19 | Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups. | |
| Limitations | 20 | Discuss the limitations of the scoping review process. | |
| Conclusions | 21 | Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps. | |
| FUNDING | | | |
| Funding | 22 | Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review. | |

JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews.

* Where *sources of evidence* (see second footnote) are compiled from, such as bibliographic databases, social media platforms, and Web sites.

† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping review as opposed to only studies. This is not to be confused with *information sources* (see first footnote).

‡ The frameworks by Arksey and O'Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to the process of data extraction in a scoping review as data charting.

§ The process of systematically examining research evidence to assess its validity, results, and relevance before using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy document).

From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med.* 2018;169:467–473. doi: 10.7326/M18-0850.



BMJ Open

Facilitators of and barriers to healthcare providers' adoption of harm reduction in cannabis use: a scoping review protocol

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2023-078427.R1 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 28-Feb-2024 |
| Complete List of Authors: | Haddad, Roula; Université de Montréal Faculté des Arts et des Sciences, Department of Psychology Dagenais, Christian; Université de Montréal Faculté des Arts et des Sciences, Department of Psychology Huynh, Christophe ; Institut Universitaire sur les Dépendances, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l'Île-de-Montréal ; Université de Montreal Département de Psychiatrie Fallu, Jean-Sébastien; University of Montreal, Psychoeducation; Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l'Île-de-Montréal du Québec, Centre de recherche en santé publique (CReSP) |
| Primary Subject Heading: | Addiction |
| Secondary Subject Heading: | Public health, Research methods |
| Keywords: | PUBLIC HEALTH, MENTAL HEALTH, Substance misuse < PSYCHIATRY, Health Services |
| | |

SCHOLARONE™
Manuscripts

Facilitators of and barriers to healthcare providers' adoption of harm reduction in cannabis use: a scoping review protocol

Roula Haddad¹, Christian Dagenais¹, Christophe Huynh^{2,3}, Jean-Sébastien Fallu^{2,4,5}

¹ Department of Psychology, Université de Montréal

² University Institute on Addictions, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l'Île-de-Montréal

³ Department of Psychiatry and Addictology, Université de Montréal

⁴ School of Psychoeducation, Université de Montréal

⁵ Centre de recherche en santé publique (CReSP), Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l'Île-de-Montréal

Correspondence to Roula Haddad; roula.haddad@umontreal.ca

ABSTRACT

Introduction. The high prevalence of cannabis use and the potential for negative effects indicate the need for effective prevention strategies and treatment of people who use cannabis (PWUC). Studies show that harm reduction (HR) in cannabis use is effective in minimizing the harmful consequences of the substance. However, health professionals often misunderstand it and resist its adoption due to various obstacles. To our knowledge, there has been no review of the scientific literature on the factors that facilitate or hinder practitioners' adoption of HR in cannabis use. To fill this gap, we aim to identify, through a scoping review, facilitators and barriers to healthcare providers' adoption of HR in cannabis use in Organisation for Economic Cooperation and Development (OECD) countries.

Methods and analysis. Our methodology will be guided by the six-step model initially proposed by Arksey and O'Malley (2005). The search strategy will be executed on different databases (Medline, PsycINFO, CINAHL, Web of Science, Embase, Sociological Abstracts, Érudit, BASE, Google Web, and Google Scholar) and will cover articles published between 1990 and October 2022. Empirical studies published in French or English in an OECD country and identifying factors

1
2
3 that facilitate or hinder healthcare providers' adoption of HR in cannabis use, will be included.
4 Reference lists of the selected articles as well as relevant systematic reviews will be scanned to
5 identify any missed publications by the electronic searches.
6
7
8
9

10 **Ethics and dissemination.** Ethics approval is not required. The results will be disseminated
11 through various activities (e.g., publication in peer-reviewed journals, conferences, webinars, and
12 knowledge translation activities). The results will also allow us to conduct a future study aiming
13 to develop and implement a knowledge translation process among healthcare practitioners working
14 with youth in Quebec in order to enhance their adoption of HR in cannabis use.
15
16
17
18
19

20 **Strengths and limitations of this study**

- 21 - The search strategy was co-developed by two information management specialists in the
22 addiction and knowledge translation fields.
23
- 24 - The search strategy will aim to retrieve published articles on several health databases and
25 unpublished studies found in the grey literature.
26
- 27 - Two reviewers will independently select the studies to be included in the scoping review
28 throughout the entire study selection stage.
29
- 30 - The included studies will be limited to those published in French or English.
31
- 32 - The included studies will be limited to those published in OECD countries.
33
34
35
36
37

38 **Key words:** *harm reduction; cannabis; knowledge translation; healthcare*
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Cannabis use

Psychoactive substances (e.g., cannabis, alcohol, nicotine) are defined as substances whose use affects mental processes (e.g., perception, cognition, emotions, mood) and behaviors without necessarily leading to addiction (1). After tobacco and alcohol, cannabis represents the third most consumed psychoactive substance globally among adults and youth (2-5). Canada remains among the developed countries with the highest rates of cannabis use among young people and adults, with high prevalence in Quebec and multiple patterns of use (e.g., smoking, eating, vaporizing, vaping) (2, 5-9). In 2023, 26% of those 16 years of age and older reported using cannabis in the 12 months prior to the study, with a higher prevalence among those aged between 20 to 24 years old (10).

Cannabis use does not necessarily lead to dependence due to several factors such as infrequency in use, consumption of cannabis with low rates of δ -9-tetrahydrocannabinol (THC), availability, legality, and social acceptability (9, 11-15). The lifetime cumulative probability of transitioning from use to dependence was found to be the lowest for people who use cannabis (PWUC) (8.9%) compared to other substances such as nicotine (67.5%), alcohol (22.7%), and cocaine (20.9%) (15). Even with long-term exposure to cannabis, PWUC do not necessarily develop severe problems or a cannabis-dependence (5, 15, 16).

However, PWUC intensively or at-risk populations (i.e., pregnant persons, people presenting respiratory problems, a mental health comorbidity, having an early onset of continued tobacco use or concurrently smoking tobacco and cannabis) may develop a cannabis use disorder or experience harm at several levels (5, 12, 16-19). These harms may include a decreased academic or professional performance, a cognitive impairment, a deterioration of mental health (e.g., development of psychosis or depression), an increased occurrence of risky behaviors (e.g., cannabis-impaired driving), etc. (3-5, 12, 14, 18, 20-22). It is important to specify that a severe cannabis-induced mental health condition (e.g., psychosis) might occur among only 2% of PWUC (5). Despite the minimal probability of leading to potentially serious adverse consequences, the high prevalence of cannabis use as well as the potential harms that might be experienced, make it essential to implement effective intervention programs among PWUC (7, 12, 15, 17).

Abstinence approach

To address this reality, prevention and treatment programs based on the abstinence approach (i.e., total elimination of cannabis use), have been widely implemented (11, 13). The emergence of these programs has been also influenced by policies such as the “War on Drugs” (23). The abstinence-based model forms the basis of many programs developed to prevent or treat problematic cannabis use and has been applied with at-risk or marginalized populations (e.g., youth in the foster care system) (21, 24). Despite its potential to decrease the frequency or amount of substance use, the abstinence approach presents limited evidence to support its effectiveness and has been criticized for various reasons (21, 24-26). First, it does not provide PWUC with the necessary skills to identify and mitigate the harms associated with their use (21, 27). Second, the abstinence approach tends to focus more on the negative consequences of use through strategies that evoke fear, without necessarily taking into consideration the social context of cannabis use (20, 21). Third, the risks of relapse and dropout in these programs are also found to be high, leaving a significant number of PWUC for whom this goal remains unattainable (20, 28). Given these limitations of abstinence-oriented programs, other alternative and more flexible treatments, such as harm reduction (HR), are essential to reduce and mitigate cannabis-related harms (14, 21, 28, 29).

Harm reduction (HR)

Description

HR in cannabis use aims to minimize the harmful consequences of the substance at the individual, psychological, legal, and social levels among PWUC (19, 20, 28, 29). It offers a public health framework based on values of pragmatism and humanism, as it does not view substance use through a moral lens, but as an inevitable societal fact of long-standing (4, 11, 30, 31). Whether among adults or adolescents, elimination of substance use is unrealistic at the population level and should be the individual’s choice without being imposed, as it represents an unwanted and impractical goal for some (e.g., in case of recreational or occasional use, in case of dual diagnosis combining psychiatric and substance use disorders) (27-29, 32, 33). HR in cannabis use also seeks to equip PWUC to make responsible and rational decisions and learn ways to reduce the negative consequences associated with their consumption (11, 12, 20, 27, 29, 31). To this end, HR clarifies the notion of safe substance use that is determined by the interaction of three components: the individual (height, weight, gender, physical and mental health status, state of mind, etc.); the drug

1
2
3 (quantity, frequency of use, tolerance to the product, combination with other products, quality,
4 etc.); and the setting (location, time of day, interpersonal relationships, conflicts, laws, etc.) (4, 20,
5 27). In addition, HR takes into account the personal characteristics of PWUC (impulsivity,
6 sensation-seeking, etc.) and addresses their potential ambivalence about stopping substance use,
7 their feelings of failure upon relapse, their engagement in treatment, their social skills, their
8 emotional regulation, etc. (20). In the “Lower Risk Cannabis Use Guidelines”, Fischer (5) updated
9 the initial recommendations to reduce the harms of cannabis use. These recommendations include
10 delaying the initiation of cannabis use until late adolescence or the completion of puberty,
11 consuming low-potency cannabis products, avoiding deep inhalation, using legal and quality-
12 controlled cannabis products, etc. (5).
13
14
15
16
17
18
19
20
21

22 HR effectiveness

23
24 Interventions based on HR for non-injected drugs have been studied across various populations
25 (e.g., youth, adults, people in housing programs presenting mental health conditions) and have
26 shown promising results in decreasing the negative consequences associated with substance use
27 (20, 28).
28

29
30 Several studies showed the effectiveness of HR strategies and current school-based HR programs
31 (e.g., SHAHRP in the United Kingdom and SCIDUA in Canada) in developing safer attitudes
32 toward substance use and in reducing negative consequences related to use (21, 22, 34, 35). The
33 effectiveness of HR among youth who use cannabis has led the University Institute on Addictions
34 (*Institut universitaire sur les dépendances*) in Quebec to recommend it as an intervention modality
35 among this clientele (36). In addition, effective early interventions targeting college and university
36 students with at-risk cannabis use are those that reduce the harms associated with cannabis use
37 (17, 36-38). Moreover, Palfai (38) found that students participating in a web-based HR
38 intervention (Marijuana eCHECKUP TO GO) showed statistically significant lower results in peer
39 cannabis use after six months ($f^2 = .11$, $[B = 7.45 (3.34), p < .05]$).
40
41
42
43
44
45
46
47

48 HR in cannabis use was also found effective among adults (17, 39). After delivering a brief HR
49 intervention for PWUC, Fischer (17) found significant reductions in risk outcome indicators only
50 among the experimental group. At the 12th month follow-up, a change was maintained for “deep
51 inhalation/breath-holding” (experimental group: $Q = 13.1; p < .05$; control group: $Q = 4.8; p > .05$),
52 and “driving after cannabis use” (experimental group: $Q = 9.3; p < .05$; control group: $Q = 0.9; p >$
53
54
55
56
57
58
59
60

1
2
3 .05) (17). Furthermore, without completely abstaining from the substance, a functional
4 improvement can be reached by treatment-seeking adults presenting a cannabis use disorder when
5 they reduce the frequency and/or quantity of cannabis use (39). Reduction in the frequency of
6 cannabis use was associated with a decrease in depression ($F = 2.76, p = .04, n_p^2 = .04$), anxiety (F
7 $= 3.70, p = .01, n_p^2 = .05$), and cannabis-related problems ($F = 8.95, p < .001, n_p^2 = .12$) (39). In
8 addition, a decrease in the quantity of cannabis consumption was associated with a decrease in
9 anxiety ($F = 3.02, p = .03, n_p^2 = .04$) and cannabis-related problems ($F = 3.24, p = .02, n_p^2 = .05$)
10 (39). A systematic review also highlighted that the adoption of HR strategies by PWUC acts as a
11 protective factor for people with poor mental health, low self-regulation, high impulsivity, and
12 high negative urgency (22).
13
14
15
16
17
18
19
20
21

22 Acceptability of harm reduction

23
24 Despite its proven effectiveness, the acceptability and applicability of HR by health and social
25 services practitioners remain limited, and various factors facilitate or hinder its adoption (21, 40-
26 42). MacCoun (43) showed that, among practitioners who did not adopt HR, some had based their
27 decision on moral grounds, regardless of its effectiveness. Various barriers limit its use by
28 practitioners. First, ambiguities in its conceptualization play an influential role; for example, some
29 practitioners perceive HR as sending the wrong message, i.e., one of tolerating or even
30 encouraging substance use (27, 28, 30, 44). Some do not perceive total cessation of substance use
31 as a legitimate goal that could be achieved through HR (45). Also, there is often confusion between
32 reducing use (frequency, quantity, etc.) and reducing harm (modifying consumption practices,
33 such as contexts and mixtures, to reduce consequences) (30). These misconceptions point to the
34 need for awareness-raising, training, and supervision of practitioners interested in this approach
35 (28). Second, the adoption of HR can be hindered by ethical dilemmas, as well as by issues related
36 to the personal and collective values of healthcare workers and the therapeutic model of abstinence
37 (30). Indeed, it runs counter to traditional treatments by tolerating risky behaviors and accepting
38 that HR in drug use is a legitimate outcome (30, 44). Practitioners may also fear the emergence of
39 legal, social, and health problems among their clients (28). Third, its adoption may be limited by
40 contextual barriers, such as lack of funding, stigma that undermines demand for care, resistance
41 from local jurisdictions, and lack of services and trained personnel, particularly in the mental
42 health sector (41). Healthcare providers' resistance to applying HR in cannabis use leads to limited
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 knowledge and utilization of effective HR techniques and guidelines among PWUC (5, 25).
4 Among the study's participants (i.e., PWUC), Kruger (25) found that less than half of the
5 participants believed that the listed HR techniques were effective and reported applying them.
6
7 However, several factors seen as HR benefits have been found to facilitate its implementation by
8 healthcare providers, such as: broadening the spectrum of acceptable goals, improving clients'
9 decision-making skills, creating positive and quality relationships, and managing relapses (28). A
10 study by Sharp (41) showed that clarifying the positive impacts of HR at the community level
11 (e.g., safety) and ensuring the availability of resources could increase the likelihood of its adoption.
12
13
14
15
16
17
18

19 **Purpose**

20 Despite its proven effectiveness, several reasons might hinder HR adoption by health professionals
21 among PWUC (30, 41). However, to date, there has been no review of the scientific literature that
22 identifies the factors that facilitate or limit the adoption of HR in cannabis use. To fill this gap, we
23 aim to identify, through a scoping review, facilitators and barriers to healthcare providers' adoption
24 of HR in cannabis use.
25
26
27
28
29
30

31 **METHODS AND ANALYSIS**

32
33 This study will follow the methodological steps of scoping reviews (46). This type of review has
34 become more prevalent in recent years and is a type of knowledge synthesis review (46, 47). There
35 is no universal definition for scoping reviews; however, a variety of factors distinguish them from
36 other types of knowledge synthesis (48). First, scoping reviews address broad research questions
37 and include studies with different designs and multiple sources of evidence to provide an overview
38 of the available knowledge around a concept (49). On the contrary, a systematic review following
39 Cochrane standards explores more specific research questions based on detailed inclusion and
40 exclusion criteria (50-52). Second, while assessment of the methodological quality of included
41 studies is recommended for scoping reviews, it is not mandatory, whereas assessment of the risk
42 of bias of included studies is required for Cochrane-type systematic reviews (50, 52). Researchers
43 undertake scoping reviews for a variety of reasons: 1) to review research activity in a given area;
44 2) to determine the feasibility and appropriateness of conducting a systematic review based on
45 Cochrane standards; 3) to summarize and disseminate the results of existing research on a topic;
46 and/or 4) to identify a gap in the literature and draw conclusions regarding a topic (49). Our
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 methodological choice is underpinned by three of these reasons: once the research activity around
4 the topic has been consulted, the findings will be summarized and used to support a second study
5 aimed at disseminating knowledge to practitioners through a knowledge translation process. This
6 will also allow us to identify gaps in the literature and draw conclusions related to the topic.
7
8

9
10 Arksey and O'Malley (49) were the first to propose a six-step model for conducting scoping
11 reviews. Our methodology will be guided by this model, which was later refined by Levac (48)
12 and revised by members of the Joanna Briggs Institute (50). The six stages we will follow are:
13

- 14 - Stage 1: Determining the research question and the objective
- 15 - Stage 2: Identifying relevant studies
- 16 - Stage 3: Selecting studies
- 17 - Stage 4: Charting the data
- 18 - Stage 5: Collating, summarizing, and reporting the results
- 19 - Stage 6: Conducting a consultation exercise

20
21
22 The research protocol will be reported using the Preferred Reporting Items for Systematic Reviews
23 and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) grid (47). This grid is an
24 extension of the PRISMA grid originally developed for Cochrane-type systematic reviews and
25 helps to ensure the transparency and reproducibility of the study (47, 50).
26
27
28
29
30
31

32 33 34 **Stage 1: Determining the research question and the objective**

35
36 Arksey and O'Malley's (49) model suggests that scoping reviews should begin not only with
37 identifying research questions but also with clarifying the resulting objectives (48, 50). Our
38 scoping review is exploratory and aims to identify facilitators and barriers to healthcare providers'
39 adoption of HR in cannabis use in OECD countries. Based on the Population–Concept–Context
40 (PCC) model, which allows the broad scope of the study to be respected without specifying
41 restrictive inclusion criteria (50), we formulated the research question: What factors influence
42 providers (population) in the healthcare field (context) to adopt HR in cannabis use (concept)?
43 Specific research questions associated with the components of the PCC model were also identified.
44
45
46
47
48

- 49 - Question 1, related to the concept and context components: What are the facilitators and
50 barriers to healthcare providers' adoption of HR in cannabis use?
51
52
- 53 - Question 2, related to the population component: Who is the clientele of the providers
54 identified in the studies?
55
56
57
58
59
60

- 1
2
3 - Question 3, related to the concept component: What is the definition of HR in cannabis
4 use?
5
6
7

8 **Stage 2: Identifying relevant studies**

9 Search strategy

10
11 The search strategy was developed through an iterative process. A senior librarian at the Quebec
12 Addiction Library (*Bibliothèque québécoise sur les dépendances*) first developed three search
13 strategies with different concepts and ran them on the Medline database. The first 50 results of
14 each strategy were consulted, which led us to opt the one that grouped key terms related to the
15 following concepts: harm reduction, clinicians, and cannabis (see Supplemental Appendix 1). The
16 search strategy was then reviewed by a second information professional working in the RENARD
17 Team for Knowledge Translation who, in turn, adapted it to the selected databases. The final search
18 strategy executed on all the databases was then validated by the RENARD Team information
19 specialist. The Peer Review of Electronic Search Strategies (PRESS) tool served as a guide for the
20 librarians in this process (53). The search strategy executed on each database is presented in
21 Supplemental Appendix 1. All search strategies were executed on October 10th, 2022.
22
23
24
25
26
27
28
29
30
31

32 Information sources

33
34 To identify relevant published and unpublished studies for inclusion in the study, various sources
35 of information will be reviewed (46, 49, 50). With the guidance of the two librarians, the search
36 strategy will be executed on the leading health and intervention databases: Medline, PsycINFO,
37 Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, Embase,
38 and Sociological Abstracts. To explore the grey literature (e.g., theses, research reports, etc.), the
39 search strategy will be adapted to the Google Web and Google Scholar search engines, as well as
40 the Érudit (French database) and BASE databases. All documents identified will be entered into
41 Zotero software for the research team members to access. To identify any missed publication by
42 the electronic searches, reference lists of selected articles will be manually searched and relevant
43 systematic reviews will be scanned to identify their included studies.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Stage 3: Study selection

After running the search strategy on the selected databases and completing the second stage, all identified duplicates will be removed. The remaining documents will then be entered into Covidence software. Two reviewers will independently select relevant documents for inclusion by reading the titles and abstracts of the identified studies. Their decisions will be based on the specified inclusion and exclusion criteria. The inter-rater agreement between the reviewers will first be calculated and then they will meet regularly to resolve selection conflicts and refine the eligibility criteria as needed. After this first step, the documents selected and deemed potentially relevant will then be the subject of the second step, the full-text reading. Again, the two reviewers will independently record their choices on Covidence. The inter-rater agreement for this step will be calculated and the reviewers will then resolve any new conflicts. A third reviewer will be called upon as needed for any conflict resolution. This will complete the document selection stage, whose steps will be presented in a PRISMA diagram (54).

Inclusion and exclusion criteria

Inclusion and exclusion criteria have been specified and will be fine-tuned as needed to select relevant studies (Table 1). Using this process, empirical studies of quantitative, qualitative, or mixed designs, identifying factors that facilitate or hinder healthcare providers' adoption of HR in cannabis use, will be selected. To facilitate comparison and generalization of the results to the Quebec context, the review will be limited to studies conducted in any of the 38 OECD countries. Articles published between 1990 and October 2022 will be included, as it was early in that decade that HR gained international prominence and its scope of application began to expand. Papers not meeting these inclusion criteria will be excluded. Systematic reviews will be excluded to avoid duplication and ensure equal representation of the selected papers; the executed search strategy might have already captured studies included in a potentially relevant systematic review. However, systematic reviews' reference lists will be examined to identify additional relevant studies that might be selected.

Table 1. Inclusion and exclusion criteria

| Criteria | Inclusion criteria | Exclusion criteria |
|---|--|---|
| Type of study | - Empirical study: quantitative, qualitative, or mixed | - Study that does not present empirical results (e.g., theoretical study, conceptual framework, etc.) or knowledge review (e.g., systematic or literature review) - Interviews |
| Type of documents | - Peer-reviewed scientific articles, research reports, dissertations, theses | - Books and practice guides |
| Conceptual framework | - Harm reduction (HR) in cannabis use - Cannabis risk reduction - Non-abstinence in cannabis use | - Another conceptual framework |
| Objective | - Identification of factors ¹ facilitating or hindering practitioners' adoption of HR ² in cannabis use | - Evaluation of the effectiveness of interventions based on HR OR - Stakeholder perceptions of the use of cannabis as an HR strategy to circumvent the effects of other drugs OR - Attitudes toward decriminalization of cannabis |
| Psychoactive substance being studied | - Marijuana, hashish, or cannabis for non-medical purposes - "Drug" if cannabis is part of its conceptualization in the study | - Any substance other than marijuana, hashish, or non-medical cannabis (e.g., tobacco, alcohol, medical cannabis, MDMA, Ecstasy) - Study that focuses on "performance and image enhancing drugs" or "crack" or "new psychoactive substances" |
| Target population | - Practitioners ³ working in the health field - Practitioners in training | - PWUC ⁴ |
| Country of study | - OECD countries | - Other countries |
| Publication date | - From 1990 onwards | - Before 1990 |
| Language | - French and/or English | - Languages other than French or English or text not available |

¹ "Factors" include perceptions, beliefs, facilitators, obstacles, oppositions, attitudes, opinions, barriers, biases, motivations, preferences, determinants, incentives, influences, and perspectives on the adoption of HR in cannabis use, as well as its acceptability and receptivity.

² “Approach” refers to strategies, interventions, practices, services, methods, techniques, treatments, programs, or guides for the HR approach in cannabis use.

³ “Practitioners” include healthcare personnel, professionals, or practitioners, allied healthcare personnel, professionals, or practitioners, social workers, counselors, psychoeducators, educators, nurses, criminologists, psychologists, clinicians, caregivers, therapists, psychotherapists, and physicians.

⁴ Studies addressing the views of people who use cannabis (PWUC) regarding HR or its adoption by practitioners will be excluded.

Stage 4: Charting the data

To analyze the selected studies on a common basis, specific variables of interest will be identified based on the research questions (49). These will form the components of summary sheets that will be developed in Microsoft Excel and used to extract results (Table 2). This method is an analytical descriptive recording of the data (49, 50, 55). The first author (RH) will extract the data from the included studies and create the summary sheets. The research supervisor (CD) will validate the summary sheets throughout the process and ensure their alignment with the research questions (50).

Table 2. Summary sheets

| General variables | Specific variables |
|---|---|
| General characteristics of the study | Study title Author(s) Language of publication Date of publication Period of publication Journal Type of article Full reference Country of study Psychoactive substance under study The legal status of cannabis in the country of study |
| Introduction | Main concepts Definition of the main concept: HR in cannabis use Research question(s) Objective(s) Hypothesis |
| Methodology | Study design |

| | |
|-------------------|--|
| | Target population |
| | Place of work of the target population |
| | Inclusion criteria of participants |
| | Recruitment method |
| | Sample size |
| | Country of origin of participants |
| | The clientele of the population recruited |
| | Data collection method |
| | Analysis steps |
| Results | Sample presentation |
| | Key findings: 1) facilitators and 2) barriers to practitioners' adoption of HR in cannabis use |
| | Secondary outcomes or other results |
| Conclusion | Study strengths |
| | Study limitations |
| | Gaps in the literature and future research needs |

Stage 5: Collating, summarizing, and reporting the results

Based on the eligibility criteria, studies deemed relevant will be collected, summarized, and reported. They will be subjected to 1) a numerical analysis, and 2) a narrative organization encompassing a descriptive qualitative analysis (47, 49, 50). A numerical analysis of the scope, nature, and distribution of the included studies will be performed to various characteristics: date of publication, country of origin of the studies, and type of document. Subsequently, a narrative organization of the results will be produced to identify the relationships between the data and the research questions. The summary sheets will be combined, tabulated, and synthesized, and will then be subjected to a descriptive qualitative analysis (Table 3).

Table 3. Narrative organization of the included studies

| Data | Study 1 | Study 2 | Study ... |
|--|---------|---------|-----------|
| Type of publication | | | |
| Date of publication | | | |
| Country of study | | | |
| Legal status of cannabis in the country of the study | | | |
| Definition of HR to cannabis use | | | |
| Design of the study | | | |

1
2
3 Target population

4 Place of work of the target population

5
6 The clientele of the target population

7
8 Data collection method

9 Key findings:

- 10 - Facilitators or enabling conditions
- 11 - Barriers or adverse conditions

12
13
14 Secondary outcomes

15 16 17 **Stage 6: Consultation exercise**

18
19 Expert consultation is an optional step that promotes methodological rigor in scoping reviews (49).
20
21 In this study, the project's supervisor and co-researchers will be solicited as consultants. Members
22 of the RENARD team and researchers involved in the field of substance use and harm reduction
23 will be consulted to help clarify findings and validate the resulting recommendations (49).
24
25 Consultations will be conducted: 1) after preliminary results have been obtained, and 2) after
26 analyses of the results have been completed.
27
28
29

30 31 **Patient and public involvement**

32 None.
33
34
35

36 37 **ETHICS AND DISSEMINATION**

38 To our knowledge, this is the first scoping review on factors that facilitate or hinder healthcare
39 providers' adoption of HR in cannabis use. Other reviews have studied HR interventions in general
40 among practitioners working with a specific population. This study will provide a clear picture of
41 the factors at play when adopting HR, and the results could potentially be generalizable to OECD
42 countries. The present study is exempt from ethics approval because it involves no patient or
43 personal data collection. The results are expected to be ready by March 2024. They will be
44 disseminated, alongside the scoping review protocol, through various activities (e.g., publication
45 in peer-reviewed journals, conferences, webinars, posters, *Three Minute Thesis* competition).
46
47 After completing the scoping review, we will be able to conduct a future study aiming to
48 implement a knowledge translation plan among practitioners working with youth in Quebec to
49 enhance and expand their adoption of HR in cannabis use.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Acknowledgments.** We wish to thank Karine Bélanger, senior librarian at the *Bibliothèque*
4 *québécoise sur les dépendances* in Quebec for developing the initial search strategy used in this
5 scoping review. We also wish to thank Julie Desnoyers, the information specialist affiliated with
6 the RENARD Team for Knowledge Translation at Université de Montréal, for validating the
7 search strategy and adapting it to the selected databases. Finally, we want to thank Donna Riley
8 for editing the manuscript.
9

10
11
12
13
14
15 **Contributors.** RH, CD, CH, and JSF conceptualized the study. RH drafted the protocol. CD, CH,
16 and JSF critically revised the manuscript. RH wrote the final draft manuscript and all the authors
17 approved it.
18
19

20
21
22 **Funding.** This work was supported by the *Ministère de la Santé et des Services sociaux* (MSSS),
23 *Fonds de recherche du Québec – Santé* (FRQS), and *Fonds de recherche du Québec – Société et*
24 *culture* (FRQSC) (Grant number: 2023-0PTR-322652). A grant obtained by the *Centre de*
25 *recherche en santé publique* (CReSP) helped in partially covering the revision and publication fees
26 of this scoping review protocol.
27
28
29

30
31
32 **Competing interests.** None declared.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FULL REFERENCES

1. World Health Organization. Drugs (psychoactive) [online]; 2022. https://www.who.int/health-topics/drugs-psychoactive#tab=tab_1 (accessed 13 Jul 2023).
2. Adinoff B, Cooper ZD. Cannabis legalization: progress in harm reduction approaches for substance use and misuse. *Am J Drug Alcohol Abuse* 2019;45(6):707–12. doi: 10.1080/00952990.2019.1680683.
3. Jiloha RC. Prevention, early intervention, and harm reduction of substance use in adolescents. *Indian J Psychiatry* 2017;59(1):111–8. doi: 10.4103%2F0019-5545.204444.
4. Melamed R. Harm reduction-the cannabis paradox. *Harm Reduct J* 2005;2(1):17. doi: 10.1186/1477-7517-2-17.
5. Fischer B, Robinson T, Bullen C, Curran V, Jutras-Aswad D, Medina-Mora ME, et al. Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. *Int J Drug Policy*. 2022;99:103381.
6. Poulin C, Elliott D. Alcohol, tobacco and cannabis use among Nova Scotia adolescents: implications for prevention and harm reduction. *CMAJ* 1997;156(10):1387–93. PMID: **9164396**.
7. Gouvernement du Québec. Plan d'action interministériel en dépendances 2018-2028 – Prévenir, réduire et traiter les conséquences associées à la consommation de substances psychoactives, à la pratique de jeux de hasard et d'argent et à l'utilisation d'Internet [online]. 2018. <https://publications.msss.gouv.qc.ca/msss/document-002078/> (accessed 13 Jul 2023).
8. Zuckermann AM, Gohari MR, Romano I, et al. Changes in cannabis use modes among Canadian youth across recreational cannabis legalization: data from the COMPASS prospective cohort study. *Addict Behav* 2021;122:107025. doi: 10.1016/j.addbeh.2021.107025.
9. Fischer B, Russell C, Sabioni P, Van Den Brink W, Le Foll B, Hall W, et al. Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. *Am J Public Health*. 2017;107(8):e1-e12.

- 1
2
3
4 10. Government of Canada. Canadian Cannabis Survey 2023: Summary [online]. 2023.
5 <https://www.canada.ca/fr/sante-canada/services/drogues->
6 [medicaments/cannabis/recherches-donnees/enquete-canadienne-cannabis-2023-](https://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/recherches-donnees/enquete-canadienne-cannabis-2023-sommaire.html#s2-2)
7 [sommaire.html#s2-2](https://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/recherches-donnees/enquete-canadienne-cannabis-2023-sommaire.html#s2-2) (accessed 13 Feb 2024).
8
9
- 10
11 11. Hathaway AD, Erickson PG. Drug reform principles and policy debates: harm reduction
12 prospects for cannabis in Canada. *J Drug Issues* 2003;33(2):465–95. doi:
13 10.1177/002204260303300209.
14
15
- 16
17 12. Swift W, Copeland J, Lenton S. Cannabis and harm reduction. *Drug Alcohol Rev*
18 2000;19(1):101–12. doi: 10.1080/09595230096200.
19
- 20
21 13. Stockings E, Hall WD, Lynskey M, et al. Prevention, early intervention, harm reduction, and
22 treatment of substance use in young people. *Lancet Psychiatry* 2016;3(3):280–96. doi:
23 10.1016/S2215-0366(16)00002-X.
24
25
- 26
27 14. Englund A, Freeman TP, Murray RM, McGuire P. Can we make cannabis safer? *Lancet*
28 *Psychiatry*. 2017;4(8):643-8. doi: 10.1016/S2215-0366(17)30075-5.
29
- 30
31 15. Lopez-Quintero C, de los Cobos JP, Hasin DS, Okuda M, Wang S, Grant BF, et al.
32 Probability and predictors of transition from first use to dependence on nicotine, alcohol,
33 cannabis, and cocaine: Results of the National Epidemiologic Survey on Alcohol and
34 Related Conditions (NESARC). *Drug Alcohol Depend*. 2011;115(1-2):120-30. doi:
35 10.1016/j.drugalcdep.2010.11.004.
36
37
- 38
39 16. Hindocha C, Shaban ND, Freeman TP, Das RK, Gale G, Schafer G, et al. Associations
40 between cigarette smoking and cannabis dependence: a longitudinal study of young cannabis
41 users in the United Kingdom. *Drug Alcohol Depend*. 2015;148:165-71. doi:
42 10.1016/j.drugalcdep.2015.01.004.
43
44
- 45
46 17. Fischer B, Jones W, Shuper P, et al. 12-month follow-up of an exploratory ‘brief
47 intervention’ for high-frequency cannabis users among Canadian university students. *Subst*
48 *Abuse Treat Prev Policy* 2012;7(1):15. doi: 10.1186/1747-597X-7-15.
49
50
- 51
52 18. Lemyre A, Poliakova N, Bélanger RE. The relationship between tobacco and cannabis use:
53 a review. *Subst Use Misuse*. 2019;54(1):130-45. doi: 10.1080/10826084.2018.1512623.
54
55
56
57
58
59

19. Winer JM, Yule AM, Hadland SE, Bagley SM. Addressing adolescent substance use with a public health prevention framework: the case for harm reduction. *Ann Med*. 2022;54(1):2123-36. doi: 10.1080/07853890.2022.2104922.
20. Bagot KS, Kaminer Y. Harm reduction for youth in treatment for substance use disorders: one size does not fit all. *Curr Addict Rep* 2018;5(3):379–85. doi: 10.1007/s40429-018-0217-8.
21. Jenkins EK, Slemon A, Haines-Saah RJ. Developing harm reduction in the context of youth substance use: insights from a multi-site qualitative analysis of young people’s harm minimization strategies. *Harm Reduct J* 2017;14(1):53. doi: 10.1186/s12954-017-0180-z.
22. González-Ponce BM, Rojas-Tejada AJ, Carmona-Márquez J, Lozano-Rojas ÓM, Díaz-Batanero C, Fernández-Calderón F. Harm reduction strategies among university students who use alcohol and cannabis, and related psychological variables: a systematic review. *J Psychoactive Drugs*. 2022;54(5):403-18. doi: 10.1080/02791072.2021.2023240.
23. Buchanan J, Young L. The war on drugs – a war on drug users? *Drugs (Abingdon Engl)* 2000;7(4):409–22. doi: 10.1080/dep.7.4.409.422.
24. Howe EJ, Bishop LD, Torraville BS, Rowe EC, Kinzel E, Donnan JR. Canadian cannabis education resources to support youth health literacy: A scoping review and environmental scan. *Health Educ J*. 2023;82(7):766-78. doi: 10.1177/00178969231191085.
25. Kruger JS, Kruger D, Collins RL. Knowledge and practice of harm reduction strategies among people who report frequent cannabis use. *Health Promot Pract*. 2021;22(1):24-30. doi: 10.1177/1524839920923999.
26. Watson TM, Valleriani J, Hyshka E, Rueda S. Cannabis legalization in the provinces and territories: missing opportunities to effectively educate youth? *Can J Public Health*. 2019;110:472-5. doi: 10.17269/s41997-019-00209-0.
27. Fallu J-S. Réduction des méfaits: histoire, concepts, pratiques, développements et enjeux [online]. *Journée de la toxicomanie*. Oral presentation, *Journée de la toxicomanie*, 23 Nov 2017; St-Liguori, Québec, Canada. https://www.reseautoxicomanie.com/wp-content/uploads/2017/12/Conférence-JS-Fallu_PNMVH-23-septembre-2017.pdf (accessed 13 Jul 2023).

- 1
2
3
4 28. Mancini MA, Linhorst DM, Broderick F, et al. Challenges to implementing the harm
5 reduction approach. *J Soc Work Pract Addict* 2008;8(3):380–408. doi:
6 10.1080/15332560802224576.
7
- 8
9 29. Karoll BR. Applying social work approaches, harm reduction, and practice wisdom to better
10 serve those with alcohol and drug use disorders. *J Soc Work* 2010;10(3):263–81. doi:
11 10.1177/1468017310363635.
12
- 13
14 30. Fallu J-S, Brisson P. La réduction des méfaits liés à l’usage des drogues: historique, état des
15 lieux, enjeux. In: Massé R, Mondou I, eds. *Réduction des méfaits et tolérance en santé*
16 *publique: enjeux éthiques et politique*. Presses de l’Université Laval 2013:105–27.
17
- 18
19 31. Ritter A, Cameron J. A review of the efficacy and effectiveness of harm reduction strategies
20 for alcohol, tobacco and illicit drugs. *Drug Alcohol Rev* 2006;25(6):611–24. doi:
21 10.1080/09595230600944529.
22
- 23
24 32. Lau N, Sales P, Averill S, Murphy F, et al. A safer alternative: cannabis substitution as harm
25 reduction. *Drug Alcohol Rev* 2015;34(6):654–9. doi: 10.1111/dar.12275.
26
- 27
28 33. Tsemberis S, Gulcur L, Nakae M. Housing first, consumer choice, and harm reduction for
29 homeless individuals with a dual diagnosis. *Am J Public Health* 2004;94(4):651–6. doi:
30 10.2105/AJPH.94.4.651.
31
- 32
33 34. McBride N, Farrington F, Midford R, et al. Harm minimization in school drug education:
34 Final results of the School Health and Alcohol Harm Reduction Project (SHAHRP).
35 *Addiction* 2004;99(3):278–91. doi: 10.1111/j.1360-0443.2003.00620.x.
36
- 37
38 35. Poulin C, Nicholson J. Should harm minimization as an approach to adolescent substance
39 use be embraced by junior and senior high schools?: empirical evidence from an integrated
40 school- and community-based demonstration intervention addressing drug use among
41 adolescents. *Int J Drug Policy* 2005;16(6):403–14. doi: 10.1016/j.drugpo.2005.11.001.
42
- 43
44 36. Bertrand K, Blanchette-Martin N, Dufour M, et al. Projet IP-Jeunes : recenser et promouvoir
45 les critères d’efficacité reconnus en intervention précoce auprès des jeunes présentant des
46 comportements à risque quant à la consommation d’alcool et d’autres drogues, à la pratique
47 des jeux de hasard et d’argent et à l’utilisation d’internet. Synthèse des résultats
48 préliminaires, 2019-2020 [online]. IUD: Institut universitaire sur les dépendances; 2020.
49
50
51
52
53
54
55
56
57
58
59

1
2
3
4 <https://chairejeunesse.ca/documentation/projet-ip-jeunes-recenser-et-promouvoir-les-criteres-defficacite-reconnus-en-intervention-precoce-aupres-des-jeunes-presentant-des-comportements-a-risque-quant-a-la-consommation-da/> (accessed 13 Jul 2023).
8

- 9 37. Grossbard JR, Mastroleo NR, Kilmer JR, et al. Substance use patterns among first-year
10 college students: secondary effects of a combined alcohol intervention. *J Subst Abuse Treat*
11 2010;39(4):384–90. doi: 10.1016/j.jsat.2010.07.001.
12
- 13 38. Palfai TP, Saitz R, Winter M, et al. Web-based screening and brief intervention for student
14 marijuana use in a university health center: pilot study to examine the implementation of
15 eCHECKUP TO GO in different contexts. *Addict Behav* 2014;39(9):1346–52. doi:
16 10.1016/j.addbeh.2014.04.025.
17
- 18 39. Sherman BJ, Sofis MJ, Borodovsky JT, Gray KM, McRae-Clark AL, Budney AJ. Evaluating
19 cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder.
20 *Psychol Addict Behav*. 2022;36(5):505. doi: 10.1037/adb0000760.
21
- 22 40. Fallu J-S, Gilbert-Lambert MH, D'Arcy Dubois L, et al. Prévention de la consommation à
23 risque ou problématique de substances psychoactives chez les jeunes hébergés en institution
24 au Québec [online]. Centre intégré universitaire de santé et de services sociaux du Centre-
25 Sud-de-l'Île-de-Montréal (Québec). Direction de l'enseignement universitaire et de la
26 recherche. Institut universitaire sur les dépendances. 2022. <https://iud.quebec/fr/etudes-et-recherche/programme-sur-lusage-et-les-dependances-aux-substances-puds/publications>
27 (accessed 13 Jul 2023).
28
- 29 41. Sharp A, Barnett JT, Vroom EB. Community perceptions of harm reduction and its
30 implications for syringe exchange policy. *J Drug Issues* 2020;50(4):507–23. doi:
31 10.1177/0022042620932289.
32
- 33 42. Lindenfeld Z, Franz B, Cronin C, Chang JE. Hospital adoption of harm reduction and risk
34 education strategies to address substance use disorders. *Am J Drug Alcohol Abuse*.
35 2023;49(2):206-15. doi: 10.1080/00952990.2023.2169832.
36
- 37 43. MacCoun RJ. Toward a psychology of harm reduction. *Am Psychol* 1998;53(11):1199–
38 1208. doi: 10.1037/0003-066X.53.11.1199.
39

- 1
2
3
4 44. Mancini MA, Wyrick-Waugh W. Consumer and practitioner perceptions of the harm
5 reduction approach in a community mental health setting. *Community Ment Health J*
6 2013;49(1):14–24. doi: 10.1007/s10597-011-9451-4.
7
8
9 45. Koutroulis G. “That original tension”. Negotiating abstinence in clinicians’ accounts of harm
10 reduction in nonresidential treatment of heroin withdrawal. *J Subst Abuse Treat*
11 2000;19(1):89–98. doi: 10.1016/S0740-5472(99)00087-2.
12
13
14 46. Peters MDJ, Godfrey CM, Khalil H, et al. Guidance for conducting systematic scoping
15 reviews. *Int J Evid Based Healthc* 2015;13(3):141–6. doi:
16 10.1097/XEB.0000000000000050.
17
18
19 47. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR):
20 checklist and explanation. *Ann Intern Med* 2018;169(7):467–73. doi: 10.7326/M18-0850.
21
22
23 48. Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology.
24 *Implement Sci* 2010;5(1):69. doi: 10.1186/1748-5908-5-69.
25
26
27 49. Arksey H, O’Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res*
28 *Methodol* 2005;8(1):19–32. doi: 10.1080/1364557032000119616.
29
30
31 50. Peters MDJ, Godfrey C, McInerney P, et al. Chapter 11: Scoping reviews. In: Aromataris E,
32 Munn Z, eds. *JBIM Manual for Evidence Synthesis*. JBI, 2020. doi: 10.46658/JBIMES-20-12.
33
34
35 51. Peterson J, Pearce PF, Ferguson LA, et al. Understanding scoping reviews: definition,
36 purpose, and process. *J Am Assoc Nurse Pract* 2017;29(1):12–6. doi: 10.1002/2327-
37 6924.12380.
38
39
40 52. Pollock D, Tricco AC, Peters MD, et al. Methodological quality, guidance, and tools in
41 scoping reviews: a scoping review protocol. *JBIM Evid Synth* 2022;20(4):1098–105. doi:
42 10.11124/JBIES-20-00570.
43
44
45 53. McGowan J, Sampson M, Salzwedel DM, et al. PRESS peer review of electronic search
46 strategies: 2015 guideline statement. *J Clin Epidemiol* 2016;75:40–6. doi:
47 10.1016/j.jclinepi.2016.01.021.
48
49
50 54. Gedda M. Traduction française des lignes directrices PRISMA pour l’écriture et la lecture
51 des revues systématiques et des méta-analyses [French translation of the PRISMA Reporting
52
53
54
55
56
57
58
59
60

1
2
3
4 Guidelines for writing and reading systematic reviews and meta-analyses]. *Kinesither Rev*
5 2015;15(157):39–44. doi: 10.1016/j.kine.2014.11.004.
6

- 7
8 55. Colquhoun HL, Levac D, O'Brien KK, et al. Scoping reviews: time for clarity in definition,
9 methods, and reporting. *J Clin Epidemiol* 2014;67(12):1291–4. doi:
10 10.1016/j.jclinepi.2014.03.013.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Facilitators of and barriers to healthcare providers' adoption of harm reduction in cannabis use: a scoping review protocol

Roula Haddad, Christian Dagenais, Christophe Huynh, Jean-Sébastien Fallu

Supplemental Appendix 1: Search strategies executed on all databases

Appendix 1: Medline Search Strategy

| # | Concept | Equations | Results |
|----|------------------------------------|---|----------|
| 1 | Harm reduction | Harm Reduction/ | 3898 |
| 2 | | Risk Reduction Behavior/ | 14132 |
| 3 | | (protective adj2 strateg*).ab,kf,ti. | 2818 |
| 4 | | ((reduc* or minimi*) adj5 (harm? or harmful or risk?)).ab,kf,ti. | 239459 |
| 5 | | 1 or 2 or 3 or 4 | 251821 |
| 6 | Clinicians | exp Health Personnel/ | 588634 |
| 7 | | Social Workers/ | 971 |
| 8 | | Counselors/ | 541 |
| 9 | | exp Health Occupations/ | 1819039 |
| 10 | | exp Allied Health Occupations/ | 52626 |
| 11 | | exp Allied Health Personnel/ | 53169 |
| 12 | | (worker? or psychoeducator? or psycho-educator? or educator? or nurse? or criminologist? or psychologist? or clinician? or practitioner? or physician? or professional? or provider? or co?nselor or co?nseors or caregiver? or giver? or therapist? or psychotherapist? or staff? or personnel? or employee? or doctor?).ab,kf,ti. | 2002544 |
| 13 | 6 or 7 or 8 or 9 or 10 or 11 or 12 | 3625104 | |
| 14 | Cannabis | Cannabis/ | 12307 |
| 15 | | "Marijuana Use"/ | 1689 |
| 16 | | Marijuana Abuse/ | 6905 |
| 17 | | Marijuana Smoking/ | 5425 |
| 18 | | (mari?uana or cannabis or hashish or Pot or weed or tetrahydrocannabinol or THC or CDB or cannabidiol or cannabinoid?).ab,kf,ti. | 100005 |
| 19 | 14 or 15 or 16 or 17 or 18 | 102988 | |
| 20 | Strategies | ("strateg*" or "approach*" or intervention? or prevent* or practice? or service? or "method*" or technique? or tactic? or co?nseing or treatment? or program? or "guide*").ab,kf,ti. | 15074452 |
| 21 | Combination of 3 concepts | 5 and 13 and 19 | 272 |
| 22 | Limit date | limit 21 to yr="1990 -Current" | 272 |
| 23 | Limit language | limit 22 to (english or french) | 263 |
| 24 | Filter OECD | | |
| 25 | TOTAL | 23 not 24 | 249 |
| 22 | Combination of 4 concepts | 5 and 13 and 19 and 20 | 251 |

Appendix 2: PsycINFO

(((((((title: (reduc*)) OR ((title: (minimi*)))) NEAR/5 (((title: (harm))) OR ((title: (harms))) OR
 ((title: (harmful))) OR ((title: (risk))) OR ((title: (risks)))) OR (((abstract: (reduc*)) OR ((abstract:
 (minimi*)))) NEAR/5 (((abstract: (harm))) OR ((abstract: (harms))) OR ((abstract: (harmful))) OR
 ((abstract: (risk))) OR ((abstract: (risks)))) OR (((Keywords: (reduc*)) OR ((Keywords:
 (minimi*)))) NEAR/5 (((Keywords: (harm))) OR ((Keywords: (harms))) OR ((Keywords:
 (harmful))) OR ((Keywords: (risk))) OR ((Keywords: (risks)))) OR (((title: (protective NEAR/2
 strateg*)))) OR (((abstract: (protective NEAR/2 strateg*)))) OR (((Keywords: (protective NEAR/2
 strateg*)))) OR (((MeSH: (Risk Reduction Behavior)))) OR (((MeSH: (Harm Reduction)))) AND
 (((MeSH: (Health Personnel)))) OR (((MeSH: (Social Workers)))) OR (((MeSH:
 (Counselors)))) OR (((MeSH: (Health Occupations)))) OR (((MeSH: (Allied Health
 Occupations)))) OR (((MeSH: (Allied Health Personnel)))) OR (((Keywords: (worker*)) OR
 ((Keywords: (psychoeducator*)) OR ((Keywords: (psycho-educator*)) OR ((Keywords:
 (educator*)) OR ((Keywords: (nurse*)) OR ((Keywords: (criminologist*)) OR ((Keywords:
 (psychologist*)) OR ((Keywords: (clinician*)) OR ((Keywords: (practitioner*)) OR
 ((Keywords: (physician*)) OR ((Keywords: (professional*)) OR ((Keywords: (provider*)) OR
 ((Keywords: (conselor)) OR ((Keywords: (conselors)) OR ((Keywords: (counselor)) OR
 ((Keywords: (counselers)) OR ((Keywords: (caregiver*)) OR ((Keywords: (giver*)) OR
 ((Keywords: (therapist*)) OR ((Keywords: (psychotherapist*)) OR ((Keywords: (staff*)) OR
 ((Keywords: (personnel*)) OR ((Keywords: (employee*)) OR ((Keywords: (doctor*)) OR
 ((abstract: (worker*)) OR ((abstract: (psychoeducator*)) OR ((abstract: (psycho-educator*))
 OR ((abstract: (educator*)) OR ((abstract: (nurse*)) OR ((abstract: (criminologist*)) OR
 ((abstract: (psychologist*)) OR ((abstract: (clinician*)) OR ((abstract: (practitioner*)) OR
 ((abstract: (physician*)) OR ((abstract: (professional*)) OR ((abstract: (provider*)) OR
 ((abstract: (conselor)) OR ((abstract: (conselors)) OR ((abstract: (counselor)) OR ((abstract:
 (counselers)) OR ((abstract: (caregiver*)) OR ((abstract: (giver*)) OR ((abstract: (therapist*))
 OR ((abstract: (psychotherapist*)) OR ((abstract: (staff*)) OR ((abstract: (personnel*)) OR
 ((abstract: (employee*)) OR ((abstract: (doctor*)))) AND (((Keywords: (marijuana)) OR
 ((Keywords: (marihuana)) OR ((Keywords: (cannabis)) OR ((Keywords: (hashish)) OR
 ((Keywords: (Pot)) OR ((Keywords: (weed)) OR ((Keywords: (tetrahydrocannabinol)) OR
 ((Keywords: (THC)) OR ((Keywords: (CDB)) OR ((Keywords: (cannabidiol)) OR ((Keywords:
 (cannabinoid)) OR ((Keywords: (cannabinoids)) OR (((abstract: (marijuana)) OR ((abstract:
 (marihuana)) OR ((abstract: (cannabis)) OR ((abstract: (hashish)) OR ((abstract: (Pot)) OR
 ((abstract: (weed)) OR ((abstract: (tetrahydrocannabinol)) OR ((abstract: (THC)) OR ((abstract:
 (CDB)) OR ((abstract: (cannabidiol)) OR ((abstract: (cannabinoid)) OR ((abstract:
 (cannabinoids)))) OR (((MeSH: (Marijuana Smoking)))) OR (((MeSH: (Marijuana Abuse))))
 OR (((MeSH: ("Marijuana Use")))) OR (((MeSH: (Cannabis)))) AND ((Year: [1990 TO
 9999])) NOT (((Keywords: (afghanistan/)) OR (Keywords: (africa/)) OR (Keywords: (africa,
 northern/)) OR (Keywords: (africa, central/)) OR (Keywords: (africa, eastern/)) OR (Keywords:
 ("africa south of the sahara" /)) OR (Keywords: (africa, southern/)) OR (Keywords: (africa,
 western/)) OR (Keywords: (albania/)) OR (Keywords: (algeria/)) OR (Keywords: (andorra/)) OR
 (Keywords: (angola/)) OR (Keywords: ("antigua and barbuda" /)) OR (Keywords: (argentina/))
 OR (Keywords: (armenia/)) OR (Keywords: (azerbaijan/)) OR (Keywords: (bahamas/)) OR
 (Keywords: (bahrain/)) OR (Keywords: (bangladesh/)) OR (Keywords: (barbados/)) OR
 (Keywords: (belize/)) OR (Keywords: (benin/)) OR (Keywords: (bhutan/)) OR (Keywords:
 (bolivia/)) OR (Keywords: (borneo/)) OR (Keywords: ("bosnia and herzegovina" /)) OR

1
2
3 (Keywords: (botswana/)) OR (Keywords: (brazil/)) OR (Keywords: (brunei/)) OR (Keywords:
4 (bulgaria/)) OR (Keywords: (burkina faso/)) OR (Keywords: (burundi/)) OR (Keywords: (cabo
5 verde/)) OR (Keywords: (cambodia/)) OR (Keywords: (cameroon/)) OR (Keywords: (central
6 african republic/)) OR (Keywords: (chad/)) OR (Keywords: (exp china/)) OR (Keywords:
7 (comoros/)) OR (Keywords: (congo/)) OR (Keywords: (cote d'ivoire/)) OR (Keywords: (croatia/))
8 OR (Keywords: (cuba/)) OR (Keywords: ("democratic republic of the congo" /)) OR (Keywords:
9 (cyprus/)) OR (Keywords: (djibouti/)) OR (Keywords: (dominica/)) OR (Keywords: (dominican
10 republic/)) OR (Keywords: (ecuador/)) OR (Keywords: (egypt/)) OR (Keywords: (el salvador/))
11 OR (Keywords: (equatorial guinea/)) OR (Keywords: (eritrea/)) OR (Keywords: (eswatini/)) OR
12 (Keywords: (ethiopia/)) OR (Keywords: (fiji/)) OR (Keywords: (gabon/)) OR (Keywords:
13 (gambia/)) OR (Keywords: ("georgia (republic)" /)) OR (Keywords: (ghana/)) OR (Keywords:
14 (grenada/)) OR (Keywords: (guatemala/)) OR (Keywords: (guinea/)) OR (Keywords: (guinea-
15 bissau/)) OR (Keywords: (guyana/)) OR (Keywords: (haiti/)) OR (Keywords: (honduras/)) OR
16 (Keywords: (independent state of samoa/)) OR (Keywords: (exp india/)) OR (Keywords: (indian
17 ocean islands/)) OR (Keywords: (indochina/)) OR (Keywords: (indonesia/)) OR (Keywords:
18 (iran/)) OR (Keywords: (iraq/)) OR (Keywords: (jamaica/)) OR (Keywords: (jordan/)) OR
19 (Keywords: (kazakhstan/)) OR (Keywords: (kenya/)) OR (Keywords: (kosovo/)) OR (Keywords:
20 (kuwait/)) OR (Keywords: (kyrgyzstan/)) OR (Keywords: (laos/)) OR (Keywords: (lebanon/)) OR
21 (Keywords: (liechtenstein/)) OR (Keywords: (lesotho/)) OR (Keywords: (liberia/)) OR
22 (Keywords: (libya/)) OR (Keywords: (madagascar/)) OR (Keywords: (malaysia/)) OR (Keywords:
23 (malawi/)) OR (Keywords: (mali/)) OR (Keywords: (malta/)) OR (Keywords: (mauritania/)) OR
24 (Keywords: (mauritiuS/)) OR (Keywords: (mekong valley/)) OR (Keywords: (melanesia/)) OR
25 (Keywords: (micronesia/)) OR (Keywords: (monaco/)) OR (Keywords: (mongolia/)) OR
26 (Keywords: (montenegro/)) OR (Keywords: (morocco/)) OR (Keywords: (mozambique/)) OR
27 (Keywords: (myanmar/)) OR (Keywords: (namibia/)) OR (Keywords: (nepal/)) OR (Keywords:
28 (nicaragua/)) OR (Keywords: (niger/)) OR (Keywords: (nigeria/)) OR (Keywords: (oman/)) OR
29 (Keywords: (pakistan/)) OR (Keywords: (palau/)) OR (Keywords: (exp panama/)) OR (Keywords:
30 (papua new guinea/)) OR (Keywords: (paraguay/)) OR (Keywords: (peru/)) OR (Keywords:
31 (philippines/)) OR (Keywords: (qatar/)) OR (Keywords: ("republic of belarus" /)) OR (Keywords:
32 ("republic of north macedonia" /)) OR (Keywords: (romania/)) OR (Keywords: (exp russia/)) OR
33 (Keywords: (rwanda/)) OR (Keywords: ("saint kitts and nevis" /)) OR (Keywords: (saint lucia/))
34 OR (Keywords: ("saint vincent and the grenadines" /)) OR (Keywords: ("sao tome and principe"
35 /)) OR (Keywords: (saudi arabia/)) OR (Keywords: (serbia/)) OR (Keywords: (sierra leone/)) OR
36 (Keywords: (senegal/)) OR (Keywords: (seychelles/)) OR (Keywords: (singapore/)) OR
37 (Keywords: (somalia/)) OR (Keywords: (south africa/)) OR (Keywords: (south sudan/)) OR
38 (Keywords: (sri lanka/)) OR (Keywords: (sudan/)) OR (Keywords: (suriname/)) OR (Keywords:
39 (syria/)) OR (Keywords: (taiwan/)) OR (Keywords: (tajikistan/)) OR (Keywords: (tanzania/)) OR
40 (Keywords: (thailand/)) OR (Keywords: (timor-leste/)) OR (Keywords: (togo/)) OR (Keywords:
41 (tonga/)) OR (Keywords: ("trinidad and tobago" /)) OR (Keywords: (tunisia/)) OR (Keywords:
42 (turkmenistan/)) OR (Keywords: (uganda/)) OR (Keywords: (ukraine/)) OR (Keywords: (united
43 arab emirates/)) OR (Keywords: (uruguay/)) OR (Keywords: (uzbekistan/)) OR (Keywords:
44 (vanuatu/)) OR (Keywords: (venezuela/)) OR (Keywords: (vietnam/)) OR (Keywords: (west
45 indies/)) OR (Keywords: (yemen/)) OR (Keywords: (zambia/)) OR (Keywords: (zimbabwe/)))
46 AND Any Field: - (((Keywords: (australasia/)) OR (Keywords: (exp australia/)) OR (Keywords:
47 (austria/)) OR (Keywords: (baltic states/)) OR (Keywords: (belgium/)) OR (Keywords: (exp
48 canada/)) OR (Keywords: (chile/)) OR (Keywords: (colombia/)) OR (Keywords: (costa rica/)) OR
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (Keywords: (czech republic/)) OR (Keywords: (exp denmark/)) OR (Keywords: (estonia/)) OR
4 (Keywords: (europe/)) OR (Keywords: (finland/)) OR (Keywords: (exp france/)) OR (Keywords:
5 (exp germany/)) OR (Keywords: (greece/)) OR (Keywords: (hungary/)) OR (Keywords:
6 (iceland/)) OR (Keywords: (ireland/)) OR (Keywords: (israel/)) OR (Keywords: (exp italy/)) OR
7 (Keywords: (exp japan/)) OR (Keywords: (korea/)) OR (Keywords: (latvia/)) OR (Keywords:
8 (lithuania/)) OR (Keywords: (luxembourg/)) OR (Keywords: (mexico/)) OR (Keywords:
9 (netherlands/)) OR (Keywords: (new zealand/)) OR (Keywords: (north america/)) OR (Keywords:
10 (exp norway/)) OR (Keywords: (poland/)) OR (Keywords: (portugal/)) OR (Keywords: (exp
11 "republic of korea" /)) OR (Keywords: ("scandinavian and nordic countries" /)) OR (Keywords:
12 (slovakia/)) OR (Keywords: (slovenia/)) OR (Keywords: (spain/)) OR (Keywords: (sweden/)) OR
13 (Keywords: (switzerland/)) OR (Keywords: (turkey/)) OR (Keywords: (exp united kingdom/)) OR
14 (Keywords: (exp united states/)) OR (Keywords: (European Union/)) OR (Keywords: (Developed
15 Countries/))))))
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix 3: CINAHL

| # | Question | Results |
|-----|---|-----------|
| S1 | MW "harm# reduction#" | 4,889 |
| S2 | MW "risk# reduction#" | 0 |
| S3 | TI protective N2 strateg* OR AB protective N2 strateg* OR SU protective N2 strateg* | 1,167 |
| S4 | SU ((reduc* or minimi*) N5 (harm# or harmful or risk#)) OR TI ((reduc* or minimi*) N5 (harm# or harmful or risk#)) OR AB ((reduc* or minimi*) N5 (harm# or harmful or risk#)) | 96,037 |
| S5 | S1 OR S2 OR S3 OR S4 | 97,005 |
| S6 | MW "Health Personnel#" | 112,080 |
| S7 | MW "Social Worker#" | 11,786 |
| S8 | MW Counselors | 4,471 |
| S9 | MW "Health Occupation#" | 5,719 |
| S10 | MW "Allied Health Occupation#" | 0 |
| S11 | MW "Allied Health Personnel#" | 4,781 |
| S12 | TI (worker or psychoeducator or psycho-educator or educator or nurse or criminologist or psychologist or clinician or practitioner or physician or professional or provider or counse#lor or counse#lors or caregiver or giver or therapist or psychotherapist or staff or personnel or employee or doctor) OR AB (worker or psychoeducator or psycho-educator or educator or nurse or criminologist or psychologist or clinician or practitioner or physician or professional or provider or counse#lor or counse#lors or caregiver or giver or therapist or psychotherapist or staff or personnel or employee or doctor) OR SU (worker or psychoeducator or psycho-educator or educator or nurse or criminologist or psychologist or clinician or practitioner or physician or professional or provider or counse#lor or counse#lors or caregiver or giver or therapist or psychotherapist or staff or personnel or employee or doctor) | 1,762,879 |
| S13 | S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 | 1,765,867 |

| | | |
|-----|---|---------|
| S14 | MW Cannabis | 11,138 |
| S15 | MW Marijuana | 2,219 |
| S16 | TI (mari#uana or cannabis or hashish or Pot or weed or tetrahydrocannabinol or THC or CDB or cannabidiol or cannabinoid#) OR AB (mari#uana or cannabis or hashish or Pot or weed or tetrahydrocannabinol or THC or CDB or cannabidiol or cannabinoid#) OR SU (mari#uana or cannabis or hashish or Pot or weed or tetrahydrocannabinol or THC or CDB or cannabidiol or cannabinoid#) | 26,526 |
| S17 | S14 OR S15 OR S16 | 26,526 |
| S18 | S5 AND S13 AND S17 | 147 |
| S19 | S5 AND S13 AND S17 | 147 |
| S20 | S5 AND S13 AND S17 | 147 |
| S21 | S5 AND S13 AND S17 | 72 |
| S22 | SU afghanistan/ or africa/ or africa, northern/ or africa, central/ or africa, eastern/ or "africa south of the sahara"/ or africa, southern/ or africa, western/ or albania/ or algeria/ or andorra/ or angola/ or "antigua and barbuda"/ or argentina/ or armenia/ or azerbaijan/ or bahamas/ or bahrain/ or bangladesh/ or barbados/ or belize/ or benin/ or bhutan/ or bolivia/ or borneo/ or "bosnia and herzegovina"/ or botswana/ or brazil/ or brunei/ or bulgaria/ or burkina faso/ or burundi/ or cabo verde/ or cambodia/ or cameroon/ or central african republic/ or chad/ or exp china/ or comoros/ or congo/ or cote d'ivoire/ or croatia/ or cuba/ or "democratic republic of the congo"/ or cyprus/ or djibouti/ or dominica/ or dominican republic/ or ecuador/ or egypt/ or el salvador/ or equatorial guinea/ or eritrea/ or eswatini/ or ethiopia/ or fiji/ or gabon/ or gambia/ or "georgia (republic)"/ or ghana/ or grenada/ or guatemala/ or guinea/ or guinea-bissau/ or guyana/ or haiti/ or honduras/ or independent state of samoa/ or exp india/ or indian ocean islands/ or indochina/ or indonesia/ or iran/ or iraq/ or jamaica/ or jordan/ or kazakhstan/ or kenya/ or kosovo/ or kuwait/ or kyrgyzstan/ or laos/ or lebanon/ or liechtenstein/ or lesotho/ or liberia/ or libya/ or madagascar/ or malaysia/ or malawi/ or | 159,916 |

| | | |
|-----|---|---------|
| | mali/ or malta/ or mauritania/ or mauritius/ or mekong valley/ or melanesia/ or micronesia/ or monaco/ or mongolia/ or montenegro/ or morocco/ or mozambique/ or myanmar/ or namibia/ or nepal/ or nicaragua/ or niger/ or nigeria/ or oman/ or pakistan/ or palau/ or exp panama/ or papua new guinea/ or paraguay/ or peru/ or philippines/ or qatar/ or "republic of belarus"/ or "republic of north macedonia"/ or romania/ or exp russia/ or rwanda/ or "saint kitts and nevis"/ or saint lucia/ or "saint vincent and the grenadines"/ or "sao tome and principe"/ or saudi arabia/ or serbia/ or sierra leone/ or senegal/ or seychelles/ or singapore/ or somalia/ or south africa/ or south sudan/ or sri lanka/ or sudan/ or suriname/ or syria/ or taiwan/ or tajikistan/ or tanzania/ or thailand/ or timor-leste/ or togo/ or tonga/ or "trinidad and tobago"/ or tunisia/ or turkmenistan/ or uganda/ or ukraine/ or united arab emirates/ or uruguay/ or uzbekistan/ or vanuatu/ or venezuela/ or vietnam/ or west indies/ or yemen/ or zambia/ or zimbabwe/ | |
| S23 | SU australasia/ or exp australia/ or austria/ or baltic states/ or belgium/ or exp canada/ or chile/ or colombia/ or costa rica/ or czech republic/ or exp denmark/ or estonia/ or europe/ or finland/ or exp france/ or exp germany/ or greece/ or hungary/ or iceland/ or ireland/ or israel/ or exp italy/ or exp japan/ or korea/ or latvia/ or lithuania/ or luxembourg/ or mexico/ or netherlands/ or new zealand/ or north america/ or exp norway/ or poland/ or portugal/ or exp "republic of korea"/ or "scandinavian and nordic countries"/ or slovakia/ or slovenia/ or spain/ or sweden/ or switzerland/ or turkey/ or exp united kingdom/ or exp united states/ OR European Union/ OR Developed Countries/ | 158,684 |
| S24 | S22 NOT S23 | 154,938 |
| S25 | S21 NOT S24 | 66 |

Appendix 4: Web of Science

| # | Question | Results |
|----|--|-----------|
| #1 | TS=(harm reduction OR risk reduction behavior OR (protective NEAR/2 strateg*) OR ((reduc* OR minimi*) NEAR/5 (harm OR harms OR harmful OR risk OR risks))) | 329,523 |
| #2 | TS=(cannabis OR marijuana OR mari\$uana OR hashish OR pot OR weed OR tetrahydrocannabinol OR THC OR CDB OR cannabidiol OR cannabinoid\$) | 305,377 |
| #3 | TS=(health personnel OR social worker\$ OR counselor\$ OR health occupation\$ OR worker\$ OR psychoeducator\$ OR psycho-educator\$ OR nurse\$ OR criminologist\$ OR psychologist\$ OR clinician\$ OR practitioner\$ OR physician\$ OR professional\$ OR provider\$ OR co\$nselor OR co\$nselors OR caregiver\$ OR giver\$ OR therapist\$ OR psychotherapist\$ OR staff\$ OR personnel\$ OR employee\$ OR doctor\$) | 2,593,408 |
| #4 | #1 AND #2 AND #3 | 331 |
| #5 | #4 and English or French (Languages) | 324 |
| #6 | #5 and [Countries/Regions filter: pays de l'OCDE] | 300 |
| | | |

Appendix 5: Embase

| | | |
|----|--|---------|
| 1 | Harm Reduction/ | 8189 |
| 2 | Risk Reduction Behavior/ | 115695 |
| 3 | (protective adj2 strateg*).ab,kf,ti. | 3987 |
| 4 | ((reduc* or minimi*) adj5 (harm? or harmful or risk?)).ab,kf,ti. | 345174 |
| 5 | 1 or 2 or 3 or 4 | 414447 |
| 6 | exp Health Personnel/ | 1843814 |
| 7 | Social Workers/ | 12409 |
| 8 | Counselors/ | 3692 |
| 9 | exp Health Occupations/ | 24456 |
| 10 | exp Allied Health Occupations/ | 392205 |
| 11 | exp Allied Health Personnel/ | 567029 |
| 12 | (worker? or (psychoeducator? or psycho-educator?) or educator? or nurse? or criminologist? or psychologist? or clinician? or practitioner? or physician? or professional? or provider? or co?nselor or co?nselors or caregiver? or giver? or therapist? or psychotherapist? or staff? or personnel? or employee? or doctor?).ab,kf,ti. | 2640146 |
| 13 | 6 or 7 or 8 or 9 or 10 or 11 or 12 | 3761559 |
| 14 | Cannabis/ | 40937 |
| 15 | "Marijuana Use"/ | 12636 |
| 16 | Marijuana Abuse/ | 6445 |
| 17 | Marijuana Smoking/ | 4026 |
| 18 | (mari?uana or cannabis or has?hish or Pot or weed or tetrahydrocannabinol or THC or CDB or cannabidiol or cannabinoid?).ab,kf,ti. | 129932 |
| 19 | 14 or 15 or 16 or 17 or 18 | 142957 |
| 20 | 5 and 13 and 19 | 569 |
| 21 | limit 32 to yr="1990 -Current" | 569 |
| 22 | limit 21 to (english or french) | 560 |
| 23 | Filtre OCDE | 520 |

Appendix 6: Sociological Abstracts

(((ti(health personnel OR social worker OR social workers OR counselor OR counselors OR conselor OR conselors OR health occupation OR health occupations OR worker* OR psychoeducator* OR psycho-educator* OR educator* OR nurse* OR criminologist* OR psychologist* OR clinician* OR professional* OR provider* OR caregiver* OR giver* OR therapist* OR psychotherapist* OR staff* OR personnel* OR employee* OR doctor*)) OR ab(health personnel OR social worker OR social workers OR counselor OR counselors OR conselor OR conselors OR health occupation OR health occupations OR worker* OR psychoeducator* OR psycho-educator* OR educator* OR nurse* OR criminologist* OR psychologist* OR clinician* OR professional* OR provider* OR caregiver* OR giver* OR therapist* OR psychotherapist* OR staff* OR personnel* OR employee* OR doctor*)) OR su(health personnel OR social worker OR social workers OR counselor OR counselors OR conselor OR conselors OR health occupation OR health occupations OR worker* OR psychoeducator* OR psycho-educator* OR educator* OR nurse* OR criminologist* OR psychologist* OR clinician* OR professional* OR provider* OR caregiver* OR giver* OR therapist* OR psychotherapist* OR staff* OR personnel* OR employee* OR doctor*)) AND (ti(cannabis OR marijuana OR mari*uana OR hashish OR pot OR weed OR tetrahydrocannabinol OR THC OR CDB OR cannabidiol OR cannabinoid*) OR ab(cannabis OR marijuana OR mari*uana OR hashish OR pot OR weed OR tetrahydrocannabinol OR THC OR CDB OR cannabidiol OR cannabinoid*) OR su(cannabis OR marijuana OR mari*uana OR hashish OR pot OR weed OR tetrahydrocannabinol OR THC OR CDB OR cannabidiol OR cannabinoid*)) AND (((reduc* OR minimi*) NEAR/5 (harm OR harms OR harmful OR risk OR risks)) OR ab((reduc* OR minimi*) NEAR/5 (harm OR harms OR harmful OR risk OR risks)) OR su((reduc* OR minimi*) NEAR/5 (harm OR harms OR harmful OR risk OR risks)))) OR (ti(protective NEAR/2 strateg*) OR ab(protective NEAR/2 strateg*) OR su(protective NEAR/2 strateg*)))) AND la.exact("ENG")) AND yr(1990-2029)

Appendix 7: Google Scholar

cannabis intitle:nurse OR intitle:clinician OR intitle:practitioner OR intitle:physician OR intitle:caregiver OR intitle:giver OR intitle:doctor "harm reduction" = 105

cannabis intitle:nurses OR intitle:clinicians OR intitle:practitioners OR intitle:physicians OR intitle:caregivers OR intitle:givers OR intitle:doctors "harm reduction" = 242

cannabis intitle:psychoeducator OR intitle:educator OR intitle:therapist OR intitle:psychotherapist OR intitle:criminologist OR intitle:psychologist "harm reduction" = 19

cannabis intitle:psychoeducators OR intitle:educators OR intitle:therapists OR intitle:psychotherapists OR intitle:criminologists OR intitle:psychologists "harm reduction" = 53

cannabis intitle:worker OR intitle:staff OR intitle:personnel OR intitle:employee OR intitle:professional OR intitle:provider OR intitle:counselor OR intitle:conselor "harm reduction" = 136

cannabis intitle: workers OR intitle:staffs OR intitle:personnels OR intitle:employees OR intitle:professionals OR intitle:providers OR intitle:counselors OR intitle:conselors "harm reduction" = 5

cannabis intitle:infirmier OR intitle:médecin OR intitle:clinicien OR intitle:psychoéducateur OR intitle:éducateur OR intitle:thérapeute OR intitle:psychothérapeute OR intitle:criminologue OR intitle:psychologue "reduction des méfaits" = 1

cannabis intitle:travailleur OR intitle:personnel OR intitle:employé OR intitle:professionnel OR intitle:conseiller OR intitle:intervenant "reduction des méfaits" = 5

cannabis intitle:infirmiers OR intitle:médecins OR intitle:cliniciens OR intitle:psychoéducateurs OR intitle:éducateurs OR intitle:thérapeutes OR intitle:psychothérapeutes OR intitle:criminologues OR intitle:psychologues "reduction des méfaits" = 3

cannabis intitle:travailleurs OR intitle:personnels OR intitle:employés OR intitle:professionnels OR intitle:conseillers OR intitle:intervenants "reduction des méfaits" = 12

cannabis intitle:infirmière OR intitle:clinicienne OR intitle:psychoéducatrice OR intitle:éducatrice OR intitle:criminologue OR intitle:psychologue "reduction des méfaits" = 2

cannabis intitle:travailleuse OR intitle:employée OR intitle:professionnelle OR intitle:conseillère OR intitle:intervenante "reduction des méfaits" = 1

cannabis intitle:infirmières OR intitle:cliniciennes OR intitle:psychoéducatrices OR intitle:éducatrices OR intitle:criminologues OR intitle:psychologues "reduction des méfaits" = 2

cannabis intitle:travailleuses OR intitle:employées OR intitle:professionnelles OR intitle:conseillères OR intitle:intervenantes "reduction des méfaits" = 2

marijuana intitle:nurse OR intitle:clinician OR intitle:practitioner OR intitle:physician OR intitle:caregiver OR intitle:giver OR intitle:doctor "harm reduction" = 139

marijuana intitle:nurses OR intitle:clinicians OR intitle:practitioners OR intitle:physicians OR intitle:caregivers OR intitle:givers OR intitle:doctors "harm reduction" = 238

marijuana intitle:psychoeducator OR intitle:educator OR intitle:therapist OR intitle:psychotherapist OR intitle:criminologist OR intitle:psychologist "harm reduction" = 19

1
2
3 marijuana intitle:psychoeducators OR intitle:educators OR intitle:therapists OR
4 intitle:psychotherapists OR intitle:criminologists OR intitle:psychologists "harm reduction" = 48

5
6 marijuana intitle:worker OR intitle:staff OR intitle:personnel OR intitle:employee OR
7 intitle:professional OR intitle:provider OR intitle:counselor OR intitle:conselor "harm reduction"
8 = 140

9
10 marijuana intitle:workers OR intitle:staffs OR intitle:personnels OR intitle:employees OR
11 intitle:professionals OR intitle:providers OR intitle:counselors OR intitle:conselors "harm
12 reduction" = 573

13
14 marijuana intitle:infirmier OR intitle:médecin OR intitle:clinicien OR intitle:psychoéducateur OR
15 intitle:éducateur OR intitle:thérapeute OR intitle:psychothérapeute OR intitle:criminologue OR
16 intitle:psychologue "réduction des méfaits" = 1

17
18 marijuana intitle:travailleur OR intitle:personnel OR intitle:employé OR intitle:professionnel OR
19 intitle:conseiller OR intitle:intervenant "réduction des méfaits" = 5

20
21 marijuana intitle:infirmiers OR intitle:médecins OR intitle:cliniciens OR intitle:psychoéducateurs
22 OR intitle:éducateurs OR intitle:thérapeutes OR intitle:psychothérapeutes OR
23 intitle:criminologues OR intitle:psychologues "réduction des méfaits" = 3

24
25 marijuana intitle:travailleurs OR intitle:personnels OR intitle:employés OR intitle:professionnels
26 OR intitle:conseillers OR intitle:intervenants "réduction des méfaits" = 12

27
28 marijuana intitle:infirmière OR intitle:clinicienne OR intitle:psychoéducatrice OR
29 intitle:éducatrice OR intitle:criminologue OR intitle:psychologue "réduction des méfaits" = 2

30
31 marijuana intitle:travailleuse OR intitle:employée OR intitle:professionnelle OR intitle:conseillère
32 OR intitle:intervenante "réduction des méfaits" = 1

33
34 marijuana intitle:infirmières OR intitle:cliniciennes OR intitle:psychoéducatrices OR
35 intitle:éducatrices OR intitle:criminologues OR intitle:psychologues "réduction des méfaits" = 2

36
37 marijuana intitle:travailleuses OR intitle:employées OR intitle:professionnelles OR
38 intitle:conseillères OR intitle:intervenantes "réduction des méfaits" = 2
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix 8: Google Web

cannabis intitle:nurse OR intitle:clinician OR intitle:practitioner OR intitle:physician OR intitle:caregiver OR intitle:giver OR intitle:doctor "harm reduction" filetype:pdf =

cannabis intitle:nurses OR intitle:clinicians OR intitle:practitioners OR intitle:physicians OR intitle:caregivers OR intitle:givers OR intitle:doctors "harm reduction" filetype:pdf =

cannabis intitle:psychoeducator OR intitle:educator OR intitle:therapist OR intitle:psychotherapist OR intitle:criminologist OR intitle:psychologist "harm reduction" filetype:pdf =

cannabis intitle:psychoeducators OR intitle:educators OR intitle:therapists OR intitle:psychotherapists OR intitle:criminologists OR intitle:psychologists "harm reduction" filetype:pdf =

cannabis intitle:worker OR intitle:staff OR intitle:personnel OR intitle:employee OR intitle:professional OR intitle:provider OR intitle:counselor OR intitle:conselor "harm reduction" filetype:pdf =

cannabis intitle: workers OR intitle:staffs OR intitle:personnels OR intitle:employees OR intitle:professionals OR intitle:providers OR intitle:counselors OR intitle:conselors "harm reduction" filetype:pdf =

cannabis intitle:infirmier OR intitle:médecin OR intitle:clinicien OR intitle:psychoéducateur OR intitle:éducateur OR intitle:thérapeute OR intitle:psychothérapeute OR intitle:criminologue OR intitle:psychologue "reduction des méfaits" filetype:pdf =

cannabis intitle:travailleur OR intitle:personnel OR intitle:employé OR intitle:professionnel OR intitle:conseiller OR intitle:intervenant "reduction des méfaits" filetype:pdf =

cannabis intitle:infirmiers OR intitle:médecins OR intitle:cliniciens OR intitle:psychoéducateurs OR intitle:éducateurs OR intitle:thérapeutes OR intitle:psychothérapeutes OR intitle:criminologues OR intitle:psychologues "reduction des méfaits" filetype:pdf =

cannabis intitle:travailleurs OR intitle:personnels OR intitle:employés OR intitle:professionnels OR intitle:conseillers OR intitle:intervenants "reduction des méfaits" filetype:pdf =

cannabis intitle:infirmière OR intitle:clinicienne OR intitle:psychoéducatrice OR intitle:éducatrice OR intitle:criminologue OR intitle:psychologue "reduction des méfaits" filetype:pdf =

cannabis intitle:travailleuse OR intitle:employée OR intitle:professionnelle OR intitle:conseillère OR intitle:intervenante "reduction des méfaits" filetype:pdf =

cannabis intitle:infirmières OR intitle:cliniciennes OR intitle:psychoéducatrices OR intitle:éducatrices OR intitle:criminologues OR intitle:psychologues "reduction des méfaits" filetype:pdf =

cannabis intitle:travailleuses OR intitle:employées OR intitle:professionnelles OR intitle:conseillères OR intitle:intervenantes "reduction des méfaits" filetype:pdf =

marijuana intitle:nurse OR intitle:clinician OR intitle:practitioner OR intitle:physician OR intitle:caregiver OR intitle:giver OR intitle:doctor "harm reduction" filetype:pdf =

marijuana intitle:nurses OR intitle:clinicians OR intitle:practitioners OR intitle:physicians OR intitle:caregivers OR intitle:givers OR intitle:doctors "harm reduction" filetype:pdf =

1
2
3 marijuana intitle:psychoeducator OR intitle:educator OR intitle:therapist OR
4 intitle:psychotherapist OR intitle:criminologist OR intitle:psychologist "harm reduction"
5 filetype:pdf =

6
7 marijuana intitle:psychoeducators OR intitle:educators OR intitle:therapists OR
8 intitle:psychotherapists OR intitle:criminologists OR intitle:psychologists "harm reduction"
9 filetype:pdf =

10
11 marijuana intitle:worker OR intitle:staff OR intitle:personnel OR intitle:employee OR
12 intitle:professional OR intitle:provider OR intitle:counselor OR intitle:conselor "harm reduction"
13 filetype:pdf =

14
15 marijuana intitle:workers OR intitle:staffs OR intitle:personnels OR intitle:employees OR
16 intitle:professionals OR intitle:providers OR intitle:counselors OR intitle:conselors "harm
17 reduction" filetype:pdf =

18
19 marijuana intitle:infirmier OR intitle:médecin OR intitle:clinicien OR intitle:psychoéducateur OR
20 intitle:éducateur OR intitle:thérapeute OR intitle:psychothérapeute OR intitle:criminologue OR
21 intitle:psychologue "reduction des méfaits" filetype:pdf =

22
23 marijuana intitle:travailleur OR intitle:personnel OR intitle:employé OR intitle:professionnel OR
24 intitle:conseiller OR intitle:intervenant "reduction des méfaits" filetype:pdf =

25
26 marijuana intitle:infirmiers OR intitle:médecins OR intitle:cliniciens OR intitle:psychoéducateurs
27 OR intitle:éducateurs OR intitle:thérapeutes OR intitle:psychothérapeutes OR
28 intitle:criminologues OR intitle:psychologues "reduction des méfaits" filetype:pdf =

29
30 marijuana intitle:travailleurs OR intitle:personnels OR intitle:employés OR intitle:professionnels
31 OR intitle:conseillers OR intitle:intervenants "reduction des méfaits" filetype:pdf =

32
33 marijuana intitle:infirmière OR intitle:clinicienne OR intitle:psychoéducatrice OR
34 intitle:éducatrice OR intitle:criminologue OR intitle:psychologue "reduction des méfaits"
35 filetype:pdf =

36
37 marijuana intitle:travailleuse OR intitle:employée OR intitle:professionnelle OR intitle:conseillère
38 OR intitle:intervenante "reduction des méfaits" filetype:pdf =

39
40 marijuana intitle:infirmières OR intitle:cliniciennes OR intitle:psychoéducatrices OR
41 intitle:éducatrices OR intitle:criminologues OR intitle:psychologues "reduction des méfaits"
42 filetype:pdf =

43
44 marijuana intitle:travailleuses OR intitle:employées OR intitle:professionnelles OR
45 intitle:conseillères OR intitle:intervenantes "reduction des méfaits" filetype:pdf =

Appendix 9: BASE

tit:(nurse* clinician* practitioner* physician* caregiver* giver* doctor* psychoeducator*
educator* therapist* psychotherapist* criminologist* psychologist* worker* staff* personnel*
employee* professional* provider* counselor*) subj:(cannabis marijuana) subj:"harm reduction"
= 4

tit:(infirmier* OU médecin* OU clinicien* OU psychoéducat* OU éducat* OU criminologue*
OU psychologue* OU travailleur* OU employé* OU professionnel* OU conseil* OU
intervenant*) subj:cannabis subj:marijuana subj:"réduction des méfaits" = 0

For peer review only

Appendix 10: Érudit

(Titre, résumé, mots-clés : harm reduction OU harm minimisation OU risk reduction OU risks reduction OU risk minimisation OU réduction des méfaits OU réduction des risques) ET (Titre, résumé, mots-clés : cannabis OU marijuana) ET (Titre, résumé, mots-clés : nurse* OU clinician* OU practitioner* OU physician* OU caregiver* OU giver* OU doctor* OU psychoeducator* OU educator* OU therapist* OU psychotherapist* OU criminologist* OU psychologist* OU worker* OU staff* OU personnel* OU employee* OU professional* OU provider* OU counselor* OU infirmier* OU médecin* OU clinicien* OU psychoéducateur* OU éducateur* OU criminologue* OU psychologue* OU travailleur* OU employé* OU professionnel* OU conseiller* OU intervenant*) = 27

For peer review only

BMJ Open

Facilitators of and barriers to healthcare providers' adoption of harm reduction in cannabis use: a scoping review protocol

| | |
|---------------------------------|---|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2023-078427.R2 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 19-Mar-2024 |
| Complete List of Authors: | Haddad, Roula; Université de Montréal Faculté des Arts et des Sciences, Department of Psychology Dagenais, Christian; Université de Montréal Faculté des Arts et des Sciences, Department of Psychology Huynh, Christophe ; Institut Universitaire sur les Dépendances, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l'Île-de-Montréal ; Université de Montreal Département de Psychiatrie Fallu, Jean-Sébastien; University of Montreal, Psychoeducation; Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l'Île-de-Montréal du Québec, Centre de recherche en santé publique (CReSP) |
| Primary Subject Heading: | Addiction |
| Secondary Subject Heading: | Public health, Research methods |
| Keywords: | PUBLIC HEALTH, MENTAL HEALTH, Substance misuse < PSYCHIATRY, Health Services |
| | |

SCHOLARONE™
Manuscripts

Facilitators of and barriers to healthcare providers' adoption of harm reduction in cannabis use: a scoping review protocol

Roula Haddad¹, Christian Dagenais¹, Christophe Huynh^{2,3}, Jean-Sébastien Fallu^{2,4,5}

¹ Department of Psychology, Université de Montréal

² University Institute on Addictions, Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l'Île-de-Montréal

³ Department of Psychiatry and Addictology, Université de Montréal

⁴ School of Psychoeducation, Université de Montréal

⁵ Centre de recherche en santé publique (CRéSP), Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l'Île-de-Montréal

Correspondence to:

Roula Haddad

roula.haddad@umontreal.ca

ABSTRACT

Introduction: The high prevalence of cannabis use and the potential for negative effects indicate the need for effective prevention strategies and treatment of people who use cannabis (PWUC). Studies show that harm reduction (HR) in cannabis use is effective in minimising the harmful consequences of the substance. However, health professionals often misunderstand it and resist its adoption due to various obstacles. To our knowledge, there has been no review of the scientific literature on the factors that facilitate or hinder practitioners' adoption of HR in cannabis use. To fill this gap, we aim to identify, through a scoping review, facilitators and barriers to healthcare providers' adoption of HR in cannabis use in Organisation for Economic Cooperation and Development (OECD) countries.

Methods and analysis: Our methodology will be guided by the six-step model initially proposed by Arksey and O'Malley (2005). The search strategy will be executed on different databases (Medline, PsycINFO, CINAHL, Web of Science, Embase, Sociological Abstracts, Érudit, BASE, Google Web, and Google Scholar) and will cover articles published between 1990 and October

2022. Empirical studies published in French or English in an OECD country and identifying factors that facilitate or hinder healthcare providers' adoption of HR in cannabis use, will be included. Reference lists of the selected articles as well as relevant systematic reviews will be scanned to identify any missed publications by the electronic searches.

Ethics and dissemination: Ethics approval is not required. The results will be disseminated through various activities (e.g., publication in peer-reviewed journals, conferences, webinars, and knowledge translation activities). The results will also allow us to conduct a future study aiming to develop and implement a knowledge translation process among healthcare practitioners working with youth in Quebec in order to enhance their adoption of HR in cannabis use.

Strengths and limitations of this study

- The search strategy was co-developed by two information management specialists in the addiction and knowledge translation fields.
- The search strategy will aim to retrieve published articles on several health databases and unpublished studies found in the grey literature.
- Two reviewers will independently select the studies to be included in the scoping review throughout the entire study selection stage.
- The included studies will be limited to those published in French or English.
- The included studies will be limited to those published in OECD countries.

Keywords: *harm reduction; cannabis; knowledge translation; healthcare*

INTRODUCTION

Cannabis use

Psychoactive substances (e.g., cannabis, alcohol, nicotine) are defined as substances whose use affects mental processes (e.g., perception, cognition, emotions, mood) and behaviors without necessarily leading to addiction (1). After tobacco and alcohol, cannabis represents the third most consumed psychoactive substance globally among adults and youth (2-5). Canada remains among the developed countries with the highest rates of cannabis use among young people and adults, with high prevalence in Quebec and multiple patterns of use (e.g., smoking, eating, vaporising, vaping) (2, 5-9). In 2023, 26% of those 16 years of age and older reported using cannabis in the 12 months prior to the study, with a higher prevalence among those aged between 20 to 24 years old (10).

The lifetime cumulative probability of transitioning from use to dependence was found to be the lowest for people who use cannabis (PWUC) (8.9%) compared to other substances such as nicotine (67.5%), alcohol (22.7%), and cocaine (20.9%); this can be due to several factors such as infrequency in use, consumption of cannabis with low rates of δ -9-tetrahydrocannabinol (THC), availability, legality, and social acceptability (9, 11-15). Even with long-term exposure to cannabis, PWUC do not necessarily develop severe problems or a cannabis-dependence (5, 15, 16).

However, PWUC intensively or at-risk populations (i.e., pregnant persons, people presenting respiratory problems, a mental health comorbidity, having an early onset of continued tobacco use or concurrently smoking tobacco and cannabis) may develop a cannabis use disorder or experience harm at several levels (5, 12, 16-19). These harms may include a decreased academic or professional performance, a cognitive impairment, a deterioration of mental health (e.g., development of psychosis or depression), an increased occurrence of risky behaviors (e.g., cannabis-impaired driving), etc. (3-5, 12, 14, 18, 20-22). It is important to specify that a severe cannabis-induced mental health condition (e.g., psychosis) might occur among only 2% of PWUC (5). Despite the minimal probability of leading to potentially serious adverse consequences, the high prevalence of cannabis use as well as the potential harms that might be experienced, make it essential to implement effective intervention programs among PWUC (7, 12, 15, 17).

Abstinence approach

To address this reality, prevention and treatment programs based on the abstinence approach (i.e., total elimination of cannabis use), have been widely implemented (11, 13). The emergence of these programs has been also influenced by policies such as the “War on Drugs” (23). The abstinence-based model forms the basis of many programs developed to prevent or treat problematic cannabis use and has been applied with at-risk or marginalised populations (e.g., youth in the foster care system) (21, 24). Despite its potential to decrease the frequency or amount of substance use, the abstinence approach presents limited evidence to support its effectiveness and has been criticised for various reasons (21, 24-26). First, it does not provide PWUC with the necessary skills to identify and mitigate the harms associated with their use (21, 27). Second, the abstinence approach tends to focus more on the negative consequences of use through strategies that evoke fear, without necessarily taking into consideration the social context of cannabis use (20, 21). Third, the risks of relapse and dropout in these programs are also found to be high, leaving a significant number of PWUC for whom this goal remains unattainable (20, 28). Given these limitations of abstinence-oriented programs, other alternative and more flexible treatments, such as harm reduction (HR), are essential to reduce and mitigate cannabis-related harms (14, 21, 28, 29).

Harm reduction (HR)

Description

HR in cannabis use aims to minimise the harmful consequences of the substance at the individual, psychological, legal, and social levels among PWUC (19, 20, 28, 29). It offers a public health framework based on values of pragmatism and humanism, as it does not view substance use through a moral lens, but as an inevitable societal fact of long-standing (4, 11, 30, 31). Whether among adults or adolescents, elimination of substance use is unrealistic at the population level and should be the individual’s choice without being imposed, as it represents an unwanted and impractical goal for some (e.g., in case of recreational or occasional use, in case of dual diagnosis combining psychiatric and substance use disorders) (27-29, 32, 33). HR in cannabis use also seeks to equip PWUC to make responsible and rational decisions and learn ways to reduce the negative consequences associated with their consumption (11, 12, 20, 27, 29, 31). To this end, HR clarifies the notion of safe substance use that is determined by the interaction of three components: the individual (height, weight, gender, physical and mental health status, state of mind, etc.); the drug

1
2
3 (quantity, frequency of use, tolerance to the product, combination with other products, quality,
4 etc.); and the setting (location, time of day, interpersonal relationships, conflicts, laws, etc.) (4, 20,
5 27). In addition, HR takes into account the personal characteristics of PWUC (impulsivity,
6 sensation-seeking, etc.) and addresses their potential ambivalence about stopping substance use,
7 their feelings of failure upon relapse, their engagement in treatment, their social skills, their
8 emotional regulation, etc. (20). In the “Lower Risk Cannabis Use Guidelines”, Fischer (5) updated
9 the initial recommendations to reduce the harms of cannabis use. These recommendations include
10 delaying the initiation of cannabis use until late adolescence or the completion of puberty,
11 consuming low-potency cannabis products, avoiding deep inhalation, using legal and quality-
12 controlled cannabis products, etc. (5).
13
14
15
16
17
18
19
20
21

22 HR effectiveness

23
24 Interventions based on HR for non-injected drugs have been studied across various populations
25 (e.g., youth, adults, people in housing programs presenting mental health conditions) and have
26 shown promising results in decreasing the negative consequences associated with substance use
27 (20, 28).
28

29
30 Several studies showed the effectiveness of HR strategies and current school-based HR programs
31 (e.g., SHAHRP in the United Kingdom and SCIDUA in Canada) in developing safer attitudes
32 toward substance use and in reducing negative consequences related to use (21, 22, 34, 35). The
33 effectiveness of HR among youth who use cannabis has led the University Institute on Addictions
34 (*Institut universitaire sur les dépendances*) in Quebec to recommend it as an intervention modality
35 among this clientele (36). In addition, effective early interventions targeting college and university
36 students with at-risk cannabis use are those that reduce the harms associated with cannabis use
37 (17, 36-38). Moreover, Palfai (38) found that students participating in a web-based HR
38 intervention (Marijuana eCHECKUP TO GO) showed statistically significant lower results in peer
39 cannabis use after six months ($f^2 = .11$, [B = 7.45 (3.34), $p < .05$]).
40
41
42
43
44
45
46
47

48 HR in cannabis use was also found effective among adults (17, 39). After delivering a brief HR
49 intervention for PWUC, Fischer (17) found significant reductions in risk outcome indicators only
50 among the experimental group. At the 12th month follow-up, a change was maintained for “deep
51 inhalation/breath-holding” (experimental group: Q = 13.1; $p < .05$; control group: Q = 4.8; $p > .05$),
52 and “driving after cannabis use” (experimental group: Q = 9.3; $p < .05$; control group: Q = 0.9; $p >$
53
54
55
56
57
58
59
60

1
2
3 .05) (17). Furthermore, without completely abstaining from the substance, a functional
4 improvement can be reached by treatment-seeking adults presenting a cannabis use disorder when
5 they reduce the frequency and/or quantity of cannabis use (39). Reduction in the frequency of
6 cannabis use was associated with a decrease in depression ($F = 2.76, p = .04, n_p^2 = .04$), anxiety (F
7 $= 3.70, p = .01, n_p^2 = .05$), and cannabis-related problems ($F = 8.95, p < .001, n_p^2 = .12$) (39). In
8 addition, a decrease in the quantity of cannabis consumption was associated with a decrease in
9 anxiety ($F = 3.02, p = .03, n_p^2 = .04$) and cannabis-related problems ($F = 3.24, p = .02, n_p^2 = .05$)
10 (39). A systematic review also highlighted that the adoption of HR strategies by PWUC acts as a
11 protective factor for people with poor mental health, low self-regulation, high impulsivity, and
12 high negative urgency (22).
13
14
15
16
17
18
19
20
21

22 Acceptability of harm reduction

23
24 Despite its proven effectiveness, the acceptability and applicability of HR by health and social
25 services practitioners remain limited, and various factors facilitate or hinder its adoption (21, 40-
26 42). MacCoun (43) showed that, among practitioners who did not adopt HR, some had based their
27 decision on moral grounds, regardless of its effectiveness. Various barriers limit its use by
28 practitioners. First, ambiguities in its conceptualisation play an influential role; for example, some
29 practitioners perceive HR as sending the wrong message, i.e., one of tolerating or even
30 encouraging substance use (27, 28, 30, 44). Some do not perceive total cessation of substance use
31 as a legitimate goal that could be achieved through HR (45). Also, there is often confusion between
32 reducing use (frequency, quantity, etc.) and reducing harm (modifying consumption practices,
33 such as contexts and mixtures, to reduce consequences) (30). These misconceptions point to the
34 need for awareness-raising, training, and supervision of practitioners interested in this approach
35 (28). Second, the adoption of HR can be hindered by ethical dilemmas, as well as by issues related
36 to the personal and collective values of healthcare workers and the therapeutic model of abstinence
37 (30). Indeed, it runs counter to traditional treatments by tolerating risky behaviors and accepting
38 that HR in drug use is a legitimate outcome (30, 44). Practitioners may also fear the emergence of
39 legal, social, and health problems among their clients (28). Third, its adoption may be limited by
40 contextual barriers, such as lack of funding, stigma that undermines demand for care, resistance
41 from local jurisdictions, and lack of services and trained personnel, particularly in the mental
42 health sector (41). Healthcare providers' resistance to applying HR in cannabis use leads to limited
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 knowledge and utilisation of effective HR techniques and guidelines among PWUC (5, 25).
4 Among the study's participants (i.e., PWUC), Kruger (25) found that less than half of the
5 participants believed that the listed HR techniques were effective and reported applying them.
6
7 However, several factors seen as HR benefits have been found to facilitate its implementation by
8 healthcare providers, such as: broadening the spectrum of acceptable goals, improving clients'
9 decision-making skills, creating positive and quality relationships, and managing relapses (28). A
10 study by Sharp (41) showed that clarifying the positive impacts of HR at the community level
11 (e.g., safety) and ensuring the availability of resources could increase the likelihood of its adoption.
12
13
14
15
16
17
18

19 **Purpose**

20 Despite its proven effectiveness, several reasons might hinder HR adoption by health professionals
21 among PWUC (30, 41). However, to date, there has been no review of the scientific literature that
22 identifies the factors that facilitate or limit the adoption of HR in cannabis use. To fill this gap, we
23 aim to identify, through a scoping review, facilitators and barriers to healthcare providers' adoption
24 of HR in cannabis use.
25
26
27
28
29
30

31 **METHODS AND ANALYSIS**

32
33 This study will follow the methodological steps of scoping reviews (46). This type of review has
34 become more prevalent in recent years and is a type of knowledge synthesis review (46, 47). There
35 is no universal definition for scoping reviews; however, a variety of factors distinguish them from
36 other types of knowledge synthesis (48). First, scoping reviews address broad research questions
37 and include studies with different designs and multiple sources of evidence to provide an overview
38 of the available knowledge around a concept (49). On the contrary, a systematic review following
39 Cochrane standards explores more specific research questions based on detailed inclusion and
40 exclusion criteria (50-52). Second, while assessment of the methodological quality of included
41 studies is recommended for scoping reviews, it is not mandatory, whereas assessment of the risk
42 of bias of included studies is required for Cochrane-type systematic reviews (50, 52). Researchers
43 undertake scoping reviews for a variety of reasons: 1) to review research activity in a given area;
44 2) to determine the feasibility and appropriateness of conducting a systematic review based on
45 Cochrane standards; 3) to summarise and disseminate the results of existing research on a topic;
46 and/or 4) to identify a gap in the literature and draw conclusions regarding a topic (49). Our
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 methodological choice is underpinned by three of these reasons: once the research activity around
4 the topic has been consulted, the findings will be summarised and used to support a second study
5 aimed at disseminating knowledge to practitioners through a knowledge translation process. This
6 will also allow us to identify gaps in the literature and draw conclusions related to the topic.
7
8

9
10 Arksey and O'Malley (49) were the first to propose a six-step model for conducting scoping
11 reviews. Our methodology will be guided by this model, which was later refined by Levac (48)
12 and revised by members of the Joanna Briggs Institute (50). The six stages we will follow are:
13

- 14 - Stage 1: Determining the research question and the objective
- 15 - Stage 2: Identifying relevant studies
- 16 - Stage 3: Selecting studies
- 17 - Stage 4: Charting the data
- 18 - Stage 5: Collating, summarising, and reporting the results
- 19 - Stage 6: Conducting a consultation exercise

20
21 The research protocol will be reported using the Preferred Reporting Items for Systematic Reviews
22 and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) grid (47). This grid is an
23 extension of the PRISMA grid originally developed for Cochrane-type systematic reviews and
24 helps to ensure the transparency and reproducibility of the study (47, 50).
25

26 27 28 29 30 31 32 33 34 **Stage 1: Determining the research question and the objective**

35
36 Arksey and O'Malley's (49) model suggests that scoping reviews should begin not only with
37 identifying research questions but also with clarifying the resulting objectives (48, 50). Our
38 scoping review is exploratory and aims to identify facilitators and barriers to healthcare providers'
39 adoption of HR in cannabis use in OECD countries. Based on the Population–Concept–Context
40 (PCC) model, which allows the broad scope of the study to be respected without specifying
41 restrictive inclusion criteria (50), we formulated the research question: What factors influence
42 providers (population) in the healthcare field (context) to adopt HR in cannabis use (concept)?
43 Specific research questions associated with the components of the PCC model were also identified.
44

- 45 - Question 1, related to the concept and context components: What are the facilitators and
46 barriers to healthcare providers' adoption of HR in cannabis use?
47
- 48 - Question 2, related to the population component: Who is the clientele of the providers
49 identified in the studies?
50

- 1
2
3 - Question 3, related to the concept component: What is the definition of HR in cannabis
4 use?
5
6
7

8 **Stage 2: Identifying relevant studies**

9 Search strategy

10
11 The search strategy was developed through an iterative process. A senior librarian at the Quebec
12 Addiction Library (*Bibliothèque québécoise sur les dépendances*) first developed three search
13 strategies with different concepts and ran them on the Medline database. The first 50 results of
14 each strategy were consulted, which led us to opt the one that grouped key terms related to the
15 following concepts: harm reduction, clinicians, and cannabis (see Supplemental Appendix). The
16 search strategy was then reviewed by a second information professional working in the RENARD
17 Team for Knowledge Translation who, in turn, adapted it to the selected databases. The final search
18 strategy executed on all the databases was then validated by the RENARD Team information
19 specialist. The Peer Review of Electronic Search Strategies (PRESS) tool served as a guide for the
20 librarians in this process (53). The search strategy executed on each database is presented in
21 Supplemental Appendix. All search strategies were executed on October 10th, 2022.
22
23
24
25
26
27
28
29
30
31

32 Information sources

33
34 To identify relevant published and unpublished studies for inclusion in the study, various sources
35 of information will be reviewed (46, 49, 50). With the guidance of the two librarians, the search
36 strategy will be executed on the leading health and intervention databases: Medline, PsycINFO,
37 Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, Embase,
38 and Sociological Abstracts. To explore the grey literature (e.g., theses, research reports, etc.), the
39 search strategy will be adapted to the Google Web and Google Scholar search engines, as well as
40 the Érudit (French database) and BASE databases. All documents identified will be entered into
41 Zotero software for the research team members to access. To identify any missed publication by
42 the electronic searches, reference lists of selected articles will be manually searched and relevant
43 systematic reviews will be scanned to identify their included studies.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Stage 3: Study selection

After running the search strategy on the selected databases and completing the second stage, all identified duplicates will be removed. The remaining documents will then be entered into Covidence software. Two reviewers will independently select relevant documents for inclusion by reading the titles and abstracts of the identified studies. Their decisions will be based on the specified inclusion and exclusion criteria. The inter-rater agreement between the reviewers will first be calculated and then they will meet regularly to resolve selection conflicts and refine the eligibility criteria as needed. After this first step, the documents selected and deemed potentially relevant will then be the subject of the second step, the full-text reading. Again, the two reviewers will independently record their choices on Covidence. The inter-rater agreement for this step will be calculated and the reviewers will then resolve any new conflicts. A third reviewer will be called upon as needed for any conflict resolution. This will complete the document selection stage, whose steps will be presented in a PRISMA diagram (54).

Inclusion and exclusion criteria

Inclusion and exclusion criteria have been specified and will be fine-tuned as needed to select relevant studies (Table 1). Using this process, empirical studies of quantitative, qualitative, or mixed designs, identifying factors that facilitate or hinder healthcare providers' adoption of HR in cannabis use, will be selected. To facilitate comparison and generalisation of the results to the Quebec context, the review will be limited to studies conducted in any of the 38 OECD countries. Articles published between 1990 and October 2022 will be included, as it was early in the 1990s that HR gained international prominence and its scope of application began to expand. Papers not meeting these inclusion criteria will be excluded. Systematic reviews will be excluded to avoid duplication and ensure equal representation of the selected papers; the executed search strategy might have already captured studies included in a potentially relevant systematic review. However, systematic reviews' reference lists will be examined to identify additional relevant studies that might be selected.

Table 1. Inclusion and exclusion criteria

| Criteria | Inclusion criteria | Exclusion criteria |
|---|--|---|
| Type of study | - Empirical study: quantitative, qualitative, or mixed | - Study that does not present empirical results (e.g., theoretical study, conceptual framework, etc.) or knowledge review (e.g., systematic or literature review) - Interviews |
| Type of documents | - Peer-reviewed scientific articles, research reports, dissertations, theses | - Books and practice guides |
| Conceptual framework | - Harm reduction (HR) in cannabis use - Cannabis risk reduction - Non-abstinence in cannabis use | - Another conceptual framework |
| Objective | - Identification of factors ¹ facilitating or hindering practitioners' adoption of HR ² in cannabis use | - Evaluation of the effectiveness of interventions based on HR OR - Stakeholder perceptions of the use of cannabis as an HR strategy to circumvent the effects of other drugs OR - Attitudes toward decriminalisation of cannabis |
| Psychoactive substance being studied | - Marijuana, hashish, or cannabis for non-medical purposes - "Drug" if cannabis is part of its conceptualisation in the study | - Any substance other than marijuana, hashish, or non-medical cannabis (e.g., tobacco, alcohol, medical cannabis, MDMA, Ecstasy) - Study that focuses on "performance and image enhancing drugs" or "crack" or "new psychoactive substances" |
| Target population | - Practitioners ³ working in the health field - Practitioners in training | - PWUC ⁴ |
| Country of study | - OECD countries | - Other countries |
| Publication date | - From 1990 onwards | - Before 1990 |
| Language | - French and/or English | - Languages other than French or English or text not available |

¹ "Factors" include perceptions, beliefs, facilitators, obstacles, oppositions, attitudes, opinions, barriers, biases, motivations, preferences, determinants, incentives, influences, and perspectives on the adoption of HR in cannabis use, as well as its acceptability and receptivity.

² “Approach” refers to strategies, interventions, practices, services, methods, techniques, treatments, programs, or guides for the HR approach in cannabis use.

³ “Practitioners” include healthcare personnel, professionals, or practitioners, allied healthcare personnel, professionals, or practitioners, social workers, counselors, psychoeducators, educators, nurses, criminologists, psychologists, clinicians, caregivers, therapists, psychotherapists, and physicians.

⁴ Studies addressing the views of people who use cannabis (PWUC) regarding HR or its adoption by practitioners will be excluded.

Stage 4: Charting the data

To analyse the selected studies on a common basis, specific variables of interest will be identified based on the research questions (49). These will form the components of summary sheets that will be developed in Microsoft Excel and used to extract results (Table 2). This method is an analytical descriptive recording of the data (49, 50, 55). The first author (RH) will extract the data from the included studies and create the summary sheets. The research supervisor (CD) will validate the summary sheets throughout the process and ensure their alignment with the research questions (50).

Table 2. Summary sheets

| General variables | Specific variables |
|---|---|
| General characteristics of the study | Study title Author(s) Language of publication Date of publication Period of publication Journal Type of article Full reference Country of study Psychoactive substance under study The legal status of cannabis in the country of study |
| Introduction | Main concepts Definition of the main concept: HR in cannabis use Research question(s) Objective(s) Hypothesis |
| Methodology | Study design |

| | |
|-------------------|--|
| | Target population |
| | Place of work of the target population |
| | Inclusion criteria of participants |
| | Recruitment method |
| | Sample size |
| | Country of origin of participants |
| | The clientele of the population recruited |
| | Data collection method |
| | Analysis steps |
| Results | Sample presentation |
| | Key findings: 1) facilitators and 2) barriers to practitioners' adoption of HR in cannabis use |
| | Secondary outcomes or other results |
| Conclusion | Study strengths |
| | Study limitations |
| | Gaps in the literature and future research needs |

Stage 5: Collating, summarising, and reporting the results

Based on the eligibility criteria, studies deemed relevant will be collected, summarised, and reported. They will be subjected to 1) a numerical analysis, and 2) a narrative organisation encompassing a descriptive qualitative analysis (47, 49, 50). A numerical analysis of the scope, nature, and distribution of the included studies will be performed to various characteristics: date of publication, country of origin of the studies, and type of document. Subsequently, a narrative organisation of the results will be produced to identify the relationships between the data and the research questions. The summary sheets will be combined, tabulated, and synthesised, and will then be subjected to a descriptive qualitative analysis (Table 3).

Table 3. Narrative organisation of the included studies

| Data | Study 1 | Study 2 | Study ... |
|--|---------|---------|-----------|
| Type of publication | | | |
| Date of publication | | | |
| Country of study | | | |
| Legal status of cannabis in the country of the study | | | |
| Definition of HR to cannabis use | | | |
| Design of the study | | | |

1
2
3 Target population

4 Place of work of the target population

5
6 The clientele of the target population

7
8 Data collection method

9 Key findings:

- 10 - Facilitators or enabling conditions
- 11 - Barriers or adverse conditions

12
13
14 Secondary outcomes

15 16 17 **Stage 6: Consultation exercise**

18
19 Expert consultation is an optional step that promotes methodological rigor in scoping reviews (49).
20
21 In this study, the project's supervisor and co-researchers will be solicited as consultants. Members
22 of the RENARD team and researchers involved in the field of substance use and harm reduction
23 will be consulted to help clarify findings and validate the resulting recommendations (49).
24 Consultations will be conducted: 1) after preliminary results have been obtained, and 2) after
25 analyses of the results have been completed.
26
27
28
29

30 31 **Patient and public involvement**

32 None.

33 34 35 **ETHICS AND DISSEMINATION**

36
37 To our knowledge, this is the first scoping review on factors that facilitate or hinder healthcare
38 providers' adoption of HR in cannabis use. Other reviews have studied HR interventions in general
39 among practitioners working with a specific population. This study will provide a clear picture of
40 the factors at play when adopting HR, and the results could potentially be generalisable to OECD
41 countries. The present study is exempt from ethics approval because it involves no patient or
42 personal data collection. The results are expected to be ready by March 2024. They will be
43 disseminated, alongside the scoping review protocol, through various activities (e.g., publication
44 in peer-reviewed journals, conferences, webinars, posters, *Three Minute Thesis* competition).
45
46 After completing the scoping review, we will be able to conduct a future study aiming to
47 implement a knowledge translation plan among practitioners working with youth in Quebec to
48 enhance and expand their adoption of HR in cannabis use.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Acknowledgements:** We wish to thank Karine Bélanger, senior librarian at the *Bibliothèque*
4 *québécoise sur les dépendances* in Quebec for developing the initial search strategy used in this
5 scoping review. We also wish to thank Julie Desnoyers, the information specialist affiliated with
6 the RENARD Team for Knowledge Translation at Université de Montréal, for validating the
7 search strategy and adapting it to the selected databases. Finally, we want to thank Donna Riley
8 for editing the manuscript.
9

10
11
12
13
14
15 **Contributors:** RH, CD, CH, and JSF conceptualised the study. RH drafted the protocol. CD, CH,
16 and JSF critically revised the manuscript. RH wrote the final draft manuscript and all the authors
17 approved it.
18
19

20
21
22 **Funding:** This work was supported by the *Ministère de la Santé et des Services sociaux* (MSSS),
23 *Fonds de recherche du Québec – Santé* (FRQS), and *Fonds de recherche du Québec – Société et*
24 *culture* (FRQSC) (Grant number: 2023-0PTR-322652). A grant obtained by the *Centre de*
25 *recherche en santé publique* (CReSP) helped in partially covering the revision and publication fees
26 of this scoping review protocol.
27
28
29

30
31
32 **Competing interests:** None declared.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. World Health Organization. Drugs (psychoactive) [online]; 2022. https://www.who.int/health-topics/drugs-psychoactive#tab=tab_1 (accessed 13 Jul 2023).
2. Adinoff B, Cooper ZD. Cannabis legalization: progress in harm reduction approaches for substance use and misuse. *Am J Drug Alcohol Abuse* 2019;45(6):707–12. doi: 10.1080/00952990.2019.1680683.
3. Jiloha RC. Prevention, early intervention, and harm reduction of substance use in adolescents. *Indian J Psychiatry* 2017;59(1):111–8. doi: 10.4103/0019-5545.204444.
4. Melamed R. Harm reduction-the cannabis paradox. *Harm Reduct J* 2005;2(1):17. doi: 10.1186/1477-7517-2-17.
5. Fischer B, Robinson T, Bullen C, Curran V, Jutras-Aswad D, Medina-Mora ME, et al. Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. *Int J Drug Policy*. 2022;99:103381.
6. Poulin C, Elliott D. Alcohol, tobacco and cannabis use among Nova Scotia adolescents: implications for prevention and harm reduction. *CMAJ* 1997;156(10):1387–93. PMID: **9164396**.
7. Gouvernement du Québec. Plan d'action interministériel en dépendances 2018-2028 – Prévenir, réduire et traiter les conséquences associées à la consommation de substances psychoactives, à la pratique de jeux de hasard et d'argent et à l'utilisation d'Internet [online]. 2018. <https://publications.msss.gouv.qc.ca/msss/document-002078/> (accessed 13 Jul 2023).
8. Zuckermann AM, Gohari MR, Romano I, et al. Changes in cannabis use modes among Canadian youth across recreational cannabis legalization: data from the COMPASS prospective cohort study. *Addict Behav* 2021;122:107025. doi: 10.1016/j.addbeh.2021.107025.
9. Fischer B, Russell C, Sabioni P, Van Den Brink W, Le Foll B, Hall W, et al. Lower-risk cannabis use guidelines: a comprehensive update of evidence and recommendations. *Am J Public Health*. 2017;107(8):e1-e12.

- 1
2
3
4 10. Government of Canada. Canadian Cannabis Survey 2023: Summary [online]. 2023.
5 <https://www.canada.ca/fr/sante-canada/services/drogues->
6 [medicaments/cannabis/recherches-donnees/enquete-canadienne-cannabis-2023-](https://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/recherches-donnees/enquete-canadienne-cannabis-2023-sommaire.html#s2-2)
7 [sommaire.html#s2-2](https://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/recherches-donnees/enquete-canadienne-cannabis-2023-sommaire.html#s2-2) (accessed 13 Feb 2024).
8
9
- 10
11 11. Hathaway AD, Erickson PG. Drug reform principles and policy debates: harm reduction
12 prospects for cannabis in Canada. *J Drug Issues* 2003;33(2):465–95. doi:
13 10.1177/002204260303300209.
14
15
- 16
17 12. Swift W, Copeland J, Lenton S. Cannabis and harm reduction. *Drug Alcohol Rev*
18 2000;19(1):101–12. doi: 10.1080/09595230096200.
19
- 20
21 13. Stockings E, Hall WD, Lynskey M, et al. Prevention, early intervention, harm reduction, and
22 treatment of substance use in young people. *Lancet Psychiatry* 2016;3(3):280–96. doi:
23 10.1016/S2215-0366(16)00002-X.
24
25
- 26
27 14. Englund A, Freeman TP, Murray RM, McGuire P. Can we make cannabis safer? *Lancet*
28 *Psychiatry*. 2017;4(8):643-8. doi: 10.1016/S2215-0366(17)30075-5.
29
- 30
31 15. Lopez-Quintero C, de los Cobos JP, Hasin DS, Okuda M, Wang S, Grant BF, et al.
32 Probability and predictors of transition from first use to dependence on nicotine, alcohol,
33 cannabis, and cocaine: Results of the National Epidemiologic Survey on Alcohol and
34 Related Conditions (NESARC). *Drug Alcohol Depend*. 2011;115(1-2):120-30. doi:
35 10.1016/j.drugalcdep.2010.11.004.
36
37
- 38
39 16. Hindocha C, Shaban ND, Freeman TP, Das RK, Gale G, Schafer G, et al. Associations
40 between cigarette smoking and cannabis dependence: a longitudinal study of young cannabis
41 users in the United Kingdom. *Drug Alcohol Depend*. 2015;148:165-71. doi:
42 10.1016/j.drugalcdep.2015.01.004.
43
44
- 45
46 17. Fischer B, Jones W, Shuper P, et al. 12-month follow-up of an exploratory ‘brief
47 intervention’ for high-frequency cannabis users among Canadian university students. *Subst*
48 *Abuse Treat Prev Policy* 2012;7(1):15. doi: 10.1186/1747-597X-7-15.
49
50
- 51
52 18. Lemyre A, Poliakova N, Bélanger RE. The relationship between tobacco and cannabis use:
53 a review. *Subst Use Misuse*. 2019;54(1):130-45. doi: 10.1080/10826084.2018.1512623.
54
55
56
57
58
59

19. Winer JM, Yule AM, Hadland SE, Bagley SM. Addressing adolescent substance use with a public health prevention framework: the case for harm reduction. *Ann Med*. 2022;54(1):2123-36. doi: 10.1080/07853890.2022.2104922.
20. Bagot KS, Kaminer Y. Harm reduction for youth in treatment for substance use disorders: one size does not fit all. *Curr Addict Rep* 2018;5(3):379–85. doi: 10.1007/s40429-018-0217-8.
21. Jenkins EK, Slemon A, Haines-Saah RJ. Developing harm reduction in the context of youth substance use: insights from a multi-site qualitative analysis of young people’s harm minimization strategies. *Harm Reduct J* 2017;14(1):53. doi: 10.1186/s12954-017-0180-z.
22. González-Ponce BM, Rojas-Tejada AJ, Carmona-Márquez J, Lozano-Rojas ÓM, Díaz-Batanero C, Fernández-Calderón F. Harm reduction strategies among university students who use alcohol and cannabis, and related psychological variables: a systematic review. *J Psychoactive Drugs*. 2022;54(5):403-18. doi: 10.1080/02791072.2021.2023240.
23. Buchanan J, Young L. The war on drugs – a war on drug users? *Drugs (Abingdon Engl)* 2000;7(4):409–22. doi: 10.1080/dep.7.4.409.422.
24. Howe EJ, Bishop LD, Torraville BS, Rowe EC, Kinzel E, Donnan JR. Canadian cannabis education resources to support youth health literacy: A scoping review and environmental scan. *Health Educ J*. 2023;82(7):766-78. doi: 10.1177/00178969231191085.
25. Kruger JS, Kruger D, Collins RL. Knowledge and practice of harm reduction strategies among people who report frequent cannabis use. *Health Promot Pract*. 2021;22(1):24-30. doi: 10.1177/1524839920923999.
26. Watson TM, Valleriani J, Hyshka E, Rueda S. Cannabis legalization in the provinces and territories: missing opportunities to effectively educate youth? *Can J Public Health*. 2019;110:472-5. doi: 10.17269/s41997-019-00209-0.
27. Fallu J-S. Réduction des méfaits: histoire, concepts, pratiques, développements et enjeux [online]. *Journée de la toxicomanie*. Oral presentation, *Journée de la toxicomanie*, 23 Nov 2017; St-Liguori, Québec, Canada. https://www.reseautoxicomanie.com/wp-content/uploads/2017/12/Conférence-JS-Fallu_PNMVH-23-septembre-2017.pdf (accessed 13 Jul 2023).

- 1
- 2
- 3
- 4 28. Mancini MA, Linhorst DM, Broderick F, et al. Challenges to implementing the harm
- 5 reduction approach. *J Soc Work Pract Addict* 2008;8(3):380–408. doi:
- 6 10.1080/15332560802224576.
- 7
- 8
- 9 29. Karoll BR. Applying social work approaches, harm reduction, and practice wisdom to better
- 10 serve those with alcohol and drug use disorders. *J Soc Work* 2010;10(3):263–81. doi:
- 11 10.1177/1468017310363635.
- 12
- 13
- 14 30. Fallu J-S, Brisson P. La réduction des méfaits liés à l’usage des drogues: historique, état des
- 15 lieux, enjeux. In: Massé R, Mondou I, eds. *Réduction des méfaits et tolérance en santé*
- 16 *publique: enjeux éthiques et politique*. Presses de l’Université Laval 2013:105–27.
- 17
- 18
- 19
- 20 31. Ritter A, Cameron J. A review of the efficacy and effectiveness of harm reduction strategies
- 21 for alcohol, tobacco and illicit drugs. *Drug Alcohol Rev* 2006;25(6):611–24. doi:
- 22 10.1080/09595230600944529.
- 23
- 24
- 25
- 26 32. Lau N, Sales P, Averill S, Murphy F, et al. A safer alternative: cannabis substitution as harm
- 27 reduction. *Drug Alcohol Rev* 2015;34(6):654–9. doi: 10.1111/dar.12275.
- 28
- 29
- 30 33. Tsemberis S, Gulcur L, Nakae M. Housing first, consumer choice, and harm reduction for
- 31 homeless individuals with a dual diagnosis. *Am J Public Health* 2004;94(4):651–6. doi:
- 32 10.2105/AJPH.94.4.651.
- 33
- 34
- 35 34. McBride N, Farrington F, Midford R, et al. Harm minimization in school drug education:
- 36 Final results of the School Health and Alcohol Harm Reduction Project (SHAHRP).
- 37 *Addiction* 2004;99(3):278–91. doi: 10.1111/j.1360-0443.2003.00620.x.
- 38
- 39
- 40
- 41 35. Poulin C, Nicholson J. Should harm minimization as an approach to adolescent substance
- 42 use be embraced by junior and senior high schools?: empirical evidence from an integrated
- 43 school- and community-based demonstration intervention addressing drug use among
- 44 adolescents. *Int J Drug Policy* 2005;16(6):403–14. doi: 10.1016/j.drugpo.2005.11.001.
- 45
- 46
- 47
- 48 36. Bertrand K, Blanchette-Martin N, Dufour M, et al. Projet IP-Jeunes : recenser et promouvoir
- 49 les critères d’efficacité reconnus en intervention précoce auprès des jeunes présentant des
- 50 comportements à risque quant à la consommation d’alcool et d’autres drogues, à la pratique
- 51 des jeux de hasard et d’argent et à l’utilisation d’internet. Synthèse des résultats
- 52 préliminaires, 2019-2020 [online]. IUD: Institut universitaire sur les dépendances; 2020.
- 53
- 54
- 55
- 56
- 57
- 58
- 59

1
2
3
4 <https://chairejeunesse.ca/documentation/projet-ip-jeunes-recenser-et-promouvoir-les-criteres-defficacite-reconnus-en-intervention-precoce-aupres-des-jeunes-presentant-des-comportements-a-risque-quant-a-la-consommation-da/> (accessed 13 Jul 2023).
8

- 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
37. Grossbard JR, Mastroleo NR, Kilmer JR, et al. Substance use patterns among first-year college students: secondary effects of a combined alcohol intervention. *J Subst Abuse Treat* 2010;39(4):384–90. doi: 10.1016/j.jsat.2010.07.001.
 38. Palfai TP, Saitz R, Winter M, et al. Web-based screening and brief intervention for student marijuana use in a university health center: pilot study to examine the implementation of eCHECKUP TO GO in different contexts. *Addict Behav* 2014;39(9):1346–52. doi: 10.1016/j.addbeh.2014.04.025.
 39. Sherman BJ, Sofis MJ, Borodovsky JT, Gray KM, McRae-Clark AL, Budney AJ. Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder. *Psychol Addict Behav*. 2022;36(5):505. doi: 10.1037/adb0000760.
 40. Fallu J-S, Gilbert-Lambert MH, D'Arcy Dubois L, et al. Prévention de la consommation à risque ou problématique de substances psychoactives chez les jeunes hébergés en institution au Québec [online]. Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l'Île-de-Montréal (Québec). Direction de l'enseignement universitaire et de la recherche. Institut universitaire sur les dépendances. 2022. <https://iud.quebec/fr/etudes-et-recherche/programme-sur-lusage-et-les-dependances-aux-substances-puds/publications> (accessed 13 Jul 2023).
 41. Sharp A, Barnett JT, Vroom EB. Community perceptions of harm reduction and its implications for syringe exchange policy. *J Drug Issues* 2020;50(4):507–23. doi: 10.1177/0022042620932289.
 42. Lindenfeld Z, Franz B, Cronin C, Chang JE. Hospital adoption of harm reduction and risk education strategies to address substance use disorders. *Am J Drug Alcohol Abuse*. 2023;49(2):206–15. doi: 10.1080/00952990.2023.2169832.
 43. MacCoun RJ. Toward a psychology of harm reduction. *Am Psychol* 1998;53(11):1199–1208. doi: 10.1037/0003-066X.53.11.1199.

- 1
2
3
4 44. Mancini MA, Wyrick-Waugh W. Consumer and practitioner perceptions of the harm
5 reduction approach in a community mental health setting. *Community Ment Health J*
6 2013;49(1):14–24. doi: 10.1007/s10597-011-9451-4.
7
- 8
9 45. Koutroulis G. “That original tension”. Negotiating abstinence in clinicians’ accounts of harm
10 reduction in nonresidential treatment of heroin withdrawal. *J Subst Abuse Treat*
11 2000;19(1):89–98. doi: 10.1016/S0740-5472(99)00087-2.
12
- 13
14 46. Peters MDJ, Godfrey CM, Khalil H, et al. Guidance for conducting systematic scoping
15 reviews. *Int J Evid Based Healthc* 2015;13(3):141–6. doi:
16 10.1097/XEB.0000000000000050.
17
- 18
19 47. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR):
20 checklist and explanation. *Ann Intern Med* 2018;169(7):467–73. doi: 10.7326/M18-0850.
21
- 22
23 48. Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology.
24 *Implement Sci* 2010;5(1):69. doi: 10.1186/1748-5908-5-69.
25
- 26
27 49. Arksey H, O’Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res*
28 *Methodol* 2005;8(1):19–32. doi: 10.1080/1364557032000119616.
29
- 30
31 50. Peters MDJ, Godfrey C, McInerney P, et al. Chapter 11: Scoping reviews. In: Aromataris E,
32 Munn Z, eds. *JBIM Manual for Evidence Synthesis*. JBI, 2020. doi: 10.46658/JBIMES-20-12.
33
- 34
35 51. Peterson J, Pearce PF, Ferguson LA, et al. Understanding scoping reviews: definition,
36 purpose, and process. *J Am Assoc Nurse Pract* 2017;29(1):12–6. doi: 10.1002/2327-
37 6924.12380.
38
- 39
40 52. Pollock D, Tricco AC, Peters MD, et al. Methodological quality, guidance, and tools in
41 scoping reviews: a scoping review protocol. *JBIM Evid Synth* 2022;20(4):1098–105. doi:
42 10.11124/JBIES-20-00570.
43
- 44
45 53. McGowan J, Sampson M, Salzwedel DM, et al. PRESS peer review of electronic search
46 strategies: 2015 guideline statement. *J Clin Epidemiol* 2016;75:40–6. doi:
47 10.1016/j.jclinepi.2016.01.021.
48
- 49
50 54. Gedda M. Traduction française des lignes directrices PRISMA pour l’écriture et la lecture
51 des revues systématiques et des méta-analyses [French translation of the PRISMA Reporting
52
53
54
55
56
57
58
59
60

1
2
3
4 Guidelines for writing and reading systematic reviews and meta-analyses]. *Kinesither Rev*
5 2015;15(157):39–44. doi: 10.1016/j.kine.2014.11.004.
6

- 7
8 55. Colquhoun HL, Levac D, O'Brien KK, et al. Scoping reviews: time for clarity in definition,
9 methods, and reporting. *J Clin Epidemiol* 2014;67(12):1291–4. doi:
10 10.1016/j.jclinepi.2014.03.013.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Facilitators of and barriers to healthcare providers' adoption of harm reduction in cannabis use: a scoping review protocol

Roula Haddad, Christian Dagenais, Christophe Huynh, Jean-Sébastien Fallu

Supplemental Appendix: Search strategies executed on all databases

Appendix 1: Medline Search Strategy

| # | Concept | Equations | Results |
|----|------------------------------------|--|----------|
| 1 | Harm reduction | Harm Reduction/ | 3898 |
| 2 | | Risk Reduction Behavior/ | 14132 |
| 3 | | (protective adj2 strateg*).ab,kf,ti. | 2818 |
| 4 | | ((reduc* or minimi*) adj5 (harm? or harmful or risk?)).ab,kf,ti. | 239459 |
| 5 | | 1 or 2 or 3 or 4 | 251821 |
| 6 | Clinicians | exp Health Personnel/ | 588634 |
| 7 | | Social Workers/ | 971 |
| 8 | | Counselors/ | 541 |
| 9 | | exp Health Occupations/ | 1819039 |
| 10 | | exp Allied Health Occupations/ | 52626 |
| 11 | | exp Allied Health Personnel/ | 53169 |
| 12 | | (worker? or psychoeducator? or psycho-educator? or educator? or nurse? or criminologist? or psychologist? or clinician? or practitioner? or physician? or professional? or provider? or co?nselor or co?nselors or caregiver? or giver? or therapist? or psychotherapist? or staff? or personnel? or employee? or doctor?).ab,kf,ti. | 2002544 |
| 13 | 6 or 7 or 8 or 9 or 10 or 11 or 12 | 3625104 | |
| 14 | Cannabis | Cannabis/ | 12307 |
| 15 | | "Marijuana Use"/ | 1689 |
| 16 | | Marijuana Abuse/ | 6905 |
| 17 | | Marijuana Smoking/ | 5425 |
| 18 | | (mari?uana or cannabis or hashish or Pot or weed or tetrahydrocannabinol or THC or CDB or cannabidiol or cannabinoid?).ab,kf,ti. | 100005 |
| 19 | 14 or 15 or 16 or 17 or 18 | 102988 | |
| 20 | Strategies | ("strateg*" or "approach*" or intervention? or prevent* or practice? or service? or "method*" or technique? or tactic? or co?nseling or treatment? or program? or "guide*").ab,kf,ti. | 15074452 |
| 21 | Combination of 3 concepts | 5 and 13 and 19 | 272 |
| 22 | Limit date | limit 21 to yr="1990 -Current" | 272 |
| 23 | Limit language | limit 22 to (english or french) | 263 |
| 24 | Filter OECD | | |
| 25 | TOTAL | 23 not 24 | 249 |
| 22 | Combination of 4 concepts | 5 and 13 and 19 and 20 | 251 |

Appendix 2: PsycINFO

(((((((title: (reduc*)) OR ((title: (minimi*)))) NEAR/5 (((title: (harm))) OR ((title: (harms))) OR
 ((title: (harmful))) OR ((title: (risk))) OR ((title: (risks)))) OR (((abstract: (reduc*)) OR ((abstract:
 (minimi*)))) NEAR/5 (((abstract: (harm))) OR ((abstract: (harms))) OR ((abstract: (harmful))) OR
 ((abstract: (risk))) OR ((abstract: (risks)))) OR (((Keywords: (reduc*)) OR ((Keywords:
 (minimi*)))) NEAR/5 (((Keywords: (harm))) OR ((Keywords: (harms))) OR ((Keywords:
 (harmful))) OR ((Keywords: (risk))) OR ((Keywords: (risks)))) OR (((title: (protective NEAR/2
 strateg*))) OR (((abstract: (protective NEAR/2 strateg*))) OR (((Keywords: (protective NEAR/2
 strateg*)))) OR (((MeSH: (Risk Reduction Behavior)))) OR (((MeSH: (Harm Reduction)))) AND
 (((MeSH: (Health Personnel)))) OR (((MeSH: (Social Workers)))) OR (((MeSH:
 (Counselors)))) OR (((MeSH: (Health Occupations)))) OR (((MeSH: (Allied Health
 Occupations)))) OR (((MeSH: (Allied Health Personnel)))) OR (((Keywords: (worker*)) OR
 ((Keywords: (psychoeducator*)) OR ((Keywords: (psycho-educator*)) OR ((Keywords:
 (educator*)) OR ((Keywords: (nurse*)) OR ((Keywords: (criminologist*)) OR ((Keywords:
 (psychologist*)) OR ((Keywords: (clinician*)) OR ((Keywords: (practitioner*)) OR
 ((Keywords: (physician*)) OR ((Keywords: (professional*)) OR ((Keywords: (provider*)) OR
 ((Keywords: (conselor)) OR ((Keywords: (conselors)) OR ((Keywords: (counselor)) OR
 ((Keywords: (counselers)) OR ((Keywords: (caregiver*)) OR ((Keywords: (giver*)) OR
 ((Keywords: (therapist*)) OR ((Keywords: (psychotherapist*)) OR ((Keywords: (staff*)) OR
 ((Keywords: (personnel*)) OR ((Keywords: (employee*)) OR ((Keywords: (doctor*)) OR
 ((abstract: (worker*)) OR ((abstract: (psychoeducator*)) OR ((abstract: (psycho-educator*))
 OR ((abstract: (educator*)) OR ((abstract: (nurse*)) OR ((abstract: (criminologist*)) OR
 ((abstract: (psychologist*)) OR ((abstract: (clinician*)) OR ((abstract: (practitioner*)) OR
 ((abstract: (physician*)) OR ((abstract: (professional*)) OR ((abstract: (provider*)) OR
 ((abstract: (conselor)) OR ((abstract: (conselors)) OR ((abstract: (counselor)) OR ((abstract:
 (counselers)) OR ((abstract: (caregiver*)) OR ((abstract: (giver*)) OR ((abstract: (therapist*))
 OR ((abstract: (psychotherapist*)) OR ((abstract: (staff*)) OR ((abstract: (personnel*)) OR
 ((abstract: (employee*)) OR ((abstract: (doctor*)))) AND (((Keywords: (marijuana)) OR
 ((Keywords: (marihuana)) OR ((Keywords: (cannabis)) OR ((Keywords: (hashish)) OR
 ((Keywords: (Pot)) OR ((Keywords: (weed)) OR ((Keywords: (tetrahydrocannabinol)) OR
 ((Keywords: (THC)) OR ((Keywords: (CDB)) OR ((Keywords: (cannabidiol)) OR ((Keywords:
 (cannabinoid)) OR ((Keywords: (cannabinoids)) OR ((abstract: (marijuana)) OR ((abstract:
 (marihuana)) OR ((abstract: (cannabis)) OR ((abstract: (hashish)) OR ((abstract: (Pot)) OR
 ((abstract: (weed)) OR ((abstract: (tetrahydrocannabinol)) OR ((abstract: (THC)) OR ((abstract:
 (CDB)) OR ((abstract: (cannabidiol)) OR ((abstract: (cannabinoid)) OR ((abstract:
 (cannabinoids)))) OR (((MeSH: (Marijuana Smoking)))) OR (((MeSH: (Marijuana Abuse))))
 OR (((MeSH: ("Marijuana Use")))) OR (((MeSH: (Cannabis)))) AND ((Year: [1990 TO
 9999])) NOT (((Keywords: (afghanistan/)) OR (Keywords: (africa/)) OR (Keywords: (africa,
 northern/)) OR (Keywords: (africa, central/)) OR (Keywords: (africa, eastern/)) OR (Keywords:
 ("africa south of the sahara" /)) OR (Keywords: (africa, southern/)) OR (Keywords: (africa,
 western/)) OR (Keywords: (albania/)) OR (Keywords: (algeria/)) OR (Keywords: (andorra/)) OR
 (Keywords: (angola/)) OR (Keywords: ("antigua and barbuda" /)) OR (Keywords: (argentina/))
 OR (Keywords: (armenia/)) OR (Keywords: (azerbaijan/)) OR (Keywords: (bahamas/)) OR
 (Keywords: (bahrain/)) OR (Keywords: (bangladesh/)) OR (Keywords: (barbados/)) OR
 (Keywords: (belize/)) OR (Keywords: (benin/)) OR (Keywords: (bhutan/)) OR (Keywords:
 (bolivia/)) OR (Keywords: (borneo/)) OR (Keywords: ("bosnia and herzegovina" /)) OR

(Keywords: (botswana/)) OR (Keywords: (brazil/)) OR (Keywords: (brunei/)) OR (Keywords: (bulgaria/)) OR (Keywords: (burkina faso/)) OR (Keywords: (burundi/)) OR (Keywords: (cabo verde/)) OR (Keywords: (cambodia/)) OR (Keywords: (cameroon/)) OR (Keywords: (central african republic/)) OR (Keywords: (chad/)) OR (Keywords: (exp china/)) OR (Keywords: (comoros/)) OR (Keywords: (congo/)) OR (Keywords: (cote d'ivoire/)) OR (Keywords: (croatia/)) OR (Keywords: (cuba/)) OR (Keywords: ("democratic republic of the congo" /)) OR (Keywords: (cyprus/)) OR (Keywords: (djibouti/)) OR (Keywords: (dominica/)) OR (Keywords: (dominican republic/)) OR (Keywords: (ecuador/)) OR (Keywords: (egypt/)) OR (Keywords: (el salvador/)) OR (Keywords: (equatorial guinea/)) OR (Keywords: (eritrea/)) OR (Keywords: (eswatini/)) OR (Keywords: (ethiopia/)) OR (Keywords: (fiji/)) OR (Keywords: (gabon/)) OR (Keywords: (gambia/)) OR (Keywords: ("georgia (republic)" /)) OR (Keywords: (ghana/)) OR (Keywords: (grenada/)) OR (Keywords: (guatemala/)) OR (Keywords: (guinea/)) OR (Keywords: (guinea-bissau/)) OR (Keywords: (guyana/)) OR (Keywords: (haiti/)) OR (Keywords: (honduras/)) OR (Keywords: (independent state of samoa/)) OR (Keywords: (exp india/)) OR (Keywords: (indian ocean islands/)) OR (Keywords: (indochina/)) OR (Keywords: (indonesia/)) OR (Keywords: (iran/)) OR (Keywords: (iraq/)) OR (Keywords: (jamaica/)) OR (Keywords: (jordan/)) OR (Keywords: (kazakhstan/)) OR (Keywords: (kenya/)) OR (Keywords: (kosovo/)) OR (Keywords: (kuwait/)) OR (Keywords: (kyrgyzstan/)) OR (Keywords: (laos/)) OR (Keywords: (lebanon/)) OR (Keywords: (liechtenstein/)) OR (Keywords: (lesotho/)) OR (Keywords: (liberia/)) OR (Keywords: (libya/)) OR (Keywords: (madagascar/)) OR (Keywords: (malaysia/)) OR (Keywords: (malawi/)) OR (Keywords: (mali/)) OR (Keywords: (malta/)) OR (Keywords: (mauritania/)) OR (Keywords: (mauritiuS/)) OR (Keywords: (mekong valley/)) OR (Keywords: (melanesia/)) OR (Keywords: (micronesia/)) OR (Keywords: (monaco/)) OR (Keywords: (mongolia/)) OR (Keywords: (montenegro/)) OR (Keywords: (morocco/)) OR (Keywords: (mozambique/)) OR (Keywords: (myanmar/)) OR (Keywords: (namibia/)) OR (Keywords: (nepal/)) OR (Keywords: (nicaragua/)) OR (Keywords: (niger/)) OR (Keywords: (nigeria/)) OR (Keywords: (oman/)) OR (Keywords: (pakistan/)) OR (Keywords: (palau/)) OR (Keywords: (exp panama/)) OR (Keywords: (papua new guinea/)) OR (Keywords: (paraguay/)) OR (Keywords: (peru/)) OR (Keywords: (philippines/)) OR (Keywords: (qatar/)) OR (Keywords: ("republic of belarus" /)) OR (Keywords: ("republic of north macedonia" /)) OR (Keywords: (romania/)) OR (Keywords: (exp russia/)) OR (Keywords: (rwanda/)) OR (Keywords: ("saint kitts and nevis" /)) OR (Keywords: (saint lucia/)) OR (Keywords: ("saint vincent and the grenadines" /)) OR (Keywords: ("sao tome and principe" /)) OR (Keywords: (saudi arabia/)) OR (Keywords: (serbia/)) OR (Keywords: (sierra leone/)) OR (Keywords: (senegal/)) OR (Keywords: (seychelles/)) OR (Keywords: (singapore/)) OR (Keywords: (somalia/)) OR (Keywords: (south africa/)) OR (Keywords: (south sudan/)) OR (Keywords: (sri lanka/)) OR (Keywords: (sudan/)) OR (Keywords: (suriname/)) OR (Keywords: (syria/)) OR (Keywords: (taiwan/)) OR (Keywords: (tajikistan/)) OR (Keywords: (tanzania/)) OR (Keywords: (thailand/)) OR (Keywords: (timor-leste/)) OR (Keywords: (togo/)) OR (Keywords: (tonga/)) OR (Keywords: ("trinidad and tobago" /)) OR (Keywords: (tunisia/)) OR (Keywords: (turkmenistan/)) OR (Keywords: (uganda/)) OR (Keywords: (ukraine/)) OR (Keywords: (united arab emirates/)) OR (Keywords: (uruguay/)) OR (Keywords: (uzbekistan/)) OR (Keywords: (vanuatu/)) OR (Keywords: (venezuela/)) OR (Keywords: (vietnam/)) OR (Keywords: (west indies/)) OR (Keywords: (yemen/)) OR (Keywords: (zambia/)) OR (Keywords: (zimbabwe/))) AND Any Field: - (((Keywords: (australasia/)) OR (Keywords: (exp australia/)) OR (Keywords: (austria/)) OR (Keywords: (baltic states/)) OR (Keywords: (belgium/)) OR (Keywords: (exp canada/)) OR (Keywords: (chile/)) OR (Keywords: (colombia/)) OR (Keywords: (costa rica/)) OR

1
2
3 (Keywords: (czech republic/)) OR (Keywords: (exp denmark/)) OR (Keywords: (estonia/)) OR
4 (Keywords: (europe/)) OR (Keywords: (finland/)) OR (Keywords: (exp france/)) OR (Keywords:
5 (exp germany/)) OR (Keywords: (greece/)) OR (Keywords: (hungary/)) OR (Keywords:
6 (iceland/)) OR (Keywords: (ireland/)) OR (Keywords: (israel/)) OR (Keywords: (exp italy/)) OR
7 (Keywords: (exp japan/)) OR (Keywords: (korea/)) OR (Keywords: (latvia/)) OR (Keywords:
8 (lithuania/)) OR (Keywords: (luxembourg/)) OR (Keywords: (mexico/)) OR (Keywords:
9 (netherlands/)) OR (Keywords: (new zealand/)) OR (Keywords: (north america/)) OR (Keywords:
10 (exp norway/)) OR (Keywords: (poland/)) OR (Keywords: (portugal/)) OR (Keywords: (exp
11 "republic of korea" /)) OR (Keywords: ("scandinavian and nordic countries" /)) OR (Keywords:
12 (slovakia/)) OR (Keywords: (slovenia/)) OR (Keywords: (spain/)) OR (Keywords: (sweden/)) OR
13 (Keywords: (switzerland/)) OR (Keywords: (turkey/)) OR (Keywords: (exp united kingdom/)) OR
14 (Keywords: (exp united states/)) OR (Keywords: (European Union/)) OR (Keywords: (Developed
15 Countries/))))))
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix 3: CINAHL

| # | Question | Results |
|-----|---|-----------|
| S1 | MW "harm# reduction#" | 4,889 |
| S2 | MW "risk# reduction#" | 0 |
| S3 | TI protective N2 strateg* OR AB protective N2 strateg* OR SU protective N2 strateg* | 1,167 |
| S4 | SU ((reduc* or minimi*) N5 (harm# or harmful or risk#)) OR TI ((reduc* or minimi*) N5 (harm# or harmful or risk#)) OR AB ((reduc* or minimi*) N5 (harm# or harmful or risk#)) | 96,037 |
| S5 | S1 OR S2 OR S3 OR S4 | 97,005 |
| S6 | MW "Health Personnel#" | 112,080 |
| S7 | MW "Social Worker#" | 11,786 |
| S8 | MW Counselors | 4,471 |
| S9 | MW "Health Occupation#" | 5,719 |
| S10 | MW "Allied Health Occupation#" | 0 |
| S11 | MW "Allied Health Personnel#" | 4,781 |
| S12 | TI (worker or psychoeducator or psycho-educator or educator or nurse or criminologist or psychologist or clinician or practitioner or physician or professional or provider or counse#lor or counse#lors or caregiver or giver or therapist or psychotherapist or staff or personnel or employee or doctor) OR AB (worker or psychoeducator or psycho-educator or educator or nurse or criminologist or psychologist or clinician or practitioner or physician or professional or provider or counse#lor or counse#lors or caregiver or giver or therapist or psychotherapist or staff or personnel or employee or doctor) OR SU (worker or psychoeducator or psycho-educator or educator or nurse or criminologist or psychologist or clinician or practitioner or physician or professional or provider or counse#lor or counse#lors or caregiver or giver or therapist or psychotherapist or staff or personnel or employee or doctor) | 1,762,879 |
| S13 | S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 | 1,765,867 |

| | | |
|-----|---|---------|
| S14 | MW Cannabis | 11,138 |
| S15 | MW Marijuana | 2,219 |
| S16 | TI (mari#uana or cannabis or hashish or Pot or weed or tetrahydrocannabinol or THC or CDB or cannabidiol or cannabinoid#) OR AB (mari#uana or cannabis or hashish or Pot or weed or tetrahydrocannabinol or THC or CDB or cannabidiol or cannabinoid#) OR SU (mari#uana or cannabis or hashish or Pot or weed or tetrahydrocannabinol or THC or CDB or cannabidiol or cannabinoid#) | 26,526 |
| S17 | S14 OR S15 OR S16 | 26,526 |
| S18 | S5 AND S13 AND S17 | 147 |
| S19 | S5 AND S13 AND S17 | 147 |
| S20 | S5 AND S13 AND S17 | 147 |
| S21 | S5 AND S13 AND S17 | 72 |
| S22 | SU afghanistan/ or africa/ or africa, northern/ or africa, central/ or africa, eastern/ or "africa south of the sahara"/ or africa, southern/ or africa, western/ or albania/ or algeria/ or andorra/ or angola/ or "antigua and barbuda"/ or argentina/ or armenia/ or azerbaijan/ or bahamas/ or bahrain/ or bangladesh/ or barbados/ or belize/ or benin/ or bhutan/ or bolivia/ or borneo/ or "bosnia and herzegovina"/ or botswana/ or brazil/ or brunei/ or bulgaria/ or burkina faso/ or burundi/ or cabo verde/ or cambodia/ or cameroon/ or central african republic/ or chad/ or exp china/ or comoros/ or congo/ or cote d'ivoire/ or croatia/ or cuba/ or "democratic republic of the congo"/ or cyprus/ or djibouti/ or dominica/ or dominican republic/ or ecuador/ or egypt/ or el salvador/ or equatorial guinea/ or eritrea/ or eswatini/ or ethiopia/ or fiji/ or gabon/ or gambia/ or "georgia (republic)"/ or ghana/ or grenada/ or guatemala/ or guinea/ or guinea-bissau/ or guyana/ or haiti/ or honduras/ or independent state of samoa/ or exp india/ or indian ocean islands/ or indochina/ or indonesia/ or iran/ or iraq/ or jamaica/ or jordan/ or kazakhstan/ or kenya/ or kosovo/ or kuwait/ or kyrgyzstan/ or laos/ or lebanon/ or liechtenstein/ or lesotho/ or liberia/ or libya/ or madagascar/ or malaysia/ or malawi/ or | 159,916 |

| | | |
|-----|---|---------|
| | mali/ or malta/ or mauritania/ or mauritius/ or mekong valley/ or melanesia/ or micronesia/ or monaco/ or mongolia/ or montenegro/ or morocco/ or mozambique/ or myanmar/ or namibia/ or nepal/ or nicaragua/ or niger/ or nigeria/ or oman/ or pakistan/ or palau/ or exp panama/ or papua new guinea/ or paraguay/ or peru/ or philippines/ or qatar/ or "republic of belarus"/ or "republic of north macedonia"/ or romania/ or exp russia/ or rwanda/ or "saint kitts and nevis"/ or saint lucia/ or "saint vincent and the grenadines"/ or "sao tome and principe"/ or saudi arabia/ or serbia/ or sierra leone/ or senegal/ or seychelles/ or singapore/ or somalia/ or south africa/ or south sudan/ or sri lanka/ or sudan/ or suriname/ or syria/ or taiwan/ or tajikistan/ or tanzania/ or thailand/ or timor-leste/ or togo/ or tonga/ or "trinidad and tobago"/ or tunisia/ or turkmenistan/ or uganda/ or ukraine/ or united arab emirates/ or uruguay/ or uzbekistan/ or vanuatu/ or venezuela/ or vietnam/ or west indies/ or yemen/ or zambia/ or zimbabwe/ | |
| S23 | SU australasia/ or exp australia/ or austria/ or baltic states/ or belgium/ or exp canada/ or chile/ or colombia/ or costa rica/ or czech republic/ or exp denmark/ or estonia/ or europe/ or finland/ or exp france/ or exp germany/ or greece/ or hungary/ or iceland/ or ireland/ or israel/ or exp italy/ or exp japan/ or korea/ or latvia/ or lithuania/ or luxembourg/ or mexico/ or netherlands/ or new zealand/ or north america/ or exp norway/ or poland/ or portugal/ or exp "republic of korea"/ or "scandinavian and nordic countries"/ or slovakia/ or slovenia/ or spain/ or sweden/ or switzerland/ or turkey/ or exp united kingdom/ or exp united states/ OR European Union/ OR Developed Countries/ | 158,684 |
| S24 | S22 NOT S23 | 154,938 |
| S25 | S21 NOT S24 | 66 |

Appendix 4: Web of Science

| # | Question | Results |
|----|--|-----------|
| #1 | TS=(harm reduction OR risk reduction behavior OR (protective NEAR/2 strateg*) OR ((reduc* OR minimi*) NEAR/5 (harm OR harms OR harmful OR risk OR risks))) | 329,523 |
| #2 | TS=(cannabis OR marijuana OR mari\$uana OR hashish OR pot OR weed OR tetrahydrocannabinol OR THC OR CDB OR cannabidiol OR cannabinoid\$) | 305,377 |
| #3 | TS=(health personnel OR social worker\$ OR counselor\$ OR health occupation\$ OR worker\$ OR psychoeducator\$ OR psycho-educator\$ OR nurse\$ OR criminologist\$ OR psychologist\$ OR clinician\$ OR practitioner\$ OR physician\$ OR professional\$ OR provider\$ OR co\$nselor OR co\$nselors OR caregiver\$ OR giver\$ OR therapist\$ OR psychotherapist\$ OR staff\$ OR personnel\$ OR employee\$ OR doctor\$) | 2,593,408 |
| #4 | #1 AND #2 AND #3 | 331 |
| #5 | #4 and English or French (Languages) | 324 |
| #6 | #5 and [Countries/Regions filter: pays de l'OCDE] | 300 |
| | | |

Appendix 5: Embase

| | | |
|----|--|---------|
| 1 | Harm Reduction/ | 8189 |
| 2 | Risk Reduction Behavior/ | 115695 |
| 3 | (protective adj2 strateg*).ab,kf,ti. | 3987 |
| 4 | ((reduc* or minimi*) adj5 (harm? or harmful or risk?)).ab,kf,ti. | 345174 |
| 5 | 1 or 2 or 3 or 4 | 414447 |
| 6 | exp Health Personnel/ | 1843814 |
| 7 | Social Workers/ | 12409 |
| 8 | Counselors/ | 3692 |
| 9 | exp Health Occupations/ | 24456 |
| 10 | exp Allied Health Occupations/ | 392205 |
| 11 | exp Allied Health Personnel/ | 567029 |
| 12 | (worker? or (psychoeducator? or psycho-educator?) or educator? or nurse? or criminologist? or psychologist? or clinician? or practitioner? or physician? or professional? or provider? or co?nselor or co?nselors or caregiver? or giver? or therapist? or psychotherapist? or staff? or personnel? or employee? or doctor?).ab,kf,ti. | 2640146 |
| 13 | 6 or 7 or 8 or 9 or 10 or 11 or 12 | 3761559 |
| 14 | Cannabis/ | 40937 |
| 15 | "Marijuana Use"/ | 12636 |
| 16 | Marijuana Abuse/ | 6445 |
| 17 | Marijuana Smoking/ | 4026 |
| 18 | (mari?uana or cannabis or has?hish or Pot or weed or tetrahydrocannabinol or THC or CDB or cannabidiol or cannabinoid?).ab,kf,ti. | 129932 |
| 19 | 14 or 15 or 16 or 17 or 18 | 142957 |
| 20 | 5 and 13 and 19 | 569 |
| 21 | limit 32 to yr="1990 -Current" | 569 |
| 22 | limit 21 to (english or french) | 560 |
| 23 | Filtre OCDE | 520 |

Appendix 6: Sociological Abstracts

(((ti(health personnel OR social worker OR social workers OR counselor OR counselors OR
conselor OR conselors OR health occupation OR health occupations OR worker* OR
psychoeducator* OR psycho-educator* OR educator* OR nurse* OR criminologist* OR
psychologist* OR clinician* OR professional* OR provider* OR caregiver* OR giver* OR
therapist* OR psychotherapist* OR staff* OR personnel* OR employee* OR doctor*)) OR
ab(health personnel OR social worker OR social workers OR counselor OR counselors OR
conselor OR conselors OR health occupation OR health occupations OR worker* OR
psychoeducator* OR psycho-educator* OR educator* OR nurse* OR criminologist* OR
psychologist* OR clinician* OR professional* OR provider* OR caregiver* OR giver* OR
therapist* OR psychotherapist* OR staff* OR personnel* OR employee* OR doctor*)) OR
su(health personnel OR social worker OR social workers OR counselor OR counselors OR
conselor OR conselors OR health occupation OR health occupations OR worker* OR
psychoeducator* OR psycho-educator* OR educator* OR nurse* OR criminologist* OR
psychologist* OR clinician* OR professional* OR provider* OR caregiver* OR giver* OR
therapist* OR psychotherapist* OR staff* OR personnel* OR employee* OR doctor*)) AND
(ti(cannabis OR marijuana OR mari*uana OR hashish OR pot OR weed OR tetrahydrocannabinol
OR THC OR CDB OR cannabidiol OR cannabinoid*) OR ab(cannabis OR marijuana OR
mari*uana OR hashish OR pot OR weed OR tetrahydrocannabinol OR THC OR CDB OR
cannabidiol OR cannabinoid*) OR su(cannabis OR marijuana OR mari*uana OR hashish OR pot
OR weed OR tetrahydrocannabinol OR THC OR CDB OR cannabidiol OR cannabinoid*)) AND
(((reduc* OR minimi*) NEAR/5 (harm OR harms OR harmful OR risk OR risks)) OR
ab((reduc* OR minimi*) NEAR/5 (harm OR harms OR harmful OR risk OR risks)) OR su((reduc*
OR minimi*) NEAR/5 (harm OR harms OR harmful OR risk OR risks))) OR (ti(protective
NEAR/2 strateg*) OR ab(protective NEAR/2 strateg*) OR su(protective NEAR/2 strateg*)))
AND la.exact("ENG")) AND yr(1990-2029)

Appendix 7: Google Scholar

cannabis intitle:nurse OR intitle:clinician OR intitle:practitioner OR intitle:physician OR intitle:caregiver OR intitle:giver OR intitle:doctor "harm reduction" = 105

cannabis intitle:nurses OR intitle:clinicians OR intitle:practitioners OR intitle:physicians OR intitle:caregivers OR intitle:givers OR intitle:doctors "harm reduction" = 242

cannabis intitle:psychoeducator OR intitle:educator OR intitle:therapist OR intitle:psychotherapist OR intitle:criminologist OR intitle:psychologist "harm reduction" = 19

cannabis intitle:psychoeducators OR intitle:educators OR intitle:therapists OR intitle:psychotherapists OR intitle:criminologists OR intitle:psychologists "harm reduction" = 53

cannabis intitle:worker OR intitle:staff OR intitle:personnel OR intitle:employee OR intitle:professional OR intitle:provider OR intitle:counselor OR intitle:conselor "harm reduction" = 136

cannabis intitle: workers OR intitle:staffs OR intitle:personnels OR intitle:employees OR intitle:professionals OR intitle:providers OR intitle:counselors OR intitle:conselors "harm reduction" = 5

cannabis intitle:infirmier OR intitle:médecin OR intitle:clinicien OR intitle:psychoéducateur OR intitle:éducateur OR intitle:thérapeute OR intitle:psychothérapeute OR intitle:criminologue OR intitle:psychologue "reduction des méfaits" = 1

cannabis intitle:travailleur OR intitle:personnel OR intitle:employé OR intitle:professionnel OR intitle:conseiller OR intitle:intervenant "reduction des méfaits" = 5

cannabis intitle:infirmiers OR intitle:médecins OR intitle:cliniciens OR intitle:psychoéducateurs OR intitle:éducateurs OR intitle:thérapeutes OR intitle:psychothérapeutes OR intitle:criminologues OR intitle:psychologues "reduction des méfaits" = 3

cannabis intitle:travailleurs OR intitle:personnels OR intitle:employés OR intitle:professionnels OR intitle:conseillers OR intitle:intervenants "reduction des méfaits" = 12

cannabis intitle:infirmière OR intitle:clinicienne OR intitle:psychoéducatrice OR intitle:éducatrice OR intitle:criminologue OR intitle:psychologue "reduction des méfaits" = 2

cannabis intitle:travailleuse OR intitle:employée OR intitle:professionnelle OR intitle:conseillère OR intitle:intervenante "reduction des méfaits" = 1

cannabis intitle:infirmières OR intitle:cliniciennes OR intitle:psychoéducatrices OR intitle:éducatrices OR intitle:criminologues OR intitle:psychologues "reduction des méfaits" = 2

cannabis intitle:travailleuses OR intitle:employées OR intitle:professionnelles OR intitle:conseillères OR intitle:intervenantes "reduction des méfaits" = 2

marijuana intitle:nurse OR intitle:clinician OR intitle:practitioner OR intitle:physician OR intitle:caregiver OR intitle:giver OR intitle:doctor "harm reduction" = 139

marijuana intitle:nurses OR intitle:clinicians OR intitle:practitioners OR intitle:physicians OR intitle:caregivers OR intitle:givers OR intitle:doctors "harm reduction" = 238

marijuana intitle:psychoeducator OR intitle:educator OR intitle:therapist OR intitle:psychotherapist OR intitle:criminologist OR intitle:psychologist "harm reduction" = 19

1
2
3 marijuana intitle:psychoeducators OR intitle:educators OR intitle:therapists OR
4 intitle:psychotherapists OR intitle:criminologists OR intitle:psychologists "harm reduction" = 48

5
6 marijuana intitle:worker OR intitle:staff OR intitle:personnel OR intitle:employee OR
7 intitle:professional OR intitle:provider OR intitle:counselor OR intitle:conselor "harm reduction"
8 = 140

9
10 marijuana intitle:workers OR intitle:staffs OR intitle:personnels OR intitle:employees OR
11 intitle:professionals OR intitle:providers OR intitle:counselors OR intitle:conselors "harm
12 reduction" = 573

13
14 marijuana intitle:infirmier OR intitle:médecin OR intitle:clinicien OR intitle:psychoéducateur OR
15 intitle:éducateur OR intitle:thérapeute OR intitle:psychothérapeute OR intitle:criminologue OR
16 intitle:psychologue "réduction des méfaits" = 1

17
18 marijuana intitle:travailleur OR intitle:personnel OR intitle:employé OR intitle:professionnel OR
19 intitle:conseiller OR intitle:intervenant "réduction des méfaits" = 5

20
21 marijuana intitle:infirmiers OR intitle:médecins OR intitle:cliniciens OR intitle:psychoéducateurs
22 OR intitle:éducateurs OR intitle:thérapeutes OR intitle:psychothérapeutes OR
23 intitle:criminologues OR intitle:psychologues "réduction des méfaits" = 3

24
25 marijuana intitle:travailleurs OR intitle:personnels OR intitle:employés OR intitle:professionnels
26 OR intitle:conseillers OR intitle:intervenants "réduction des méfaits" = 12

27
28 marijuana intitle:infirmière OR intitle:clinicienne OR intitle:psychoéducatrice OR
29 intitle:éducatrice OR intitle:criminologue OR intitle:psychologue "réduction des méfaits" = 2

30
31 marijuana intitle:travailleuse OR intitle:employée OR intitle:professionnelle OR intitle:conseillère
32 OR intitle:intervenante "réduction des méfaits" = 1

33
34 marijuana intitle:infirmières OR intitle:cliniciennes OR intitle:psychoéducatrices OR
35 intitle:éducatrices OR intitle:criminologues OR intitle:psychologues "réduction des méfaits" = 2

36
37 marijuana intitle:travailleuses OR intitle:employées OR intitle:professionnelles OR
38 intitle:conseillères OR intitle:intervenantes "réduction des méfaits" = 2
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix 8: Google Web

cannabis intitle:nurse OR intitle:clinician OR intitle:practitioner OR intitle:physician OR intitle:caregiver OR intitle:giver OR intitle:doctor "harm reduction" filetype:pdf =

cannabis intitle:nurses OR intitle:clinicians OR intitle:practitioners OR intitle:physicians OR intitle:caregivers OR intitle:givers OR intitle:doctors "harm reduction" filetype:pdf =

cannabis intitle:psychoeducator OR intitle:educator OR intitle:therapist OR intitle:psychotherapist OR intitle:criminologist OR intitle:psychologist "harm reduction" filetype:pdf =

cannabis intitle:psychoeducators OR intitle:educators OR intitle:therapists OR intitle:psychotherapists OR intitle:criminologists OR intitle:psychologists "harm reduction" filetype:pdf =

cannabis intitle:worker OR intitle:staff OR intitle:personnel OR intitle:employee OR intitle:professional OR intitle:provider OR intitle:counselor OR intitle:conselor "harm reduction" filetype:pdf =

cannabis intitle: workers OR intitle:staffs OR intitle:personnels OR intitle:employees OR intitle:professionals OR intitle:providers OR intitle:counselors OR intitle:conselors "harm reduction" filetype:pdf =

cannabis intitle:infirmier OR intitle:médecin OR intitle:clinicien OR intitle:psychoéducateur OR intitle:éducateur OR intitle:thérapeute OR intitle:psychothérapeute OR intitle:criminologue OR intitle:psychologue "reduction des méfaits" filetype:pdf =

cannabis intitle:travailleur OR intitle:personnel OR intitle:employé OR intitle:professionnel OR intitle:conseiller OR intitle:intervenant "reduction des méfaits" filetype:pdf =

cannabis intitle:infirmiers OR intitle:médecins OR intitle:cliniciens OR intitle:psychoéducateurs OR intitle:éducateurs OR intitle:thérapeutes OR intitle:psychothérapeutes OR intitle:criminologues OR intitle:psychologues "reduction des méfaits" filetype:pdf =

cannabis intitle:travailleurs OR intitle:personnels OR intitle:employés OR intitle:professionnels OR intitle:conseillers OR intitle:intervenants "reduction des méfaits" filetype:pdf =

cannabis intitle:infirmière OR intitle:clinicienne OR intitle:psychoéducatrice OR intitle:éducatrice OR intitle:criminologue OR intitle:psychologue "reduction des méfaits" filetype:pdf =

cannabis intitle:travailleuse OR intitle:employée OR intitle:professionnelle OR intitle:conseillère OR intitle:intervenante "reduction des méfaits" filetype:pdf =

cannabis intitle:infirmières OR intitle:cliniciennes OR intitle:psychoéducatrices OR intitle:éducatrices OR intitle:criminologues OR intitle:psychologues "reduction des méfaits" filetype:pdf =

cannabis intitle:travailleuses OR intitle:employées OR intitle:professionnelles OR intitle:conseillères OR intitle:intervenantes "reduction des méfaits" filetype:pdf =

marijuana intitle:nurse OR intitle:clinician OR intitle:practitioner OR intitle:physician OR intitle:caregiver OR intitle:giver OR intitle:doctor "harm reduction" filetype:pdf =

marijuana intitle:nurses OR intitle:clinicians OR intitle:practitioners OR intitle:physicians OR intitle:caregivers OR intitle:givers OR intitle:doctors "harm reduction" filetype:pdf =

1
2
3 marijuana intitle:psychoeducator OR intitle:educator OR intitle:therapist OR
4 intitle:psychotherapist OR intitle:criminologist OR intitle:psychologist "harm reduction"
5 filetype:pdf =

6
7 marijuana intitle:psychoeducators OR intitle:educators OR intitle:therapists OR
8 intitle:psychotherapists OR intitle:criminologists OR intitle:psychologists "harm reduction"
9 filetype:pdf =

10
11 marijuana intitle:worker OR intitle:staff OR intitle:personnel OR intitle:employee OR
12 intitle:professional OR intitle:provider OR intitle:counselor OR intitle:conselor "harm reduction"
13 filetype:pdf =

14
15 marijuana intitle:workers OR intitle:staffs OR intitle:personnels OR intitle:employees OR
16 intitle:professionals OR intitle:providers OR intitle:counselors OR intitle:conselors "harm
17 reduction" filetype:pdf =

18
19 marijuana intitle:infirmier OR intitle:médecin OR intitle:clinicien OR intitle:psychoéducateur OR
20 intitle:éducateur OR intitle:thérapeute OR intitle:psychothérapeute OR intitle:criminologue OR
21 intitle:psychologue "reduction des méfaits" filetype:pdf =

22
23 marijuana intitle:travailleur OR intitle:personnel OR intitle:employé OR intitle:professionnel OR
24 intitle:conseiller OR intitle:intervenant "reduction des méfaits" filetype:pdf =

25
26 marijuana intitle:infirmiers OR intitle:médecins OR intitle:cliniciens OR intitle:psychoéducateurs
27 OR intitle:éducateurs OR intitle:thérapeutes OR intitle:psychothérapeutes OR
28 intitle:criminologues OR intitle:psychologues "reduction des méfaits" filetype:pdf =

29
30 marijuana intitle:travailleurs OR intitle:personnels OR intitle:employés OR intitle:professionnels
31 OR intitle:conseillers OR intitle:intervenants "reduction des méfaits" filetype:pdf =

32
33 marijuana intitle:infirmière OR intitle:clinicienne OR intitle:psychoéducatrice OR
34 intitle:éducatrice OR intitle:criminologue OR intitle:psychologue "reduction des méfaits"
35 filetype:pdf =

36
37 marijuana intitle:travailleuse OR intitle:employée OR intitle:professionnelle OR intitle:conseillère
38 OR intitle:intervenante "reduction des méfaits" filetype:pdf =

39
40 marijuana intitle:infirmières OR intitle:cliniciennes OR intitle:psychoéducatrices OR
41 intitle:éducatrices OR intitle:criminologues OR intitle:psychologues "reduction des méfaits"
42 filetype:pdf =

43
44 marijuana intitle:travailleuses OR intitle:employées OR intitle:professionnelles OR
45 intitle:conseillères OR intitle:intervenantes "reduction des méfaits" filetype:pdf =

Appendix 9: BASE

tit:(nurse* clinician* practitioner* physician* caregiver* giver* doctor* psychoeducator* educator* therapist* psychotherapist* criminologist* psychologist* worker* staff* personnel* employee* professional* provider* counselor*) subj:(cannabis marijuana) subj:"harm reduction" = 4

tit:(infirmier* OU médecin* OU clinicien* OU psychoéducat* OU éducat* OU criminologue* OU psychologue* OU travailleur* OU employé* OU professionnel* OU conseil* OU intervenant*) subj:cannabis subj:marijuana subj:"réduction des méfaits" = 0

For peer review only

Appendix 10: Érudit

(Titre, résumé, mots-clés : harm reduction OU harm minimisation OU risk reduction OU risks reduction OU risk minimisation OU réduction des méfaits OU réduction des risques) ET (Titre, résumé, mots-clés : cannabis OU marijuana) ET (Titre, résumé, mots-clés : nurse* OU clinician* OU practitioner* OU physician* OU caregiver* OU giver* OU doctor* OU psychoeducator* OU educator* OU therapist* OU psychotherapist* OU criminologist* OU psychologist* OU worker* OU staff* OU personnel* OU employee* OU professional* OU provider* OU counselor* OU infirmier* OU médecin* OU clinicien* OU psychoéducateur* OU éducateur* OU criminologue* OU psychologue* OU travailleur* OU employé* OU professionnel* OU conseiller* OU intervenant*) = 27

For peer review only